<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN"  "JATS-archivearticle1-3-mathml3.dtd"><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic" pub-type="epub">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">87386</article-id><article-id pub-id-type="doi">10.7554/eLife.87386</article-id><article-id pub-id-type="doi" specific-use="version">10.7554/eLife.87386.3</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Microbiology and Infectious Disease</subject></subj-group></article-categories><title-group><article-title>The acetylase activity of Cdu1 regulates bacterial exit from infected cells by protecting <italic>Chlamydia</italic> effectors from degradation</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes" id="author-309235"><name><surname>Bastidas</surname><given-names>Robert J</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-9219-572X</contrib-id><email>robert.bastidas@duke.edu</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund1"/><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-311534"><name><surname>Kędzior</surname><given-names>Mateusz</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" equal-contrib="yes" id="author-340757"><name><surname>Davidson</surname><given-names>Robert K</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" equal-contrib="yes" id="author-340758"><name><surname>Walsh</surname><given-names>Stephen C</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-309380"><name><surname>Dolat</surname><given-names>Lee</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-309381"><name><surname>Sixt</surname><given-names>Barbara S</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-309382"><name><surname>Pruneda</surname><given-names>Jonathan N</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-0304-4418</contrib-id><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="other" rid="fund4"/><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-2261"><name><surname>Coers</surname><given-names>Jörn</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="fund3"/><xref ref-type="fn" rid="con8"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-97562"><name><surname>Valdivia</surname><given-names>Raphael H</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-0961-073X</contrib-id><email>raphael.valdivia@duke.edu</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="fund2"/><xref ref-type="fn" rid="con9"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00py81415</institution-id><institution>Department of Integrative Immunobiology, Duke University</institution></institution-wrap><addr-line><named-content content-type="city">Durham</named-content></addr-line><country>United States</country></aff><aff id="aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00py81415</institution-id><institution>Department of Molecular Genetics and Microbiology, Duke University</institution></institution-wrap><addr-line><named-content content-type="city">Duke</named-content></addr-line><country>United States</country></aff><aff id="aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/05kb8h459</institution-id><institution>Deparment of Molecular Biology, Umeå University</institution></institution-wrap><addr-line><named-content content-type="city">Umeå</named-content></addr-line><country>Sweden</country></aff><aff id="aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/05kb8h459</institution-id><institution>The Laboratory for Molecular Infection Medicine Sweden (MIMS), Umeå University</institution></institution-wrap><addr-line><named-content content-type="city">Umeå</named-content></addr-line><country>Sweden</country></aff><aff id="aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/05kb8h459</institution-id><institution>Umeå Centre for Microbial Research (UCMR), Umeå University</institution></institution-wrap><addr-line><named-content content-type="city">Umeå</named-content></addr-line><country>Sweden</country></aff><aff id="aff6"><label>6</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/009avj582</institution-id><institution>Department of Molecular Microbiology &amp; Immunology, Oregon Health &amp; Science University</institution></institution-wrap><addr-line><named-content content-type="city">Portland</named-content></addr-line><country>United States</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Kana</surname><given-names>Bavesh D</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03rp50x72</institution-id><institution>University of the Witwatersrand</institution></institution-wrap><country>South Africa</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Kana</surname><given-names>Bavesh D</given-names></name><role>Senior Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03rp50x72</institution-id><institution>University of the Witwatersrand</institution></institution-wrap><country>South Africa</country></aff></contrib></contrib-group><author-notes><fn fn-type="con" id="equal-contrib1"><label>†</label><p>These authors contributed equally to this work</p></fn></author-notes><pub-date publication-format="electronic" date-type="publication"><day>15</day><month>02</month><year>2024</year></pub-date><volume>12</volume><elocation-id>RP87386</elocation-id><history><date date-type="sent-for-review" iso-8601-date="2023-03-22"><day>22</day><month>03</month><year>2023</year></date></history><pub-history><event><event-desc>This manuscript was published as a preprint.</event-desc><date date-type="preprint" iso-8601-date="2023-02-28"><day>28</day><month>02</month><year>2023</year></date><self-uri content-type="preprint" xlink:href="https://doi.org/10.1101/2023.02.28.530337"/></event><event><event-desc>This manuscript was published as a reviewed preprint.</event-desc><date date-type="reviewed-preprint" iso-8601-date="2023-05-12"><day>12</day><month>05</month><year>2023</year></date><self-uri content-type="reviewed-preprint" xlink:href="https://doi.org/10.7554/eLife.87386.1"/></event><event><event-desc>The reviewed preprint was revised.</event-desc><date date-type="reviewed-preprint" iso-8601-date="2024-01-10"><day>10</day><month>01</month><year>2024</year></date><self-uri content-type="reviewed-preprint" xlink:href="https://doi.org/10.7554/eLife.87386.2"/></event></pub-history><permissions><copyright-statement>© 2023, Bastidas et al</copyright-statement><copyright-year>2023</copyright-year><copyright-holder>Bastidas et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-87386-v2.pdf"/><self-uri content-type="figures-pdf" xlink:href="elife-87386-figures-v2.pdf"/><abstract><p>Many cellular processes are regulated by ubiquitin-mediated proteasomal degradation. Pathogens can regulate eukaryotic proteolysis through the delivery of proteins with de-ubiquitinating (DUB) activities. The obligate intracellular pathogen <italic>Chlamydia trachomatis</italic> secretes Cdu1 (ChlaDUB1), a dual deubiquitinase and Lys-acetyltransferase, that promotes Golgi remodeling and survival of infected host cells presumably by regulating the ubiquitination of host and bacterial proteins. Here, we determined that Cdu1’s acetylase but not its DUB activity is important to protect Cdu1 from ubiquitin-mediated degradation. We further identified three <italic>C. trachomatis</italic> proteins on the pathogen-containing vacuole (InaC, IpaM, and CTL0480) that required Cdu1‘s acetylase activity for protection from degradation and determined that Cdu1 and these Cdu1-protected proteins are required for optimal egress of <italic>Chlamydia</italic> from host cells. These findings highlight a non-canonical mechanism of pathogen-mediated protection of virulence factors from degradation after their delivery into host cells and the coordinated regulation of secreted effector proteins.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd><italic>Chlamydia trachomatis</italic></kwd><kwd>acetylase</kwd><kwd>deubiquitinase</kwd><kwd>bacterial host exit</kwd><kwd>ubiquitin</kwd><kwd>bacterial effectors</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Other</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>AI140019</award-id><principal-award-recipient><name><surname>Bastidas</surname><given-names>Robert J</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>AI134891</award-id><principal-award-recipient><name><surname>Valdivia</surname><given-names>Raphael H</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>AI103197</award-id><principal-award-recipient><name><surname>Coers</surname><given-names>Jörn</given-names></name></principal-award-recipient></award-group><award-group id="fund4"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>GM142486</award-id><principal-award-recipient><name><surname>Pruneda</surname><given-names>Jonathan N</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>Genetic and biochemical analyses show that <italic>Chlamydia</italic> protects secreted effectors necessary for its exit from infected cells, preventing them from undergoing ubiquitination and degradation.</meta-value></custom-meta><custom-meta specific-use="meta-only"><meta-name>publishing-route</meta-name><meta-value>prc</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>Ubiquitination is a conserved and ubiquitous post-translational modification (PTM) of proteins involving the conjugation of the carboxy-terminal glycine residue of ubiquitin (Ub) to lysine residues of target proteins. Poly-ubiquitination of substrates involves further conjugation of a Ub internal lysine residue or amino-terminal methionine (M1) with a second Ub molecule. Seven internal lysines in Ub (K6, K11, K27, K29, K33, K48, K63) and M1 are utilized by Ub conjugating enzymes to form homogeneous, branched, or mixed poly-ubiquitin (polyUb) chains (<xref ref-type="bibr" rid="bib38">Komander and Rape, 2012</xref>). PolyUb chains with different linkage types exhibit distinct structures and functions. For example, K48- and K11-linked polyUb chains exhibit a compact conformation and are substrates for 26 S proteasome-mediated degradation (<xref ref-type="bibr" rid="bib82">Varadan et al., 2002</xref>; <xref ref-type="bibr" rid="bib80">Tenno et al., 2004</xref>; <xref ref-type="bibr" rid="bib19">Eddins et al., 2007</xref>; <xref ref-type="bibr" rid="bib9">Bremm et al., 2010</xref>; <xref ref-type="bibr" rid="bib71">Saeki, 2017</xref>). In contrast, K63-linked polyUb conjugates adopt more open conformations that enable the recruitment of multiprotein complexes that regulate the function of the target protein by proteolytic independent events (<xref ref-type="bibr" rid="bib37">Komander et al., 2009b</xref>; <xref ref-type="bibr" rid="bib87">Weeks et al., 2009</xref>; <xref ref-type="bibr" rid="bib16">Datta et al., 2009</xref>; <xref ref-type="bibr" rid="bib38">Komander and Rape, 2012</xref>). Mixed and branched polyUb chains are also emerging as important regulators of physiological functions (<xref ref-type="bibr" rid="bib79">Swatek and Komander, 2016</xref>; <xref ref-type="bibr" rid="bib61">Ohtake and Tsuchiya, 2017</xref>).</p><p>Protein ubiquitination regulates numerous eukaryotic cell processes including protein degradation, signal transduction, cell cycle regulation, selective autophagy, the DNA damage response, and programmed cell death. Ub also plays key roles in modulating host innate immune responses to bacterial infection (<xref ref-type="bibr" rid="bib46">Li et al., 2016</xref>), bacterial proteins, pathogen-containing vacuoles, and bacteria themselves by targeting them for Ub-mediated degradation by proteasomal or autophagic machineries (<xref ref-type="bibr" rid="bib46">Li et al., 2016</xref>). Because the Ub system is critical for pathogen containment, many pathogens have evolved mechanisms to counteract the impact of this PTM (<xref ref-type="bibr" rid="bib83">Vozandychova et al., 2021</xref>). For instance, bacterial deubiquitinases (DUBs) can remove Ub from ubiquitinated substrates thereby dampening inflammatory and cell-autonomous defense mechanisms (<xref ref-type="bibr" rid="bib40">Kubori et al., 2019</xref>). Many DUBs are cysteine proteases with a catalytic Cys, a nearby His and an Asn/Asp (<xref ref-type="bibr" rid="bib36">Komander et al., 2009a</xref>). DUBs are typically dedicated to the removal of Ub moieties and are unable to hydrolyze other Ub-like (Ubl) modifications such as SUMO or NEDD8. However, the CE clan of Ubl proteases (ULPs) can catalyze the removal of both SUMO and NEDD8 (<xref ref-type="bibr" rid="bib69">Ronau et al., 2016</xref>). Bacterial pathogens also encode CE clan enzymes that function as DUBs, ULPs or both. For instance, <italic>Salmonella</italic> Typhimurium SseL,<italic> Escherichia coli</italic> ElaD, and <italic>Shigella flexneri</italic> ShiCE function as Ub specific proteases (<xref ref-type="bibr" rid="bib70">Rytkönen et al., 2007</xref>; <xref ref-type="bibr" rid="bib11">Catic et al., 2007</xref>; <xref ref-type="bibr" rid="bib64">Pruneda et al., 2016</xref>) while RickCE from <italic>Rickettsia belli</italic> functions as a protease directed towards both Ub and NEDD8 as does SidE from <italic>Legionella pneumophila</italic> which displays mixed activities towards Ub, NEDD8, and ISG15 (<xref ref-type="bibr" rid="bib75">Sheedlo et al., 2015</xref>; <xref ref-type="bibr" rid="bib64">Pruneda et al., 2016</xref>). Similarly, XopD from <italic>Xanthamonas campestris</italic> and LotB from <italic>L. pneumophila</italic> are isopeptidases exhibiting cross reactivity towards both Ub and SUMO (<xref ref-type="bibr" rid="bib64">Pruneda et al., 2016</xref>; <xref ref-type="bibr" rid="bib73">Schubert et al., 2020</xref>). Some CE clan bacterial effectors display acetyltransferase activity. <italic>L. pneumophila</italic> LegCE, <italic>S</italic>. Typhimurium AvrA, and YopJ from <italic>Yersinia pestis</italic> function exclusively as acetyltransferases (<xref ref-type="bibr" rid="bib54">Mittal et al., 2006</xref>; <xref ref-type="bibr" rid="bib57">Mukherjee et al., 2006</xref>; <xref ref-type="bibr" rid="bib33">Jones et al., 2008</xref>; <xref ref-type="bibr" rid="bib64">Pruneda et al., 2016</xref>). In contrast, the <italic>Chlamydia trachomatis</italic> (Ct) effector Cdu1/<italic>Chla</italic>DUB1 is a CE clan protein that exhibits both acetyltransferase and deubiquitinating activities (<xref ref-type="bibr" rid="bib52">Misaghi et al., 2006</xref>; <xref ref-type="bibr" rid="bib64">Pruneda et al., 2016</xref>; <xref ref-type="bibr" rid="bib20">Fischer et al., 2017</xref>; <xref ref-type="bibr" rid="bib65">Pruneda et al., 2018</xref>).</p><p>Ct is an obligate intracellular bacterial pathogen responsible for human diseases of significant clinical and public health importance (<xref ref-type="bibr" rid="bib25">Haggerty et al., 2010</xref>). Ct has a biphasic developmental cycle in which the Ct infectious propagule or elementary body (EB) invades the target host cell. Upon internalization the EB transitions to the reticulate body (RB). RBs replicate by binary fission within a pathogenic vacuole (‘inclusion’) and asynchronously differentiate back to EBs. In cell culture, starting at around 48 hours-post infection (hpi) Ct will egress after lysis of the host cell or by a process termed extrusion, wherein the intact inclusion exits from the infected cell (<xref ref-type="bibr" rid="bib56">Moulder, 1991</xref>; <xref ref-type="bibr" rid="bib1">Abdelrahman and Belland, 2005</xref>; <xref ref-type="bibr" rid="bib30">Hybiske and Stephens, 2007</xref>; <xref ref-type="bibr" rid="bib44">Lee et al., 2018</xref>). The effector Cdu1 was originally identified as a deneddylating and deubiquitinating enzyme and subsequently shown to exhibit in vitro isopeptidase activity towards both Lys48 and Lys63 linked di-Ub substrates (<xref ref-type="bibr" rid="bib52">Misaghi et al., 2006</xref>; <xref ref-type="bibr" rid="bib14">Claessen et al., 2013</xref>; <xref ref-type="bibr" rid="bib64">Pruneda et al., 2016</xref>; <xref ref-type="bibr" rid="bib20">Fischer et al., 2017</xref>). Cdu1 is unique among CE clan enzymes in that it also functions as a bona fide lysine acetylase with both is acetylase and DUB activities catalyzed by the same catalytic active site (<xref ref-type="bibr" rid="bib65">Pruneda et al., 2018</xref>). Intriguingly, Cdu1 autoacetylation is directed towards lysines unlike other CE clan acetylases that predominantly target serine and threonine residues (<xref ref-type="bibr" rid="bib65">Pruneda et al., 2018</xref>). In transfected cells, Cdu1 protects the NFκB cytoplasmic retention factor IκBα from ubiquitination and proteasomal degradation (<xref ref-type="bibr" rid="bib43">Le Negrate et al., 2008</xref>). In infected cells, Cdu1 localizes to the inclusion membrane where it functions to stabilize the anti-apoptotic protein Mcl-1 and to promote the repositioning of Golgi ministacks around the Ct inclusion (<xref ref-type="bibr" rid="bib20">Fischer et al., 2017</xref>; <xref ref-type="bibr" rid="bib85">Wang et al., 2018</xref>; <xref ref-type="bibr" rid="bib65">Pruneda et al., 2018</xref>; <xref ref-type="bibr" rid="bib42">Kunz et al., 2019</xref>; <xref ref-type="bibr" rid="bib5">Auer et al., 2020</xref>). However, the mechanism by which Cdu1 promotes redeployment of Golgi ministacks and any additional roles that Cdu1 may play during Ct infection of epithelial cells remains unknown.</p><p>In this study, we show that Cdu1 protects itself and three secreted Ct effectors, InaC, IpaM, and CTL0480 from targeted ubiquitination and proteasomal degradation. InaC, IpaM, and CTL0480 are members of a larger family of bacterial proteins embedded within the inclusion membrane (Inc proteins; <xref ref-type="bibr" rid="bib6">Bannantine et al., 2000</xref>; <xref ref-type="bibr" rid="bib68">Rockey et al., 2002</xref>; <xref ref-type="bibr" rid="bib12">Chen et al., 2006</xref>; <xref ref-type="bibr" rid="bib45">Li et al., 2008</xref>; <xref ref-type="bibr" rid="bib4">Alzhanov et al., 2009</xref>; <xref ref-type="bibr" rid="bib17">Dehoux et al., 2011</xref>; <xref ref-type="bibr" rid="bib48">Lutter et al., 2012</xref>; <xref ref-type="bibr" rid="bib49">Lutter et al., 2013</xref>; <xref ref-type="bibr" rid="bib35">Kokes et al., 2015</xref>; <xref ref-type="bibr" rid="bib86">Weber et al., 2015</xref>). We show that Cdu1-mediated protection from degradation is independent from its DUB activity but relies upon its Lys acetylase activity. We show that Cdu1 protects InaC to promote repositioning of Golgi ministacks and formation of actin scaffolds around the Ct inclusion, and CTL0480 to promote recruitment of myosin phosphatase target subunit 1 (MYPT1) to the inclusion. In addition, we determined that Cdu1 and Cdu1-protected Incs are required for optimal extrusion of inclusions from host cells at the late stages of infection.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>The <italic>C. trachomatis</italic> inclusion membrane proteins InaC, IpaM, and CTL0480 are differentially ubiquitinated in the absence of Cdu1</title><p>Cdu1 is required for Golgi repositioning around the Ct inclusion (<xref ref-type="bibr" rid="bib65">Pruneda et al., 2018</xref>; <xref ref-type="bibr" rid="bib5">Auer et al., 2020</xref>). To understand how Cdu1 promotes Golgi redistribution, we first generated a <italic>cdu1</italic> null strain in a Ct L2 background by TargeTron mediated insertional mutagenesis (pDFTT3-<italic>aadA</italic>) (<xref ref-type="bibr" rid="bib47">Lowden et al., 2015</xref>; <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref>). Loss of Cdu1 expression in the resulting L2 <italic>cdu1</italic>::GII <italic>aadA</italic> (<italic>cdu1</italic>::GII) strain was verified by western blot analysis and by indirect immunofluorescence with antibodies raised against Cdu1 (<xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2A and B</xref>). Because <italic>cdu2</italic> resides directly downstream of the <italic>cdu1</italic> locus and encodes a second Ct DUB (Cdu2/<italic>Chla</italic>DUB2) (<xref ref-type="bibr" rid="bib52">Misaghi et al., 2006</xref>), we first determined whether the disruption of <italic>cdu1</italic> impacted the expression of <italic>cdu2</italic>. We detected <italic>cdu1</italic> and <italic>cdu2</italic> transcripts in HeLa cells infected with Ct L2 but not for the juncture between <italic>cdu1</italic> and <italic>cdu2</italic> (<xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2C</xref>). In cells infected with Ct <italic>cdu1</italic>::GII we only detected <italic>cdu2</italic> transcripts (<xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2C</xref>) confirming that <italic>cdu1</italic> and <italic>cdu2</italic> are not co-expressed as part of an operon in accordance with previous observations (<xref ref-type="bibr" rid="bib3">Albrecht et al., 2010</xref>).</p><p>In transfected HeLa cells, Cdu1’s DUB activity has been linked to fragmentation of the Golgi apparatus (<xref ref-type="bibr" rid="bib65">Pruneda et al., 2018</xref>). We therefore hypothesized that Cdu1s’ DUB activity in infected cells promoted Golgi redistribution around inclusions and that we could identify potential targets by comparing the protein ubiquitination profile of cells infected with WT or <italic>cdu1</italic>::GII strains by quantitative mass spectrometry (MS). HeLa cell were mock infected or infected with either WT L2 or <italic>cdu1</italic>::GII strains. At 24 hpi, poly-ubiquitinated proteins were enriched from lysed cells using Tandem Ubiquitin Binding Entities (TUBEs; LifeSensors). TUBEs consist of concatenated Ub binding associated domains (UBAs) that bind to polyUb-modified proteins with nanomolar affinities. Poly-ubiquitinated proteins of both human and Ct origin were enriched and identified by quantitative LC-MS/MS analysis.</p><p>Over 2000 non-ubiquitinated proteins co-precipitated with TUBE1-bound proteins across all three conditions (mock, L2, and <italic>cdu1</italic>::GII infected HeLa cells) and three biological replicates (<xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>). Among these, 47 human proteins were significantly enriched in mock infected HeLa cells and 50 human proteins were significantly enriched during Ct infection (L2 and <italic>cdu1</italic>::GII) (<xref ref-type="supplementary-material" rid="supp3">Supplementary file 3</xref>, <xref ref-type="fig" rid="fig1s3">Figure 1—figure supplement 3</xref>). Pathway enrichment analysis revealed that proteins involved in RNA metabolism were overrepresented among co-precipitating proteins from mock infected cells (<xref ref-type="supplementary-material" rid="supp4">Supplementary file 4</xref>, <xref ref-type="fig" rid="fig1s4">Figure 1—figure supplement 4</xref>) while no biological pathways or processes were overrepresented in proteins enriched from infected cells (<xref ref-type="fig" rid="fig1s4">Figure 1—figure supplement 4</xref>). We also identified eight TUBE1 co-precipitating Ct proteins in HeLa cells infected with L2 and <italic>cdu1</italic>::GII (<xref ref-type="supplementary-material" rid="supp5">Supplementary file 5</xref>, <xref ref-type="fig" rid="fig1s3">Figure 1—figure supplement 3</xref>).</p><p>TUBE1 affinity capture lead to the identification of 43 ubiquitinated proteins (35 human proteins and 8 Ct proteins across all 3 conditions and replicates) based on the presence of peptides containing a di-glycine remnant motif (<xref ref-type="bibr" rid="bib63">Peng et al., 2003</xref>; <xref ref-type="supplementary-material" rid="supp6 supp7 supp8">Supplementary files 6-8</xref>). The lack of widespread poly-ubiquitination of either human or Ct proteins in response to Ct infection (<xref ref-type="fig" rid="fig1">Figure 1</xref>) was surprising given that wholesale changes in protein ubiquitination has been reported during infection of HeLa cells by intracellular pathogens like <italic>S</italic>. Typhimurium (<xref ref-type="bibr" rid="bib21">Fiskin et al., 2016</xref>). It is also possible that had we conducted our analysis at different time points post-infection (hpi), we might have identified additional Cdu1 targets, such as Mcl1 and IκBα (<xref ref-type="bibr" rid="bib43">Le Negrate et al., 2008</xref>; <xref ref-type="bibr" rid="bib20">Fischer et al., 2017</xref>) which were not identified in our analysis. However, given that we observed Cdu1 at the inclusion membrane as early as 1 hpi (data not shown), we opted to focus on an earlier stage of the infection cycle. Only two human ubiquitinated proteins (ZC3H7A and DDIT4) were found to be significantly enriched in response to WT L2 infection at 24 hpi (<xref ref-type="fig" rid="fig1">Figure 1A and C</xref>, <xref ref-type="supplementary-material" rid="supp8">Supplementary file 8</xref>) while only one human protein (MGC3121) was preferentially ubiquitinated in HeLa cells infected with the <italic>cdu1</italic>::GII mutant strain (<xref ref-type="fig" rid="fig1">Figure 1B and C</xref>, <xref ref-type="supplementary-material" rid="supp8">Supplementary file 8</xref>). In contrast three Ct proteins, InaC (K104, K107, and K149), IpaM (K29), and CTL0480 (K115) were ubiquitinated at Lys residues in the absence of Cdu1 (<xref ref-type="fig" rid="fig1">Figure 1B, C and D</xref>, <xref ref-type="supplementary-material" rid="supp8">Supplementary file 8</xref>).</p><fig-group><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>The <italic>C. </italic><italic>trachomatis</italic> inclusion membrane proteins InaC, IpaM, and CTL0480 are ubiquitinated in the absence of Cdu1.</title><p>(<bold>A–C</bold>) Volcano plots (pairwise comparisons) of the relative abundance of human and Ct ubiquitinated peptides.(<bold>A</bold>) Mock infected HeLa cells versus HeLa cells infected with WT Ct (L2 434 Bu pBOMB) (24 hpi). (<bold>B</bold>) Mock infected HeLa cells versus HeLa cells infected with a <italic>cdu1</italic> null strain (<italic>cdu1</italic>::GII pBOMB) (24 hpi) (<bold>C</bold>) HeLa cells infected with WT Ct (24 hpi) versus HeLa cells infected with a <italic>cdu1</italic> null strain (24 hpi). Significance values were interpolated from 3 independent biological replicates. Ubiquitinated proteins were enriched with magnetic TUBE1 beads (binds to polyubiquitinated proteins) and peptides identified by quantitative LC MS/MS analysis. Three Ct inclusion membrane proteins, InaC, IpaM, and CTL0480 were differentially ubiquitinated in the absence of Cdu1. (<bold>D</bold>) InaC was ubiquitinated at K104, K107, and K149, IpaM at K290, and CTL0480 at K115 in the absence of Cdu1. TMD: Transmembrane domain. Numbering corresponds to amino acids in the protein sequence of each respective inclusion membrane protein.</p><p><supplementary-material id="fig1sdata1"><label>Figure 1—source data 1.</label><caption><title>Excel file containing MaxQuant intensity values used to generate volcano plots in <xref ref-type="fig" rid="fig1">Figure 1A–C</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-87386-fig1-data1-v2.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-87386-fig1-v2.tif"/></fig><fig id="fig1s1" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 1.</label><caption><title>TargeTron mediated disruption of the L2 <italic>cdu1</italic> ORF.</title><p>(<bold>A</bold>) Depiction of the <italic>cdu1</italic> ORFs in WT L2 and <italic>cdu1</italic>::GII strains with corresponding diagnostic PCR amplicons. (<bold>B</bold>) PCR analysis of the disrupted <italic>cdu1</italic> ORF in the <italic>cdu1</italic>::GII strain. *Amplification of <italic>cdu1</italic> ORF in <italic>cdu1</italic>::GII strain was unsuccessful due to size of amplicon. + control: WT <italic>cdu2</italic>.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-87386-fig1-figsupp1-v2.tif"/></fig><fig id="fig1s2" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 2.</label><caption><title>Generation of a <italic>cdu1</italic> null strain in <italic>C. </italic><italic>trachomatis</italic> (L2).</title><p>(<bold>A</bold>) Western blot analysis of protein lysates derived from HeLa cells infected with a Ct L2 434 Bu parental strain (L2) and an L2 <italic>cdu1</italic>::GII <italic>aadA</italic> (<italic>cdu1</italic>::GII) strain for 24 hr. Blots were probed with antibodies raised against recombinant Cdu1 (amino acids 71–401), Ct RpoB (bacterial RNA polymerase), and human αtubulin. (<bold>B</bold>) HeLa cells infected with L2 transformed with pBOMB4-MCI empty vector (L2 pBOMB) and <italic>cdu1</italic>::GII transformed with empty pBOMB4-MCI (<italic>cdu1</italic>::GII pBOMB) were fixed at 24 hpi and stained with Cdu1 antisera. Cdu1 signal is depicted in green, Ct cells expressing mCherry (encoded in pBOMB4-MCI vector) are shown in red, and DNA stained with Hoechst in blue. Scale bar: 10 μm. (<bold>C</bold>) Total RNA isolated from HeLa cells infected with L2 and <italic>cdu1</italic>::GII strains for 24 hr was used to synthesize cDNAs which served as templates for PCR analysis of <italic>cdu1</italic>, <italic>cdu2</italic>, and <italic>cdu1-cdu2</italic> bicistronic expression. RT+: Total RNA +reverse transcriptase. RT-: Total RNA without reverse transcriptase. gDNA: Genomic DNA.</p><p><supplementary-material id="fig1s2sdata1"><label>Figure 1—figure supplement 2—source data 1.</label><caption><title>Original files used for western blot analysis shown in <xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2A</xref> (anti-Cdu1, anti-RpoB, and anti-α-tubulin).</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-87386-fig1-figsupp2-data1-v2.zip"/></supplementary-material></p><p><supplementary-material id="fig1s2sdata2"><label>Figure 1—figure supplement 2—source data 2.</label><caption><title>Files containing original scans of western blot analysis shown in <xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2A</xref> (anti-Cdu1, anti-RpoB, and anti-α-Tubulin) with sample labels and highlighted bands.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-87386-fig1-figsupp2-data2-v2.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-87386-fig1-figsupp2-v2.tif"/></fig><fig id="fig1s3" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 3.</label><caption><title>Proteins co-precipitating (non ubiquitinated) with human and Ct proteins enriched by TUBE1 pulldowns.</title><p>(<bold>A</bold>) Volcano plots (pairwise comparisons) of human proteins (non-ubiquitinated) that co-precipitate with TUBE1-bound proteins in mock infected HeLa cells and HeLa cells infected with L2 or <italic>cdu1</italic> null strains (24 hpi). (<bold>B</bold>) Volcano plots (pairwise comparisons) of Ct TUBE1 co-precipitating proteins (non-ubiquitinated) identified in mock infected HeLa cells and HeLa cells infected with L2 or <italic>cdu1</italic> null strains (24 hpi).</p><p><supplementary-material id="fig1s3sdata1"><label>Figure 1—figure supplement 3—source data 1.</label><caption><title>Excel file containing MaxQuant intensity values used to generate volcano plots in panels A and B.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-87386-fig1-figsupp3-data1-v2.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-87386-fig1-figsupp3-v2.tif"/></fig><fig id="fig1s4" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 4.</label><caption><title>Pathway enrichment analysis of human and Ct proteins that co-precipitate (non ubiquitinated) with TUBE1-bound proteins.</title><p>(<bold>A</bold>) Metascape functional enrichment analysis of human co-precipitating proteins in mock infected HeLa cells. (<bold>B</bold>) Metascape functional enrichment analysis of human co-precipitating proteins in <italic>cdu1</italic> null infected HeLa cells. (<bold>C</bold>) DAVID pathway enrichment analysis of Ct co-precipitating proteins enriched in infected (L2 and <italic>cdu1</italic> null) HeLa cells.</p><p><supplementary-material id="fig1s4sdata1"><label>Figure 1—figure supplement 4—source data 1.</label><caption><title>Excel file with Metascape compiled GO clusters and associated p-values for GO analysis of human co-precipitating proteins in mock-infected Hela cells (panel A).</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-87386-fig1-figsupp4-data1-v2.zip"/></supplementary-material></p><p><supplementary-material id="fig1s4sdata2"><label>Figure 1—figure supplement 4—source data 2.</label><caption><title>Excel file with Metascape compiled GO clusters and associated p-values for GO analysis of human co-precipitating proteins in <italic>cdu1</italic> null infected HeLa cells (panel B).</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-87386-fig1-figsupp4-data2-v2.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-87386-fig1-figsupp4-v2.tif"/></fig></fig-group><p>InaC, IpaM, and CTL0480 are Ct effector proteins that localize to the inclusion membrane (<xref ref-type="bibr" rid="bib12">Chen et al., 2006</xref>; <xref ref-type="bibr" rid="bib4">Alzhanov et al., 2009</xref>; <xref ref-type="bibr" rid="bib49">Lutter et al., 2013</xref>; <xref ref-type="bibr" rid="bib35">Kokes et al., 2015</xref>). These Type 3 secretion substrates belong to a family of over 36 inclusion membrane proteins (Incs) that contain a signature bi-lobal hydrophobic transmembrane domain (<xref ref-type="bibr" rid="bib6">Bannantine et al., 2000</xref>; <xref ref-type="bibr" rid="bib68">Rockey et al., 2002</xref>; <xref ref-type="bibr" rid="bib45">Li et al., 2008</xref>; <xref ref-type="bibr" rid="bib17">Dehoux et al., 2011</xref>; <xref ref-type="bibr" rid="bib48">Lutter et al., 2012</xref>). Incs provide many functions important for Ct intracellular replication ranging from providing structural integrity to the inclusion membrane, to regulating membrane trafficking, to mediating interactions with host organelles and cytoskeletal structures (reviewed in <xref ref-type="bibr" rid="bib10">Bugalhão and Mota, 2019</xref>). InaC facilitates the activation of the small GTPase RhoA, a crucial step for the assembly of actin scaffolds around the inclusion (<xref ref-type="bibr" rid="bib26">Haines et al., 2021</xref>; <xref ref-type="bibr" rid="bib41">Kumar and Valdivia, 2008</xref>). Additionally, InaC plays a pivotal role in the activation of Arf GTPases. This activation subsequently induces PTMs of microtubules in close proximity to the inclusion membrane, which are essential for Ct to initiate the repositioning of Golgi ministacks around the inclusion (<xref ref-type="bibr" rid="bib88">Wesolowski et al., 2017</xref>). IpaM exhibits localization to discrete patches in the inclusion termed microdomains (<xref ref-type="bibr" rid="bib4">Alzhanov et al., 2009</xref>; <xref ref-type="bibr" rid="bib18">Dumoux et al., 2015</xref>). Upon ectopic expression, IpaM induces alterations in microtubule organization (<xref ref-type="bibr" rid="bib18">Dumoux et al., 2015</xref>). CTL0480, facilitates the recruitment of MYPT1 (myosin phosphatase target subunit 1) to the inclusion membrane. Recrutiment of MYPT1 is required for the efficient exit of Ct from host cells (<xref ref-type="bibr" rid="bib49">Lutter et al., 2013</xref>; <xref ref-type="bibr" rid="bib74">Shaw et al., 2018</xref>). Because Cdu1 also localizes to the inclusion membrane (<xref ref-type="bibr" rid="bib20">Fischer et al., 2017</xref>; <xref ref-type="bibr" rid="bib85">Wang et al., 2018</xref>; <xref ref-type="bibr" rid="bib65">Pruneda et al., 2018</xref>; <xref ref-type="bibr" rid="bib42">Kunz et al., 2019</xref>) we postulated that Cdu1 directly protects InaC, IpaM, and CTL0480 from ubiquitination.</p></sec><sec id="s2-2"><title>Cdu1 associates with InaC, IpaM, and CTL0480</title><p>We first determined if Cdu1 co-localized with InaC, IpaM, and CTL0480 at the inclusion membrane. HeLa cells were infected for 24 hr with WT L2 or L2 expressing CTL0480-Flag from its endogenous promoter and immunostained with antibodies against Cdu1, InaC, IpaM, or the Flag epitope. Both InaC and CTL0480-Flag localized throughout the inclusion membrane while IpaM was restricted to discrete microdomains as previously reported (<xref ref-type="bibr" rid="bib4">Alzhanov et al., 2009</xref>; <xref ref-type="bibr" rid="bib18">Dumoux et al., 2015</xref>; <xref ref-type="fig" rid="fig2">Figure 2A</xref>). Cdu1 co-localized with InaC and CTL0480-Flag and with IpaM at microdomains (<xref ref-type="fig" rid="fig2">Figure 2A and B</xref>). All four antibodies specifically recognized their corresponding antigens since immunostaining for Cdu1, InaC, IpaM or the Flag epitope was not observed in Ct strains lacking Cdu1 (<italic>cdu1</italic>::GII), InaC (M407, <xref ref-type="bibr" rid="bib35">Kokes et al., 2015</xref>) IpaM (<italic>ipaM</italic>::GII, <xref ref-type="bibr" rid="bib51">Meier et al., 2023</xref>), or a strain that does not express CTL0480-Flag (<xref ref-type="fig" rid="fig2">Figure 2A</xref>).</p><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>Cdu1 associates with InaC, IpaM, and CTL0480.</title><p>(<bold>A</bold>) Co-localization of Cdu1(magenta) with endogenous InaC (green), IpaM (green), and ectopically expressed CTL0480-Flag (green) at the Ct (L2) inclusion membrane of HeLa cells infected for 24 hr. HeLa cells infected with an <italic>inaC</italic> null strain (M407), an <italic>ipaM</italic> null strain (<italic>ipaM</italic>::GII), and WT Ct (L2 434 Bu pBOMB) were used as controls for antibody specificity. DNA stained with Hoechst is shown in blue. Scale bar: 10 μm. Images are representative of multiple images captured across three independent replicates. (<bold>B</bold>) Line scan profiles of fluorescent signal intensities displayed in (<bold>A</bold>) showing co-localization of fluorescence intensities for endogenous Cdu1 with endogenous InaC and IpaM, and with CTL0480-Flag along the L2 inclusion membrane. (<bold>C</bold>) Schematic of Cdu1-GFP(C) (L2) fusion (Cdu1-GFP) and Cdu1-GFP variants used in co-transfections of HEK 293 cells. GFP: Green fluorescent protein. TMD: Transmembrane domain. PRD: Proline rich domain. CD: Catalytic domain. FL: Full length. TMD-: Cdu1-GFP variant lacking TMD domain. CD-: Cdu1-GFP variant lacking CD domain. (<bold>D–G</bold>) Western blot analysis of GFP immunoprecipitates from HEK 293 cells co-transfected with mammalian plasmids expressing: Cdu1-GFP variants and (<bold>D</bold>) truncated 3XFlag(N)-InaC (D/UW-3/CX CT813, amino acids 96–264), (<bold>E</bold>) V5(N)-IpaM (L2, full length), (<bold>F</bold>) V5(N)-CTL0480 (L2, full length), and (<bold>G</bold>) V5(N)-CpoS (L2, full length). Vec1: Empty pOPINN-GFP vector. Vec2: Empty pDEST53 vector. Vec3: Empty pcDNA3.1/nV5-DEST vector. Western blot images are representative from two independent experiments.</p><p><supplementary-material id="fig2sdata1"><label>Figure 2—source data 1.</label><caption><title>Excel files with pixel intensity values for generating line scan profiles in <xref ref-type="fig" rid="fig2">Figure 2B</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-87386-fig2-data1-v2.zip"/></supplementary-material></p><p><supplementary-material id="fig2sdata2"><label>Figure 2—source data 2.</label><caption><title>Original western blot scans used to generate <xref ref-type="fig" rid="fig2">Figure 2D</xref> (anti-GFP [input], anti-Flag [input], anti-α-tubulin [input], anti-GFP [IP:GFP], and anti-Flag [IP:GFP]).</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-87386-fig2-data2-v2.zip"/></supplementary-material></p><p><supplementary-material id="fig2sdata3"><label>Figure 2—source data 3.</label><caption><title>Original western blot scans with labeled samples and highlighted bands for <xref ref-type="fig" rid="fig2">Figure 2D</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-87386-fig2-data3-v2.zip"/></supplementary-material></p><p><supplementary-material id="fig2sdata4"><label>Figure 2—source data 4.</label><caption><title>Original western blot scans used to generate <xref ref-type="fig" rid="fig2">Figure 2E</xref> (anti-GFP [input], anti-V5 [input], anti-α-tubulin [input], anti-GFP [IP:GFP], and anti-V5 [IP:GFP]).</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-87386-fig2-data4-v2.zip"/></supplementary-material></p><p><supplementary-material id="fig2sdata5"><label>Figure 2—source data 5.</label><caption><title>Original western blot scans with labeled samples and highlighted bands for <xref ref-type="fig" rid="fig2">Figure 2E</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-87386-fig2-data5-v2.zip"/></supplementary-material></p><p><supplementary-material id="fig2sdata6"><label>Figure 2—source data 6.</label><caption><title>Original western blot scans used to generate <xref ref-type="fig" rid="fig2">Figure 2F</xref> (anti-GFP [input], anti-V5 [input], anti-α-tubulin [input], anti-GFP [IP:GFP], and anti-V5 [IP:GFP]).</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-87386-fig2-data6-v2.zip"/></supplementary-material></p><p><supplementary-material id="fig2sdata7"><label>Figure 2—source data 7.</label><caption><title>Original western blot scans with labeled samples and highlighted bands for <xref ref-type="fig" rid="fig2">Figure 2F</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-87386-fig2-data7-v2.zip"/></supplementary-material></p><p><supplementary-material id="fig2sdata8"><label>Figure 2—source data 8.</label><caption><title>Original western blot scans used to generate <xref ref-type="fig" rid="fig2">Figure 2G</xref> (anti-GFP [input], anti-V5 [input], anti-α-tubulin [input], anti-GFP [IP:GFP], and anti-V5 [IP:GFP]).</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-87386-fig2-data8-v2.zip"/></supplementary-material></p><p><supplementary-material id="fig2sdata9"><label>Figure 2—source data 9.</label><caption><title>Original western blot scans with labeled samples and highlighted bands for <xref ref-type="fig" rid="fig2">Figure 2G</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-87386-fig2-data9-v2.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-87386-fig2-v2.tif"/></fig><p>We next determined if Cdu1 can interact with InaC, IpaM, and CTL0480 by co-transfecting HEK 293 cells with vectors expressing either full length Cdu1-GFP or truncated versions of Cdu1-GFP lacking transmembrane or catalytic domains (<xref ref-type="fig" rid="fig2">Figure 2C</xref>), and vectors expressing Flag-InaC, V5-IpaM, and V5-CTL0480. Transfected cells were lysed and Cdu1-GFP was immunoprecipitated with antibodies against GFP. Western blot analysis of the immunoprecipitates showed that Flag-InaC, V5-IpaM, and V5-CTL0480 co-precipitated with Cdu1-GFP (<xref ref-type="fig" rid="fig2">Figure 2D–F</xref>). Moreover, the transmembrane domain of Cdu1 was necessary for Cdu1-GFP to interact with all three Incs (<xref ref-type="fig" rid="fig2">Figure 2D–F</xref>). The interaction between Cdu1-GFP and the three tagged Incs was specific since we did not detect interactions between Cdu1-GFP and a V5-tagged version of the inclusion membrane protein CpoS (<xref ref-type="bibr" rid="bib76">Sixt et al., 2017</xref>; <xref ref-type="fig" rid="fig2">Figure 2G</xref>). We expected these interactions to be transient at the inclusion membrane as the engagement of Cdu1 with its target(s) should mimic that of most enzymes with their substrates. Therefore, while we could capture these complexes in co-immunoprecipitations in the context of overexpression, this assay was not sensitive enough to reliably document the formation of complexes among low abundance endogenous Ct proteins. Nevertheless, our findings from transfection experiments lead us to conclude that Cdu1 can selectively interact with all three Incs even in the absence of infection, and these interactions are facilitated by the transmembrane domain of Cdu1.</p></sec><sec id="s2-3"><title>Cdu1 protects InaC, IpaM, and CTL0480 proteins from degradation during infection</title><p>We next assessed if Cdu1 was required to stabilize endogenous InaC, IpaM, and CTL0480 in infected cells. HeLa cells were infected with either WT L2 or <italic>cdu1</italic>::GII strains and at various time points in the Ct infectious cycle crude cell lysates were analyzed by western blot to assess the relative abundance of Inc proteins. At 36 and 48 hpi, the levels of InaC protein were found to be undetectable in cells infected with <italic>cdu1</italic>::GII in comparison to cells infected with the WT L2 strain (<xref ref-type="fig" rid="fig3">Figure 3A and B</xref>). Conversely, IpaM protein levels exhibited a decrease at 36 and 48 hpi in cells infected with <italic>cdu1</italic>::GII (<xref ref-type="fig" rid="fig3">Figure 3C and D</xref>). We were not able to detect CTL0480 levels by western blot but were successful in following CTL0480 expression by indirect immunofluorescence (<xref ref-type="fig" rid="fig3">Figure 3E</xref>). The relative abundance of CTL0480 at inclusion membranes was not affected in <italic>cdu1</italic>::GII inclusions at 24 hpi. However, at 36 hpi, a subpopulation of cells lost CTL0480 immunoreactivity and by 48 hpi, inclusion membranes of the <italic>cdu1</italic>::GII strain were devoid of CTL0480 while CTL0480 was prominently detected at the inclusion membranes of WT L2 (<xref ref-type="fig" rid="fig3">Figure 3E</xref> and <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1</xref>). As controls for the specificity of antibodies used for western blots and for indirect immunofluorescence, we included cells infected with Ct lacking <italic>ipaM (ipaM</italic>::GII, <xref ref-type="bibr" rid="bib51">Meier et al., 2023</xref>), with an <italic>inaC</italic> nonsense mutant (M407, <xref ref-type="bibr" rid="bib35">Kokes et al., 2015</xref>), and with Ct lacking <italic>ctl0480</italic> (<italic>ctl0480</italic>::GII, <xref ref-type="bibr" rid="bib74">Shaw et al., 2018</xref>). Overall, our results indicate that steady state protein levels of InaC and IpaM and CTL0480 localization at the inclusion membrane, especially at late stages of infection, are dependent on Cdu1, and that Cdu1 acts at different stages in the infection cycle.</p><fig-group><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>Cdu1 stabilizes InaC, IpaM, and CTL0480.</title><p>(<bold>A</bold>) Western blot analysis of endogenous InaC in HeLa cells infected for 24, 36, and 48 hr with Wt Ct (L2 pBOMB), <italic>cdu1</italic> null (<italic>cdu1</italic>::GII pBOMB), and <italic>inaC</italic> null (M407) strains. Ct Slc1 and human alpha tubulin were used to determine Ct burdens and equal loading of protein extracts respectively. Western blot images are representative of 2 independent experiments. (<bold>B</bold>) Quantification of InaC abundance (InaC western blot signal from (<bold>A</bold>)) normalized to Slc1 western blot signal (from panel A) in HeLa cells infectedwith a <italic>cdu1</italic> null strain, relative to normalized InaC abundance in HeLa cells infected with Wt Ct. Error bars depict standard deviation. (<bold>C</bold>) Western blot analysis of endogenous IpaM in HeLa cells infected for 24, 36, and 48 hr with Wt Ct, <italic>cdu1</italic> null, and <italic>ipam</italic> null (<italic>ipam</italic>::GII) strains. Western blot images are representative of two independent experiments. (<bold>D</bold>) Quantification of normalized IpaM abundance from (<bold>C</bold>) in HeLa cells infectedwith a <italic>cdu1</italic> null strain, relative to normalized IpaM abundance in HeLa cells infected with Wt Ct. Error bars depict standard deviation. (<bold>E</bold>) Localization of CTL0480 during Ct infection of HeLa cells at 24, 36, and 48 hpi. CTL0480 signal (green) co-localizes with the inclusion membrane protein IncA (magenta) at the Ct inclusion membrane. Arrowheads highlight <italic>cdu1</italic> null inclusions lacking CTL0480 at 36 hpi. DNA stained with Hoechst is shown in blue. Scale bar: 10 μm. Quantification of CTL0480 localization at inclusion membranes can be found in <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1</xref>.</p><p><supplementary-material id="fig3sdata1"><label>Figure 3—source data 1.</label><caption><title>Original western blot scans used to generate <xref ref-type="fig" rid="fig3">Figure 3A</xref> (anti-InaC, anti-Slc1, and anti-α-tubulin).</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-87386-fig3-data1-v2.zip"/></supplementary-material></p><p><supplementary-material id="fig3sdata2"><label>Figure 3—source data 2.</label><caption><title>Original western blot scans with labeled samples and highlighted bands for <xref ref-type="fig" rid="fig3">Figure 3A</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-87386-fig3-data2-v2.zip"/></supplementary-material></p><p><supplementary-material id="fig3sdata3"><label>Figure 3—source data 3.</label><caption><title>Excel file containing densitometry data for <xref ref-type="fig" rid="fig3">Figure 3B</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-87386-fig3-data3-v2.zip"/></supplementary-material></p><p><supplementary-material id="fig3sdata4"><label>Figure 3—source data 4.</label><caption><title>Original western blot scans used to generate <xref ref-type="fig" rid="fig3">Figure 3C</xref> (anti-IpaM, anti-Slc1, and anti-α-tubulin).</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-87386-fig3-data4-v2.zip"/></supplementary-material></p><p><supplementary-material id="fig3sdata5"><label>Figure 3—source data 5.</label><caption><title>Original western blot scans with labeled samples and highlighted bands for <xref ref-type="fig" rid="fig3">Figure 3C</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-87386-fig3-data5-v2.zip"/></supplementary-material></p><p><supplementary-material id="fig3sdata6"><label>Figure 3—source data 6.</label><caption><title>Excel file containing densitometry data for <xref ref-type="fig" rid="fig3">Figure 3D</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-87386-fig3-data6-v2.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-87386-fig3-v2.tif"/></fig><fig id="fig3s1" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 1.</label><caption><title>Quantification of CTL0480 at Ct inclusion membranes.</title><p>Quantification of CTL0480 localization at Ct inclusion membranes as shown in <xref ref-type="fig" rid="fig3">Figure 3E</xref>. CTL0480 fluorescent signal was used to determine the percent of inclusions displaying CTL0480 at the inclusion membranes. Representative images and quantification of CTL0480-positive inclusions are derived from Ct inclusions imaged in 10 fields across 3 independent biological replicates. Error bars depict standard deviation. p values were determined by a student paired t-test. For cells infected with WT Ct (sum across 3 replicates) n=297 inclusions at 24 hpi , n=296 inclusions at 36 hpi , and n=269 inclusions at 48 hpi. For cells infected with <italic>cdu1</italic>::GII (sum across 3 replicates) n=296 inclusions at 24 hpi, n=121 inclusions at 36 hpi, and n=254 at 48 hpi. For cells infected with <italic>ctl0480</italic>::GII (sum across 3 replicates) n=252 inclusions at 24 hpi , n=214 inclusions at 36 hpi , and n=239 inclusions at 48 hpi.</p><p><supplementary-material id="fig3s1sdata1"><label>Figure 3—figure supplement 1—source data 1.</label><caption><title>Excel files with numerical data for quantifying CTL0480 localization to WT and <italic>cdu1</italic>::GII inclusions.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-87386-fig3-figsupp1-data1-v2.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-87386-fig3-figsupp1-v2.tif"/></fig></fig-group></sec><sec id="s2-4"><title>The acetylase activity of Cdu1 is required for Cdu1 to protect itself, InaC, and IpaM from polyubiquitination and proteasomal degradation</title><p>The crystal structures of Cdu1 bound to Ub or Coenzyme A indicated that the adenosine and phosphate groups of Coenzyme A make contact with a helix in variable region 3 (VR-3) of Cdu1 while the Ile36-patch of Ub binds to the opposite face of the same helix (<xref ref-type="bibr" rid="bib65">Pruneda et al., 2018</xref>). Although Cdu1 catalyzes both of its DUB and acetylase (Act) activities with the same active site (<xref ref-type="bibr" rid="bib65">Pruneda et al., 2018</xref>) the two activities of Cdu1 can be uncoupled by the amino acid substitution K268E in VR-3 which disrupts Coenzyme A binding required for Act activity and by the amino acid substitution I225A in the Ub-binding region of VR-3 required for DUB activity (<xref ref-type="bibr" rid="bib65">Pruneda et al., 2018</xref>). These substitutions allowed us to test which of Cdu1’s enzymatic functions are required for the observed effects on protein stability. We generated Ct shuttle plasmids, expressing WT Cdu1, a catalytically inactive variant of Cdu1 lacking both DUB and Act activities (Cdu1<sup>C345A</sup>; <xref ref-type="bibr" rid="bib65">Pruneda et al., 2018</xref>), a Cdu1 DUB-deficient variant (Cdu1<sup>I225A</sup>), and a Cdu1 Act-deficient variant (Cdu1<sup>K268E</sup>). All Cdu1 constructs were expressed from the <italic>cdu1</italic> endogenous promoter as 3 X Flag epitope-tagged proteins.</p><p>Plasmids expressing each Cdu1 variant were transformed into the <italic>cdu</italic>1::GII mutant and the resulting strains used to infect HeLa cells for 36 and 48 hr. The levels of endogenous InaC and IpaM in cell extracts of infected cells were monitored by western blot analysis. At 36 hpi, InaC protein levels drastically decreased in cells infected with <italic>cdu1</italic> null strains transformed with empty vector or expressing the catalytic inactive variant of Cdu1 (Cdu1<sup>C345A</sup>-Flag; <xref ref-type="fig" rid="fig4">Figure 4A</xref>). Likewise, IpaM protein levels diminished at 48 hpi during infection with the same strains (<xref ref-type="fig" rid="fig4">Figure 4B</xref>). Both InaC and IpaM protein levels were restored to wild type levels in <italic>cdu1</italic> null strains complemented with wild type Cdu1-Flag (<xref ref-type="fig" rid="fig4">Figure 4A and B</xref>). Unexpectedly, cells infected with a <italic>cdu1</italic> null strain ectopically expressing the DUB-deficient Cdu1 variant (Cdu1<sup>I225A</sup>-Flag) displayed wild type levels of InaC and IpaM while the Act-deficient variant (Cdu1<sup>K268E</sup>-Flag) did not (<xref ref-type="fig" rid="fig4">Figure 4A and B</xref>). These results suggest that the acetylase activity of Cdu1 rather than its DUB activity is required for Cdu1’s ability to stabilize InaC and IpaM proteins.</p><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>The acetylase activity of Cdu1 is required to stabilize Cdu1, InaC, and IpaM.</title><p>(<bold>A</bold>) Western blot analysis of endogenous InaC and Cdu1-Flag catalytic variants expressed from a plasmid (pBOMB). HeLa cells were infected for 36 hr with WT Ct (L2 434 Bu pBOMB), a <italic>cdu1</italic> null strain (<italic>cdu1</italic>::GII pBOMB), and <italic>cdu1</italic> null strains expressing wild type Cdu1-Flag and the Cdu1 variants C345A-Flag (catalytic inactive), I225A-Flag (DUB deficient), and K268E-Flag (Act deficient). Cdu1-Flag variants were expressed from a pBOMB shuttle plasmid. Protein lysates from HeLa cells infected with an <italic>inaC</italic> null (M407) strain were used to control for the specificity of anti-InaC antibodies. Western blot images are representative of two independent experiments. (<bold>B</bold>) Western blot analysis of endogenous IpaM and Cdu1-FLAG variants in crude extracts of HeLa cells infected for 48 hr with the same strains as describe in (<bold>A</bold>). Infection of HeLa cells with <italic>ipaM</italic>::GII was used to test for the specificity of the anti-IpaM antibody. Western blot images are representative of two independent experiments. (<bold>C</bold>) Western blot analysis of Cdu1<sup>C345A</sup>-Flag (catalytic inactive) and Cdu1<sup>K268E</sup>-Flag (Act deficient) expressed in a <italic>cdu1</italic> null strain or WT Ct (L2 434 Bu) background after infection of HeLa cells for 24 hr. Both Cdu1 variants are stabilized by Cdu1 expressed in WT Ct. (<bold>D</bold>) Western blot analysis of Cdu1-Flag and Cdu1<sup>C345A</sup>-Flag expressed in a <italic>cdu1</italic> null strain and Cdu1<sup>C345A</sup>-Flag expressed in WT Ct (L2 434 Bu) following immunoprecipitation (anti-Flag) from HeLa cell extracts after infection for 24 hr and treatment with MG132 (25 μM, 5 hr). Western blot image is a representative blot from at least three independent experiments. (<bold>E</bold>) Western blot analysis of endogenous InaC and IpaM following immunoprecipitation of inclusion membrane enriched subcellular fractions (24hpi) with anti-acetylated lysine antibodies. Western blot image is representative of two independent experiments. (<bold>F</bold>) Western blot analysis (Flag WB) of acetylated lysine immunoprecipitates generated from inclusion membrane enriched subcellular fractions (40 hpi) derived from HeLa cells infected with WT Ct strains expressing Cdu1-Flag, CTL0480-Flag, or IpaM-Flag. Western blot image is representative of two independent experiments. (<bold>G</bold>) WB of acetylated lysine immunoprecipitates of inclusion membrane enriched fractions (24 hpi) of HeLa cells infected with WT Ct and with an <italic>inaC</italic> null strain (M407) expressing InaC-Flag. Western blot image is representative of two independent experiments. (<bold>H</bold>) The initiator methionine, Lys10, Lys126, and Lys263 of Cdu1 are acetylated by 24 hpi. One tyrosine (Y) residue and multiple serine (S) and threonine (T) residues in Cdu1 are also phosphorylated during Ct infection of HeLa cells (24 hpi). Three PX(S/T)P MAPK phosphorylation consensus sequence motifs were identified in the proline rich domain of Cdu1. Modified residues were identified by quantitative LC MS/MS analysis of immunoprecipitated Cdu1-Flag across three independent biological replicates. TMD: Transmembrane domain. PR: Proline rich. PSTP: PX(S/T)P motifs. Ac: Acetylation. P: Phosphorylation. Numbering corresponds to amino acids in Cdu1 protein sequence.</p><p><supplementary-material id="fig4sdata1"><label>Figure 4—source data 1.</label><caption><title>Original western blot scans used to generate <xref ref-type="fig" rid="fig4">Figure 4A</xref> (anti-InaC, anti-Flag, anti-Slc1, and anti-α-tubulin).</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-87386-fig4-data1-v2.zip"/></supplementary-material></p><p><supplementary-material id="fig4sdata2"><label>Figure 4—source data 2.</label><caption><title>Original western blot scans with labeled samples and highlighted bands for <xref ref-type="fig" rid="fig4">Figure 4A</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-87386-fig4-data2-v2.zip"/></supplementary-material></p><p><supplementary-material id="fig4sdata3"><label>Figure 4—source data 3.</label><caption><title>Original western blot scans used to generate <xref ref-type="fig" rid="fig4">Figure 4B</xref> (anti-IpaM, anti-Flag, anti-Slc1, and anti-α-tubulin).</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-87386-fig4-data3-v2.zip"/></supplementary-material></p><p><supplementary-material id="fig4sdata4"><label>Figure 4—source data 4.</label><caption><title>Original western blot scans with labeled samples and highlighted bands for <xref ref-type="fig" rid="fig4">Figure 4B</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-87386-fig4-data4-v2.zip"/></supplementary-material></p><p><supplementary-material id="fig4sdata5"><label>Figure 4—source data 5.</label><caption><title>Original western blot scans used to generate <xref ref-type="fig" rid="fig4">Figure 4C</xref> (anti-Flag, anti-Slc1, and anti-α-tubulin).</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-87386-fig4-data5-v2.zip"/></supplementary-material></p><p><supplementary-material id="fig4sdata6"><label>Figure 4—source data 6.</label><caption><title>Original western blot scans with labeled samples and highlighted bands for <xref ref-type="fig" rid="fig4">Figure 4C</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-87386-fig4-data6-v2.zip"/></supplementary-material></p><p><supplementary-material id="fig4sdata7"><label>Figure 4—source data 7.</label><caption><title>Original western blot scans used to generate <xref ref-type="fig" rid="fig4">Figure 4D</xref> (anti-Flag [input], anti-Slc1 [input], anti-α-tubulin [input], anti-Flag [IP:Flag], and anti-lys48 pUb [IP:Flag]).</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-87386-fig4-data7-v2.zip"/></supplementary-material></p><p><supplementary-material id="fig4sdata8"><label>Figure 4—source data 8.</label><caption><title>Original western blot scans with labeled samples and highlighted bands for <xref ref-type="fig" rid="fig4">Figure 4D</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-87386-fig4-data8-v2.zip"/></supplementary-material></p><p><supplementary-material id="fig4sdata9"><label>Figure 4—source data 9.</label><caption><title>Original western blot scans used to generate <xref ref-type="fig" rid="fig4">Figure 4E</xref> (anti-IncA [input], anti-InaC [input], anti-IpaM [input], anti-InaC [IP:Acetylated lysines], anti-IpaM [IP:Acetylated lysines], and anti-IncA [IP:Acetylated lysines]).</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-87386-fig4-data9-v2.zip"/></supplementary-material></p><p><supplementary-material id="fig4sdata10"><label>Figure 4—source data 10.</label><caption><title>Original western blot scans with labeled samples and highlighted bands for <xref ref-type="fig" rid="fig4">Figure 4E</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-87386-fig4-data10-v2.zip"/></supplementary-material></p><p><supplementary-material id="fig4sdata11"><label>Figure 4—source data 11.</label><caption><title>Original western blot scans used to generate <xref ref-type="fig" rid="fig4">Figure 4F</xref> (anti-IncA [input], anti-Flag [input], and anti-Flag [IP:Acetylated lysines]).</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-87386-fig4-data11-v2.zip"/></supplementary-material></p><p><supplementary-material id="fig4sdata12"><label>Figure 4—source data 12.</label><caption><title>Original western blot scans with labeled samples and highlighted bands for <xref ref-type="fig" rid="fig4">Figure 4F</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-87386-fig4-data12-v2.zip"/></supplementary-material></p><p><supplementary-material id="fig4sdata13"><label>Figure 4—source data 13.</label><caption><title>Original western blot scans used to generate <xref ref-type="fig" rid="fig4">Figure 4G</xref> (anti-IncA [input], anti-Flag [input], and anti-Flag [IP:Acetylated lysines]).</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-87386-fig4-data13-v2.zip"/></supplementary-material></p><p><supplementary-material id="fig4sdata14"><label>Figure 4—source data 14.</label><caption><title>Original western blot scans with labeled samples and highlighted bands for <xref ref-type="fig" rid="fig4">Figure 4G</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-87386-fig4-data14-v2.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-87386-fig4-v2.tif"/></fig><p>When we monitored the stability of each Flag-tagged Cdu1 variant, we observed that the catalytically inactive variant of Cdu1 (C345A-Flag) was destabilized (<xref ref-type="fig" rid="fig4">Figure 4A and B</xref>- Flag WB). We reasoned that Cdu1 also protects itself from being targeted for degradation in infected cells. As with InaC and IpaM, the acetylase but not the DUB activity of Cdu1 was required for Cdu1’s stability (<xref ref-type="fig" rid="fig4">Figure 4A and B</xref>). Although the C345A (DUB-, Act-) and K268E (Act-) amino acid substitutions in Cdu1 do not destabilize Cdu1 expressed in <italic>E. coli</italic> (<xref ref-type="bibr" rid="bib65">Pruneda et al., 2018</xref>), it was possible that these substitutions impacted the expression and/or folding of Cdu1 in <italic>Chlamydia</italic>. To determine if these Cdu1 mutants were inherently unstable, we expressed Cdu1<sup>C345A</sup>-Flag and Cdu1<sup>K268E</sup>-Flag in WT L2 in the presence of endogenous Cdu1. We found that each Flag-tagged variant was stabilized (<xref ref-type="fig" rid="fig4">Figure 4C</xref>), indicating that endogenous Cdu1 protected the catalytically-deficient Cdu1 variants in trans. In addition, western blot analysis of immunoprecipitated Cdu1-Flag and Cdu1<sup>C345A</sup>-Flag expressed in a <italic>cdu1</italic>::GII mutant showed that while WT Cdu1-Flag was not modified by Lys48-linked poly-ubiquitination, Cdu1<sup>C345A</sup>-Flag was robustly modified by Lys48-linked polyUb in the presence of the proteasome inhibitor MG132 (<xref ref-type="fig" rid="fig4">Figure 4D</xref>). Moreover, endogenous Cdu1 protected Cdu1<sup>C345A</sup>-Flag from Lys48-linked polyUb when Cdu1<sup>C345A</sup>-Flag was expressed in a wild type L2 background (<xref ref-type="fig" rid="fig4">Figure 4D</xref>). These results indicate that the loss of Cdu1 activity likely leads to its Lys48-linked poly-ubiquitination and subsequent proteasome-dependent degradation.</p><p>Because Cdu1 autoacetylates itself and its Act activity is directed towards lysines (<xref ref-type="bibr" rid="bib65">Pruneda et al., 2018</xref>) we postulated that Cdu1 may stabilize proteins from degradation by acetylating lysine residues that are potential targets of ubiquitination. We tested this hypothesis by assessing whether Cdu1, InaC, CTL0480, and IpaM are acetylated at lysines during infection. Fractions enriched for inclusion membranes were isolated by sub-cellular fractionation from HeLa cells infected with wild-type L2 (24 hpi), and proteins acetylated at lysines were immunoprecipitated. Western blot analysis of acetyl-lysine immunoprecipitates indicated that InaC and IpaM, but not the Inc protein IncA, were acetylated (<xref ref-type="fig" rid="fig4">Figure 4E</xref>). Western blot analysis of anti-acetyl-lysine immunoprecipitates of inclusion membrane-enriched membrane fractions of HeLa cells infected with L2 expressing Cdu1-Flag (24 hpi), CTL0480-Flag (40 hpi), and IpaM-Flag (40 hpi) also showed that all three Flag tagged effectors were acetylated at lysines (<xref ref-type="fig" rid="fig4">Figure 4F</xref>). We also determined that Flag-tagged InaC expressed in an <italic>inaC</italic> null (M407) background was acetylated at lysines as determined by western blot analysis of anti-acetyl-lysine immunoprecipitates (<xref ref-type="fig" rid="fig4">Figure 4G</xref>). In addition, we identified acetylated forms of Cdu1 from mass spectrometric analysis of Flag immunoprecipitates derived from extracts of HeLa cells infected with L2 expressing Cdu1-Flag, (24 hpi) (<xref ref-type="fig" rid="fig4">Figure 4H</xref>).</p></sec><sec id="s2-5"><title>Cdu1’s acetylase activity shields inclusions from ubiquitination but is not sufficient to protect against IFNγ mediated antimicrobial activity</title><p>We reasoned that the lysine acetylase activity of Cdu1 is a prominent mechanism by which Cdu1 protects client proteins (at 24 hpi), since loss of Cdu1 or expression of the acetylase-deficient variant of Cdu1 (Cdu1<sup>K268E</sup>-Flag) leads to a marked increase in Ub immunostaining at or near the periphery of <italic>cdu1</italic>::GII inclusions (&gt;80% of inclusions) compared to HeLa cells infected with <italic>cdu1</italic>::GII strains complemented with wild type or DUB-deficient (I225A-Flag) Cdu1 strains (<xref ref-type="fig" rid="fig5">Figure 5A and B</xref>, and <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1A</xref>). Given that Cdu1 appears to localize exclusively at inclusion membranes, we predicted that its activity would be spatially restricted to the inclusion periphery. We tested this premise by co-infecting HeLa cells with an <italic>incA</italic> null strain (M923 (IncA<sup>R197*</sup>), <xref ref-type="bibr" rid="bib35">Kokes et al., 2015</xref>) and the <italic>cdu1</italic>::GII strain. IncA mediates homotypic fusion of inclusion membranes and loss of IncA results in the accumulation of multiple unfused inclusions in cells infected at high MOIs (<xref ref-type="bibr" rid="bib24">Hackstadt et al., 1999</xref>; <xref ref-type="bibr" rid="bib78">Suchland et al., 2000</xref>; <xref ref-type="bibr" rid="bib62">Pannekoek et al., 2005</xref>; <xref ref-type="fig" rid="fig5">Figure 5C</xref>). As expected, <italic>incA</italic> mutants which retain Cdu1 activity did not accumulate Ub at or near the periphery of inclusion membranes. In HeLa cells coinfected with both <italic>cdu1</italic>::GII and M923 (IncA<sup>R197*</sup>), <italic>cdu1::GII</italic> Cdu1<sup>C345A</sup> and M923, or <italic>cdu1</italic>::GII Cdu1<sup>K268E</sup> and M923, only the <italic>incA</italic> null inclusions were protected from ubiquitination (<xref ref-type="fig" rid="fig5">Figure 5C and D</xref>, and <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1B</xref>). Based on these observations, we conclude that the acetylase activity of Cdu1 protects proteins in cis and that this activity is constrained to the membrane of the pathogenic vacuole consistent with previous reports (<xref ref-type="bibr" rid="bib5">Auer et al., 2020</xref>).</p><fig-group><fig id="fig5" position="float"><label>Figure 5.</label><caption><title>The DUB activity of Cdu1 is not required for blocking the ubiquitination of inclusion membranes and Cdu1 is not required for protection against IFNγ mediated cellular immunity.</title><p>(<bold>A</bold>) Representative images of Ct inclusions decorated with ubiquitin during infection of HeLa cells with a <italic>cdu1</italic>::GII strain for 24 hr. Representative images of infected HeLa cells used for quantification of ubiquitin decorated inclusions in (<bold>B</bold>) are shown in <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1A</xref>. Antisera against the membrane protein Cap1 (green) was used to mark inclusion membranes. DNA stained with Hoechst is shown in blue. Scale bar: 10 μm. (<bold>B</bold>) Quantification of ubiquitinated inclusions as shown in (<bold>A</bold>). The Ub fluorescent signal was used to determine the number of infected cells with Ub decorated inclusions. The total number of ubiquitinated inclusions was divided by the total number of inclusions analyzed (defined by Cap1 staining). 87%, 86%, and 91% of inclusions were decorated with Ub in HeLa cells infected with a <italic>cdu1</italic> null strain and <italic>cdu1</italic> null strains expressing Cdu1<sup>C345A</sup> (DUB-, Act-), and Cdu1<sup>K268E</sup> (Act-) variants respectively. Representative images (panel (<bold>A</bold>) and <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1A</xref>) and quantification of ubiquitinated inclusions were obtained from inclusions imaged in 10 fields across 3 independent biological replicates for each strain. p values were determined by a student paired t-test. For cells infected with the strains WT Ct, <italic>cdu1</italic>::GII, and <italic>cdu1</italic>::GII strains expressing WT Cdu1 and the variants C345A, I225A and K268E, n (across 3 replicates) = 262, 1505, 652, 1229, 389, and 1413 respectively. Error bars depict standard deviation.(<bold>C</bold>) Representative images of HeLa cells co-infected with <italic>cdu1</italic>::GII (<italic>cdu1Δ</italic>) and <italic>incA</italic> null (<italic>incA</italic>Δ, M923) strains at 24 hpi. IncA-deficient inclusions do not fuse with other inclusions. In co-infected cells, Cdu1 present on the inclusion membranes of <italic>incAΔ</italic> strains did not block ubiquitination events at or near the inclusion membranes of neighboring <italic>cdu1Δ</italic> strains (mCherry signal from pBOMB4-MCI plasmid). Representative images of HeLa cells infected with strains quantified in (<bold>D</bold>) are shown in <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1B</xref>. DNA stained with Hoechst is shown in blue. Scale bar: 10 μm. (<bold>D</bold>) Quantification of <italic>cdu1Δ</italic> inclusions as shown in (<bold>C</bold>) in which ubiquitination events are observed in regions of <italic>cdu1Δ</italic> inclusion membranes that are in direct apposition to <italic>incAΔ</italic> inclusion membranes (junctions). The total number of <italic>cdu1Δ</italic> inclusions ubiquitinated at inclusion junctions was divided by the total number of inclusions analyzed (Cap1 staining). 66% and 61% of <italic>cdu1Δ</italic> inclusions were decorated with Ub at junctions in HeLa cells co-infected with <italic>incAΔ</italic> and <italic>cdu1Δ</italic> strains or with <italic>incAΔ</italic> and a <italic>cdu1Δ</italic> strain ectopically expressing Cdu1<sup>K268E</sup> (Act-) respectively. Representative images (panel (<bold>C</bold>) and <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1B</xref>) and quantification of <italic>cdu1Δ</italic> inclusions ubiquitinated at junctions are derived from inclusions imaged in six fields across three independent biological replicates for each condition. p values were determined by a student paired t-test. For cells infected with the strains <italic>cdu1</italic>::GII and <italic>incA</italic> null, n (across 3 replicates) = 547 and 420 respectively. For cells co-infected with the <italic>incA</italic> null strain and <italic>cdu1</italic>::GII, or <italic>cdu1</italic>::GII strains expressing WT Cdu1 and the variants C345A, I225A and K268E, n (across 3 replicates) = 234, 188, 165, and 207 respectively. Error bars depict standard deviation. (<bold>E</bold>) Quantification of Ct inclusion production during infection of unprimed and IFNγ-primed (100 U/mL) A549 cells at 24 hours post infection. Inclusions were quantified by high-content imaging analysis. Plot reflects inclusion counts across nine fields of view and three independent biological replicates. Inclusion counts by each strain in unprimed A549 cells were set to 100%. Inclusion counts resulting from <italic>cdu1</italic>::GII and <italic>garD</italic>::GII strains were normalized to corresponding parental Ct inclusion (100%) counts in unprimed cells. p-values were calculated by two-way ANOVA analysis. For unprimed A549 cells infected with strains WT Ct (<italic>garD</italic>::GII parent), <italic>garD</italic>::GII, WT Ct (<italic>cdu1</italic>::GII parent), and <italic>cdu1</italic>::GII, n (across 3 replicates) = 20,212, 15,356, 10,931, and 9,535 respectively. For A549 cells pretreated with 100 U/mL IFNγ and infected with strains WT Ct (<italic>garD</italic>::GII parent), <italic>garD</italic>::GII, WT Ct (<italic>cdu1</italic>::GII parent), and c<italic>du1</italic>::GII, n (across 3 replicates) = 19,082, 1,170, 7,842, and 6,368 respectively. Error bars depict standard deviation. (<bold>F</bold>) Representative images of RNF213 localizing to inclusions of WT Ct, <italic>garD</italic>::GII, and <italic>cdu1</italic>::GII strains during infection of A549 cells primed with IFNγ (100 U/mL). (<bold>G</bold>) Quantification of RNF213 localizing to Ct inclusions during infection of unprimed and IFNγ-primed (100 U/mL) A549 cells at 24 hours post infection. Plot reflects inclusion counts across six fields and three independent biological replicates. For unprimed A549 cells infected with strains WT Ct, <italic>garD</italic>::GII, and <italic>cdu1</italic>::GII, n (across 3 replicates) = 830, 817, and 620 respectively. For A549 cells pretreated with 100 U/mL IFNγ and infected with strains WT Ct, <italic>garD</italic>::GII, and c<italic>du1</italic>::GII, n (across 3 replicates) = 816, 520, and 617 respectively. Error bars depict standard deviation.</p><p><supplementary-material id="fig5sdata1"><label>Figure 5—source data 1.</label><caption><title>Excel file with numerical data for quantifying ubiquitinated inclusions in HeLa cells infected with WT CT and <italic>cdu1</italic>::GII strains, and <italic>cdu1</italic>::GII strains expressing Cdu1 C345A, I225A, and K268E variants (<xref ref-type="fig" rid="fig5">Figure 5B</xref>).</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-87386-fig5-data1-v2.zip"/></supplementary-material></p><p><supplementary-material id="fig5sdata2"><label>Figure 5—source data 2.</label><caption><title>Excel files with numerical data for quantifying the number of ubiquitinated inclusions in HeLa cells infected with <italic>cdu1</italic>::GII and <italic>incA</italic> null strains, and <italic>cdu1</italic>::GII strains expressing Cdu1 variants that are ubiquitinated at inclusion junctions in co-infected HeLa cells (<xref ref-type="fig" rid="fig5">Figure 5D</xref>).</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-87386-fig5-data2-v2.zip"/></supplementary-material></p><p><supplementary-material id="fig5sdata3"><label>Figure 5—source data 3.</label><caption><title>Excel file containing numerical data for quantifying the number of inclusions in IFN-γ-primed A549 cells infected with WT CT, <italic>garD</italic>::GII, and <italic>cdu1</italic>::GII strains (<xref ref-type="fig" rid="fig5">Figure 5E</xref>).</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-87386-fig5-data3-v2.zip"/></supplementary-material></p><p><supplementary-material id="fig5sdata4"><label>Figure 5—source data 4.</label><caption><title>Excel file containing numerical data for quantifying the number of RNF213-positive inclusions in IFN-γ-primed A549 cells infected with WT CT, <italic>garD</italic>::GII, and <italic>cdu1</italic>::GII strains (<xref ref-type="fig" rid="fig5">Figure 5G</xref>).</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-87386-fig5-data4-v2.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-87386-fig5-v2.tif"/></fig><fig id="fig5s1" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 1.</label><caption><title>The Acetylase activity of Cdu1 is the predominant activity of Cdu1 responsible for protecting Ct inclusions from ubiquitination.</title><p>(<bold>A</bold>) Representative images of Ct inclusions (green, Cap1) decorated with Ubiquitin (magenta, FK2 antibody) in HeLa cells infected for 24 hr. Strains used: WT Ct (L2 434 Bu), cdu1::GII pBOMB MCI, <italic>cdu1</italic>::GII pBOMB MCI-Cdu1 Flag, <italic>cdu1</italic>::GII pBOMB MCI-Cdu1<sup>C345A</sup> Flag, <italic>cdu1</italic>::GII pBOMB MCI-Cdu1<sup>I225A</sup> Flag, and <italic>cdu1</italic>::GII pBOMB MCI-Cdu1<sup>K268E</sup> Flag. (<bold>B</bold>) Representative images of HeLa cells co-infected with an <italic>incA</italic> null strain and <italic>cdu1</italic>::GII strains expressing Cdu1 variants for 24 hr. Strains used: <italic>cdu1</italic>::GII pBOMB MCI, <italic>inaC</italic> null (M923), <italic>cdu1</italic>::GII pBOMB MCI-Cdu1 Flag, <italic>cdu1</italic>::GII pBOMB MCI-Cdu1<sup>C345A</sup> Flag, <italic>cdu1</italic>::GII pBOMB MCI-Cdu1<sup>I225A</sup> Flag, and <italic>cdu1</italic>::GII pBOMB MCI-Cdu1<sup>K268E</sup> Flag. DNA stained with Hoechst is shown in blue. Scale bar: 10 μm. MCI = mCherry.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-87386-fig5-figsupp1-v2.tif"/></fig></fig-group><p>Recently, the Ct inclusion membrane protein GarD was identified as a Ct effector that shields Ct from γ-interferon mediated ubiquitination by the IFNγ-inducible human ubiquitin E3 ligase RNF213 (<xref ref-type="bibr" rid="bib84">Walsh et al., 2022</xref>). Because Cdu1 also protects the Ct inclusion from ubiquitination, we tested if Cdu1 also plays a role in protecting Ct from IFNγ-induced cell immunity. A549 cells were pretreated with IFNγ (100 U/mL) and infected with WT Ct, <italic>cdu1</italic>::GII, or <italic>garD</italic>::GII strains. Infections with a <italic>garD</italic>::GII strain led to an approximate 90% decrease in the number of inclusions formed relative to infections with its parental WT Ct strain (<xref ref-type="fig" rid="fig5">Figure 5E</xref>) while infections with a <italic>cdu1</italic>::GII or its parental WT Ct strain showed a modest reduction in inclusion formation (approximately 26% and 12%, respectively) (<xref ref-type="fig" rid="fig5">Figure 5E</xref>). These results suggest that Cdu1 likely does not play a role in protecting Ct from IFNγ-mediated cellular immunity.</p><p>We also tested whether RNF213 localizes to inclusions that lack Cdu1, as observed in IFNγ-primed A549 cells infected with <italic>garD:</italic>:GII strains (<xref ref-type="bibr" rid="bib84">Walsh et al., 2022</xref>). RNF213 did not localize to Ct inclusions when cells were infected with either WT Ct or <italic>cdu1</italic>::GII strains, regardless of whether or not the A549 cells were treated with IFNγ (<xref ref-type="fig" rid="fig5">Figure 5F and G</xref>). In contrast, RNF213 localized to approximately 37% of inclusions in cells infected with <italic>garD</italic>::GII mutants of unprimed A549 cells, and 81% in IFNγ-treated cells (<xref ref-type="fig" rid="fig5">Figure 5F and G</xref>). Based on these results, we conclude that Cdu1 does not play a role in protecting Ct from IFNγ-induced antimicrobial activity.</p></sec><sec id="s2-6"><title>Cdu1 is required for F-actin assembly and Golgi ministack repositioning around the Ct inclusion, and for MYPT1 recruitment to Ct inclusions</title><p>InaC is required for Ct to assemble F-actin scaffolds and to reposition Golgi mini stacks around the periphery of the inclusion membrane (<xref ref-type="bibr" rid="bib35">Kokes et al., 2015</xref>; <xref ref-type="bibr" rid="bib88">Wesolowski et al., 2017</xref>; <xref ref-type="bibr" rid="bib26">Haines et al., 2021</xref>). Because Cdu1 regulates InaC levels, we predicted that <italic>cdu1</italic> mutants would phenocopy <italic>inaC</italic> mutants. We quantified the number of inclusions surrounded by F-actin cages at 40 hpi. In cells infected with WT L2 (parental strain of M407 (<italic>inaC</italic> null), <xref ref-type="bibr" rid="bib59">Nguyen and Valdivia, 2012</xref>; <xref ref-type="bibr" rid="bib35">Kokes et al., 2015</xref>), approximately 25% of inclusions were surrounded by F-actin, consistent with previous observations (<xref ref-type="bibr" rid="bib13">Chin et al., 2012</xref>; <xref ref-type="bibr" rid="bib35">Kokes et al., 2015</xref>; <xref ref-type="fig" rid="fig6">Figure 6A and B</xref>, and <xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1</xref>). The number of inclusions surrounded by F-actin decreased to approximately 7% in cells infected with an <italic>inaC</italic> null strain (M407) and increased to approximately 49% in HeLa cells infected with an <italic>inaC</italic> null strain (M407) complemented with wild type InaC (<xref ref-type="fig" rid="fig6">Figure 6A and B</xref>, and <xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1</xref>). Cells infected with <italic>cdu1</italic>::GII mutants transformed with an empty plasmid or expressing Cdu1<sup>C345A</sup>-Flag (DUB- Act-) and Cdu1<sup>K268E</sup>-Flag (Act-) resulted in approximately 8%, 13%, and 10% of of F-actin positive inclusions respectively (<xref ref-type="fig" rid="fig6">Figure 6A and B</xref>, and <xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1</xref>). In contrast, cells infected with <italic>cdu1</italic>::GII mutants expressing Cdu1-Flag and Cdu1<sup>I225A</sup>-Flag (DUB-) led to a marked increase in F-actin inclusions (approximately 52% and 46%, respectively) (<xref ref-type="fig" rid="fig6">Figure 6A and B</xref>, and <xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1</xref>). From these observations we conclude that the acetylase activity of Cdu1 is required for Ct to promote assembly of F-actin around the Ct inclusion likely through the stabilization of InaC.</p><fig-group><fig id="fig6" position="float"><label>Figure 6.</label><caption><title>Cdu1 is required for assembly of F-actin, Golgi ministack repositioning, and MYPT1 recruitment to the inclusion.</title><p>(<bold>A</bold>) Examples of representative images of F-actin (arrowheads) (green, Alexa Fluor Phalloidin) assembled around the Ct inclusion (magenta, anti Cdu1 and Cap1 staining) in HeLa cells infected for 40 hr. Representative images for each strain analyzed can be found in <xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1</xref>. (<bold>B</bold>) Quantification of Ct inclusion surrounded by F-actin normalized to the total number of inclusions analyzed during infection of HeLa cells at 40 hpi. Quantification of surrounding F-actin were obtained from inclusions imaged in six fields across three independent biological replicates. p values were determined by one-way ANOVAs with a Student-Newman-Keuls post hoc test. Strains used: WT L2 (Rif-R 434 Bu, parent of M407), M407 (<italic>inaC</italic> null strain) p2TK2, M407 p2TK2-InaC, WT L2 (434 Bu) pBOMB, <italic>cdu1</italic>::GII pBOMB, <italic>cdu1</italic>::GII pBOMB-Cdu1 Flag, <italic>cdu1</italic>::GII pBOMB-Cdu1<sup>C345A</sup> Flag, <italic>cdu1</italic>::GII pBOMB-Cdu1<sup>I225A</sup> Flag, and <italic>cdu1</italic>::GII pBOMB-Cdu1<sup>K268E</sup> Flag. For cells infected with the strains WT CT (parent of M407), <italic>inaC</italic> null, <italic>inaC</italic> null + InaC, WT L2, <italic>cdu1</italic>::GII, and <italic>cdu1</italic>::GII strains expressing WT Cdu1 and the variants C345A, I225A and K268E, n (across 3 replicates) = 259, 708, 780, 477, 538, 496, 370, 438, and 472 respectively. Error bars depict standard deviation.(<bold>C</bold>) Sample representative images of Golgi (anti GM130 staining, magenta) around Ct inclusions in HeLa cells infected for 24 hours. Representative images for each strain analyzed can be found in <xref ref-type="fig" rid="fig6s2">Figure 6—figure supplement 2</xref>. (<bold>D</bold>) Quantification of Golgi dispersal around the Ct inclusion during infection of HeLa cells for 24 hpi. The length of Golgi dispersed around each Ct inclusion imaged was measured and normalized to the perimeter length of each inclusion (% Golgi dispersion around the inclusion). Golgi dispersal around Ct inclusions was quantified from inclusions imaged in six fields across three independent biological replicates. p values were determined by a student paired t-test. Strains analyzed were the same ones as mentioned in (<bold>B</bold>). For cells infected with the strains WT CT (parent of M407), <italic>inaC</italic> null, <italic>inaC</italic> null + InaC, WT L2, <italic>cdu1</italic>::GII, and <italic>cdu1</italic>::GII strains expressing WT Cdu1 and the variants C345A, I225A and K268E, n (across 3 replicates) = 351, 187, 147, 169, 198, 284,187, 143, and 130 respectively. Error bars depict standard deviation. (<bold>E</bold>) Representative images of MYPT1 (magenta) at Ct inclusions (green, anti-IncA staining). Arrowheads represent <italic>cdu1</italic> null inclusions with low MYPT1 signal. DNA stained with Hoechst is shown in blue in panels C and E. Scale bar: 10 μm. (<bold>F</bold>) Quantification of MYPT1 at Ct inclusions as shown in (<bold>E</bold>). Representative images in (<bold>E</bold>) and quantification of MYPT1 recruitment in (<bold>F</bold>) were obtained from inclusions imaged in six fields across three independent replicates. Error bars depict standard deviation. p values were determined by a student paired t-test. For cells infected with WT Ct n (across 3 replicates) = 187 inclusions at 36 hpi and n=204 inclusions at 48 hpi. For cells infected with <italic>cdu1</italic>::GII n (across 3 replicates) = 202 inclusions at 36 hpi and n=168 at 48 hpi. For cells infected with <italic>ctl0480</italic>::GII n (across 3 replicates) = 175 inclusions at 36 hpi and n=203 inclusions at 48 hpi.</p><p><supplementary-material id="fig6sdata1"><label>Figure 6—source data 1.</label><caption><title>Excel file containing numerical data for quantifying the number of inclusions surrounded by filamentous actin in HeLa cells infected with WT CT, <italic>inaC</italic> null, <italic>inaC</italic> null complemented with InaC, <italic>cdu1</italic>::GII, and <italic>cdu1</italic>::GII strains expressing Cdu1, Cdu1 C345A, I225A, and K268E variants (<xref ref-type="fig" rid="fig6">Figure 6B</xref>).</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-87386-fig6-data1-v2.zip"/></supplementary-material></p><p><supplementary-material id="fig6sdata2"><label>Figure 6—source data 2.</label><caption><title>Excel files containing numerical data for quantifying the number of inclusions surrounded by dispersed Golgi mini stacks in HeLa cells infected with WT CT, <italic>inaC</italic> null, <italic>inaC</italic> null complemented with InaC, <italic>cdu1</italic>::GII, and <italic>cdu1</italic>::GII strains expressing Cdu1, Cdu1 C345A, I225A, and K268E variants (<xref ref-type="fig" rid="fig6">Figure 6D</xref>).</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-87386-fig6-data2-v2.zip"/></supplementary-material></p><p><supplementary-material id="fig6sdata3"><label>Figure 6—source data 3.</label><caption><title>Excel files with numerical data for quantifying the localization of MYPT1 to WT and <italic>cdu1</italic>::GII inclusions (<xref ref-type="fig" rid="fig6">Figure 6F</xref>).</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-87386-fig6-data3-v2.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-87386-fig6-v2.tif"/></fig><fig id="fig6s1" position="float" specific-use="child-fig"><label>Figure 6—figure supplement 1.</label><caption><title>The DUB activity of Cdu1 is not required for assembly of F-actin around the Ct inclusion.</title><p>Representative images of F-actin (arrowheads) (green, Alexa Fluor Phalloidin) assembled around the Ct inclusion (magenta, antiCdu1 and Cap1 staining) in HeLa cells infected for 40 hr. Strains used: WT L2 (Rif-R 434 Bu, parent of M407), M407 (<italic>inaC</italic> null strain) p2TK2, M407 p2TK2-InaC, WT L2 (434 Bu) pBOMB, <italic>cdu1</italic>::GII pBOMB, <italic>cdu1</italic>::GII pBOMB-Cdu1 Flag, <italic>cdu1</italic>::GII pBOMB-Cdu1<sup>C345A</sup> Flag, <italic>cdu1</italic>::GII pBOMB-Cdu1<sup>I225A</sup> Flag, and <italic>cdu1</italic>::GII pBOMB-Cdu1<sup>K268E</sup> Flag. DNA stained with Hoechst is shown in blue. Scale bar: 10 μm.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-87386-fig6-figsupp1-v2.tif"/></fig><fig id="fig6s2" position="float" specific-use="child-fig"><label>Figure 6—figure supplement 2.</label><caption><title>The DUB activity of Cdu1 is not required for Golgi ministack repositioning around the Ct inclusion.</title><p>Representative images of Golgi (anti-GM130 staining, magenta) around Ct inclusions in HeLa cells infected for 24 hr. Strains used: WT L2 (Rif-R 434 Bu, parent of M407), M407 (<italic>inaC</italic> null strain) p2TK2, M407 p2TK2-InaC, WT L2 (434 Bu) pBOMB, <italic>cdu1</italic>::GII pBOMB, <italic>cdu1</italic>::GII pBOMB-Cdu1 Flag, <italic>cdu1</italic>::GII pBOMB-Cdu1<sup>C345A</sup> Flag, <italic>cdu1</italic>::GII pBOMB-Cdu1<sup>I225A</sup> Flag, and <italic>cdu1</italic>::GII pBOMB-Cdu1<sup>K268E</sup> Flag. DNA stained with Hoechst is shown in blue. Scale bar: 10 μm.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-87386-fig6-figsupp2-v2.tif"/></fig></fig-group><p>We next quantified Golgi dispersal in infected HeLa cells at 24 hpi, a process that is also dependent on InaC (<xref ref-type="bibr" rid="bib35">Kokes et al., 2015</xref>; <xref ref-type="bibr" rid="bib88">Wesolowski et al., 2017</xref>). In HeLa cells infected with an <italic>inaC</italic> null strain (M407) Golgi dispersal was limited to approximately 26% of the Ct inclusion perimeter. In contrast, cells infected with either its parental WT L2 or with an <italic>inaC</italic> null strain (M407) complemented with wild type InaC, the Golgi is dispersed around 45% of the inclusion perimeter (<xref ref-type="fig" rid="fig6">Figure 6C and D</xref>, and <xref ref-type="fig" rid="fig6s2">Figure 6—figure supplement 2</xref>). Similarly, Golgi dispersal around inclusions during infection with WT L2 and in <italic>cdu1</italic>::GII mutants expressing wild type Cdu1-Flag or Cdu1<sup>I225A</sup>-Flag (DUB-) was approximately 43%, 41%, and 43%, respectively (<xref ref-type="fig" rid="fig6">Figure 6C and D</xref>, and <xref ref-type="fig" rid="fig6s2">Figure 6—figure supplement 2</xref>). In HeLa cells infected with <italic>cdu1</italic>::GII and <italic>cdu1</italic>::GII strains expressing Cdu1<sup>C345A</sup>-Flag (DUB- Act-), and Cdu1<sup>K268E</sup>-Flag (Act-), Golgi repositioning was restricted to approximately 24%, 23%, and 23% of inclusion perimeters, respectively (<xref ref-type="fig" rid="fig6">Figure 6C and D</xref>, and <xref ref-type="fig" rid="fig6s2">Figure 6—figure supplement 2</xref>). These results confirm that both InaC and Cdu1 are required for efficient repositioning of the Golgi around the Ct inclusion as previously reported (<xref ref-type="bibr" rid="bib35">Kokes et al., 2015</xref>; <xref ref-type="bibr" rid="bib88">Wesolowski et al., 2017</xref>; <xref ref-type="bibr" rid="bib65">Pruneda et al., 2018</xref>; <xref ref-type="bibr" rid="bib5">Auer et al., 2020</xref>) and that this process is independent of Cdu1’s DUB activity but requires its acetylase activity. Moreover, our results suggest that Cdu1 promotes Golgi repositioning by protecting InaC-mediated redistribution of the Golgi around the Ct inclusion.</p><p>CTL0480 promotes recruitment of the myosin phosphatase subunit MYPT1 to the inclusion membrane where it regulates the extrusion of intact inclusions from host cells (<xref ref-type="bibr" rid="bib49">Lutter et al., 2013</xref>; <xref ref-type="bibr" rid="bib74">Shaw et al., 2018</xref>). Consistent with the gradual loss of CTL0480 from inclusions in cells infected with the <italic>cdu1</italic>::GII strain starting at 36 hpi (<xref ref-type="fig" rid="fig3">Figure 3E</xref> and <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1</xref>) we also observed a complete loss of MYPT1 recruitment to inclusions by 48 hpi (<xref ref-type="fig" rid="fig6">Figure 6E and F</xref>).</p></sec><sec id="s2-7"><title>Cdu1, InaC, IpaM, and CTL0480 are required for optimal extrusion of Ct from host cells</title><p>In the absence of Cdu1, the levels of InaC, CTL0480, and IpaM decreased late in infection (36 hpi and 48 hpi, <xref ref-type="fig" rid="fig3">Figures 3</xref> and <xref ref-type="fig" rid="fig4">4</xref>) suggesting that a prominent role of Cdu1 is to protect these Incs from degradation late in infection. At the end of its developmental cycle, <italic>Chlamydia</italic> exits host cells by promoting cellular lysis or by extrusion of intact inclusions (<xref ref-type="bibr" rid="bib30">Hybiske and Stephens, 2007</xref>). Ct host cell exit by extrusion is an active process requiring a remodeling of the actin cytoskeleton and the function of Inc proteins (<xref ref-type="bibr" rid="bib30">Hybiske and Stephens, 2007</xref>; <xref ref-type="bibr" rid="bib13">Chin et al., 2012</xref>; <xref ref-type="bibr" rid="bib49">Lutter et al., 2013</xref>; <xref ref-type="bibr" rid="bib74">Shaw et al., 2018</xref>; <xref ref-type="bibr" rid="bib60">Nguyen et al., 2018</xref>). CTL0480 recruits MYPT1 (an inhibitor of Myosin II motor complexes) to the inclusion membrane which prevents premature extrusion of Ct inclusions and loss of CTL0480 leads to increased rates of extrusion by Ct from infected HeLa cells (<xref ref-type="bibr" rid="bib49">Lutter et al., 2013</xref>; <xref ref-type="bibr" rid="bib74">Shaw et al., 2018</xref>; <xref ref-type="fig" rid="fig7">Figure 7</xref>). Actin polymerization is also required for Ct extrusion (<xref ref-type="bibr" rid="bib30">Hybiske and Stephens, 2007</xref>; <xref ref-type="bibr" rid="bib13">Chin et al., 2012</xref>) suggesting that InaC dependent recruitment of F-actin to the inclusion may also contribute to optimal Ct extrusion. IpaM localizes to microdomains in the inclusion membrane that are proposed to function as foci for extrusion (<xref ref-type="bibr" rid="bib60">Nguyen et al., 2018</xref>). Based on these observations, we postulated that Cdu1-mediated protection of CTL0480, InaC, and IpaM regulates the extrusion of Ct inclusions. We quantified the number of extrusions released from infected HeLa cells at 52 hpi and observed a 60% reduction in the number of extrusions in HeLa cells infected with the <italic>cdu1</italic>::GII strain relative to cells infected with WT L2 (<xref ref-type="fig" rid="fig7">Figure 7A and B</xref>). Complementation of <italic>cdu1</italic>::GII with either wild type Cdu1-Flag or Cdu1<sup>I225A</sup>-Flag (DUB-) restored extrusion production to near wild type levels. In contrast, HeLa cells infected with <italic>cdu1</italic>::GII mutants expressing Cdu1<sup>K268E</sup>-Flag (Act-), or <italic>inaC</italic> (<italic>inaC</italic>::GII, <xref ref-type="bibr" rid="bib88">Wesolowski et al., 2017</xref>) and <italic>ipaM</italic> (<italic>ipaM</italic>::GII, <xref ref-type="bibr" rid="bib51">Meier et al., 2023</xref>) null strains led to a 42%, 75%, and 58% reduction in extrusion production respectively (<xref ref-type="fig" rid="fig7">Figure 7A and B</xref>). The decrease in the number of extruded inclusions by these strains was not attributed to defects in inclusion biogenesis as they produced a comparable number of inclusions at 48 hpi relative to cells infected with WT L2 (<xref ref-type="fig" rid="fig7s1">Figure 7—figure supplement 1</xref>). Consequently, we infer that InaC, IpaM, and Cdu1 collectively contribute to the promotion of optimal extrusion of Ct inclusions from host cells, with Cdu1 playing a central regulatory role by protecting these effectors from degradation.</p><fig-group><fig id="fig7" position="float"><label>Figure 7.</label><caption><title>Cdu1, InaC, and IpaM are required for optimal extrusion of Ct inclusions from HeLa cells.</title><p>(<bold>A</bold>) Representative images of extrusions isolated from HeLa cell monolayers infected with Ct strains for 52 hr. Scale bar: 200 μm (<bold>B</bold>) Quantification of the number of extruded inclusions produced by infected HeLa cell monolayers. p values were determined by a student paired t-test. (<bold>C</bold>) Quantification of the size of extruded inclusions quantified in (<bold>B</bold>). Extruded inclusions varied in size among cells infected with wild type L2 (average:43 μm), <italic>ipaM</italic> mutants (average: 56 μm) and <italic>cdu1</italic> mutants complemented wild type Cdu1 (average: 52 μm) and Cdu1<sup>I225A</sup> (DUB-) (average: 60 μm). <italic>p</italic> values were determined by one-way ANOVAs with a Student-Newman-Keuls post hoc test. Representative images in (<bold>A</bold>) and quantification of extrusion number in (<bold>B</bold>) and extrusion size in (<bold>C</bold>) are based on images obtained from six fields across three independent biological replicates. For extrusions isolated from Hela cells infected with WT CT, <italic>cdu1</italic>::GII, <italic>inaC</italic>::GII, <italic>ipaM</italic>::GII, <italic>ctl0480</italic>::GII, and <italic>cdu1</italic>::GII strains expressing WT Cdu1 and the variants I225A and K268E, n (across 3 replicates) = 2,580, 1,025, 637, 1,194, 3,726, 2,321, 2,198, and 1,091 respectively. Error bars depict standard deviation.</p><p><supplementary-material id="fig7sdata1"><label>Figure 7—source data 1.</label><caption><title>Excel files containing numerical data for quantifying the number of extrusions produced and the size of extrusions in WT CT, <italic>cdu1</italic>::GII strains, and <italic>cdu1</italic>::GII strains expressing Cdu1, I225A, and K268E variants from infected HeLa cells (<xref ref-type="fig" rid="fig7">Figure 7B and C</xref>).</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-87386-fig7-data1-v2.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-87386-fig7-v2.tif"/></fig><fig id="fig7s1" position="float" specific-use="child-fig"><label>Figure 7—figure supplement 1.</label><caption><title>The number of inclusions and the size of inclusions in <italic>cdu1</italic> null, <italic>inaC</italic> null, <italic>ipaM</italic> null, and <italic>ctl0480</italic> null strains are similar across each strain.</title><p>(<bold>A</bold>) Representative images of inclusions in infected HeLa cell monolayers at 48 hpi. Scale bar: 200 μm (<bold>B</bold>) Quantification of the number of inclusions in infected HeLa cell monolayers. To determine the number of inclusions for the strains WT CT, <italic>cdu1</italic>::GII, <italic>inaC</italic>::GII, <italic>ipaM</italic>::GII, <italic>ctl0480</italic>::GII, and <italic>cdu1</italic>::GII strain expressing WT Cdu1 and the variants I225A and K268E, the respective sample sizes (across 3 replicates) were as follows: 1.2E+06, 1.3E+06, 1.6E +06, 1.4E +06, 1.6E+06, 1.5E+06, 1.4E+06, and 1.2E+06. Error bars depict standard deviation.(<bold>C</bold>) Quantification of inclusion size. To determine the inclusion size for the strains WT CT, <italic>cdu1</italic>::GII, <italic>inaC</italic>::GII, <italic>ipaM</italic>::GII, <italic>ctl0480</italic>::GII, and <italic>cdu1</italic>::GII strain expressing WT Cdu1 and the variants I225A and K268E, the respective sample sizes (across 3 replicates) were as follows: 250, 218, 220, 225, 225, 222, 225, and 269 respectively. Error bars depict standard deviation.</p><p><supplementary-material id="fig7s1sdata1"><label>Figure 7—figure supplement 1—source data 1.</label><caption><title>Excel files with numerical data for quantifying the number of inclusions produced and inclusion size in WT CT, <italic>cdu1</italic>::GII strains, and <italic>cdu1</italic>::GII strains expressing Cdu1, I225A, and K268E variants in infected HeLa cells (panels B and C).</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-87386-fig7-figsupp1-data1-v2.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-87386-fig7-figsupp1-v2.tif"/></fig></fig-group><p>In contrast, infection of HeLa cells with a <italic>ctl0480::GII</italic> mutant strain led to an increase in the number of extruded inclusions as previously observed (<xref ref-type="bibr" rid="bib74">Shaw et al., 2018</xref>; <xref ref-type="fig" rid="fig7">Figure 7A and B</xref>). Therefore, even though the Cdu1-mediated protection of InaC and IpaM is important for the extrusion of inclusions and <italic>cdu1</italic> mutants phenocopy the loss of InaC and IpaM, the phenotypic similarities do not extend to the increased number of extruded inclusions observed in cells infected with the <italic>ctl0480</italic>::GII mutant strain (<xref ref-type="fig" rid="fig7">Figure 7A and B</xref>). We infer from these observations that functions for both InaC and IpaM in the extrusion of inclusions are epistatic to CTL0480. Extruded inclusions produced during infection of HeLa cells also varied in size with an average diameter of 40 μm (<xref ref-type="fig" rid="fig7">Figure 7A and C</xref>). Interestingly, the loss of IpaM and over expression of Cdu1-Flag and Cdu1<sup>I225A</sup>-Flag (DUB-) shifted the size distribution of extrusions toward larger extrusions (<xref ref-type="fig" rid="fig7">Figure 7A and C</xref>) suggesting that Ct regulates the size of extruded inclusions through Cdu1.</p></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>Several <italic>Chlamydia</italic> Inc proteins regulate interactions between the pathogenic vacuole and the host cytoskeleton, organelles, and vesicular trafficking pathways. These Inc proteins also modulate host cell death programs and promote <italic>Chlamydia</italic> exit from host cells (reviewed in <xref ref-type="bibr" rid="bib10">Bugalhão and Mota, 2019</xref>). Given the central roles that Incs play in promoting <italic>Chlamydia</italic> intracellular infection, it is not surprising that they are targeted for inactivation by host cellular defenses. In response, <italic>Chlamydia</italic> has evolved mechanisms to protect Incs. In this study, we show that the acetylase activity of the effector Cdu1 protects itself and three Inc proteins; InaC, IpaM, and CTL0480, from ubiquitination and degradation (<xref ref-type="fig" rid="fig8">Figure 8</xref>). Interestingly, all three Inc proteins play prominent roles in regulating the extrusion of inclusions from host cells (<xref ref-type="fig" rid="fig7">Figure 7</xref>). Observations that the encapsulation of <italic>Chlamydia</italic> within an extruded inclusion enhances survival of <italic>Chlamydia</italic> within macrophages (<xref ref-type="bibr" rid="bib92">Zuck et al., 2017</xref>) together with the broad conservation of extrusion as an exit strategy among <italic>Chlamydia</italic> (<xref ref-type="bibr" rid="bib91">Zuck et al., 2016</xref>) suggests that this mechanism is important for <italic>Chlamydia</italic> pathogenesis. Notably, a <italic>cdu1</italic> mutant strain (<italic>cdu1</italic>:: Tn, <xref ref-type="bibr" rid="bib20">Fischer et al., 2017</xref>) displays reduced bacterial loads in a murine model of upper genital tract infections (<xref ref-type="bibr" rid="bib20">Fischer et al., 2017</xref>). While neither this strain nor our <italic>cdu1</italic>::GII mutant strain shows evident growth impairments during infection of HeLa cells (data not shown), the observed reduction in bacterial load in the absence of Cdu1 in animal models of infection could potentially stem from defects in extrusion production or from perturbations in Cdu1-dependent regulation of extrusion size. Thus, targeting Inc proteins that regulate extrusion for Ub-mediated destruction may be advantageous for the host. For instance, targeting InaC for degradation would limit F-actin dependent extrusions (<xref ref-type="bibr" rid="bib30">Hybiske and Stephens, 2007</xref>; <xref ref-type="bibr" rid="bib13">Chin et al., 2012</xref>) and InaC-dependent microtubule scaffolds around the inclusion (<xref ref-type="bibr" rid="bib88">Wesolowski et al., 2017</xref>; <xref ref-type="bibr" rid="bib26">Haines et al., 2021</xref>). CTL0480 functions as an inhibitor of extrusions through its role in modulating the activity of myosin light chain 2 (MLC<sub>2</sub>) (<xref ref-type="bibr" rid="bib49">Lutter et al., 2013</xref>; <xref ref-type="bibr" rid="bib74">Shaw et al., 2018</xref>). IpaM localizes to specialized microdomains in the inclusion membrane which are also sites of enrichment for over 9 inclusion membrane proteins including Ctl0480 and MrcA, both of which are required for <italic>Chlamydia</italic> extrusion (<xref ref-type="bibr" rid="bib53">Mital et al., 2010</xref>; <xref ref-type="bibr" rid="bib49">Lutter et al., 2013</xref>; <xref ref-type="bibr" rid="bib60">Nguyen et al., 2018</xref>). We also find that the loss of IpaM shifted the size distribution of extrusions towards larger inclusions (<xref ref-type="fig" rid="fig7">Figure 7</xref>). We speculate that heterogeneity in the size of extrusions might facilitate uptake of some extrusions by innate immune cells at infected mucosal sites to promote <italic>Chlamydia</italic> LGV dissemination to distal sites in the genital tract and avoid clearance of <italic>Chlamydia</italic> by other immune cells (<xref ref-type="bibr" rid="bib92">Zuck et al., 2017</xref>).</p><fig id="fig8" position="float"><label>Figure 8.</label><caption><title>A model for acetylation mediated protection of the Inc proteins InaC, IpaM, and Ctl0480 from degradation.</title><p>The cellular Ub machinery targets <italic>C. trachomatis</italic> effectors, including the Inc proteins InaC, IpaM, and CTL0480 for ubiquitination and subsequent protein degradation. <italic>C. trachomatis</italic> counters such defense mechanisms by translocating Cdu1 which protect itself and all three Inc proteins from being targeted for ubiquitination and degradation through its acetylase activity. Cdu1 protects InaC and enables the recruitment of F-actin scaffolds and Golgi ministacks to the inclusion perimeter and CTL0480 to recruit the Myosin II regulator MYPT1. All three inclusion proteins and Cdu1 promote extrusion and dissemination of <italic>C. trachomatis</italic> inclusions late in infection.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-87386-fig8-v2.tif"/><permissions><copyright-statement>© 2024, Bastidas et al</copyright-statement><copyright-year>2024</copyright-year><copyright-holder>Bastidas et al</copyright-holder><license><ali:license_ref>https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p>Figure 8 was created using <ext-link ext-link-type="uri" xlink:href="https://www.biorender.com/">BioRender</ext-link>, and is published under a <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">CC BY-NC-ND 4.0</ext-link> license. Further reproductions must adhere to the terms of this license.</license-p></license></permissions></fig><p>Effectors that modulate the activity of other translocated effectors are referred to as ‘metaeffectors’, a term coined by Kubori and colleagues after observing that the <italic>L. pneumophila</italic> effector LubX which functions as an E3 ligase, ubiquitinates the translocated effector SidH leading to its degradation (<xref ref-type="bibr" rid="bib39">Kubori et al., 2010</xref>). Several other effector-metaeffector interactions have been described in <italic>L. pneumophila</italic>, <italic>Salmonella enterica</italic>, and <italic>Brucella abortus</italic> which regulate the activity of other effectors either directly or indirectly by modifying the same host target or cellular process (<xref ref-type="bibr" rid="bib39">Kubori et al., 2010</xref>; <xref ref-type="bibr" rid="bib58">Neunuebel et al., 2011</xref>; <xref ref-type="bibr" rid="bib32">Jeong et al., 2015</xref>; <xref ref-type="bibr" rid="bib81">Urbanus et al., 2016</xref>; <xref ref-type="bibr" rid="bib77">Smith et al., 2020</xref>; <xref ref-type="bibr" rid="bib31">Iyer and Das, 2021</xref>). In this context, we propose that Cdu1 functions as a metaeffector in Ct to protect multiple effectors. We also observed that Cdu1 interactions with InaC, IpaM, and CTL0480 likely occur independently from each other and that the kinetics of degradation in the absence of Cdu1 varies for each Inc (<xref ref-type="fig" rid="fig3">Figure 3</xref>).</p><p>Our findings indicate that the DUB activity of Cdu1 was not required to protect InaC, IpaM, and CTL0480 from ubiquitination. Instead we find that Cdu1’s lysine acetylase activity is required to protect these Inc proteins and Cdu1 itself from ubiquitination. Indeed, we found that all three Incs and Cdu1 are acetylated at lysines in infected cells. However, we were unable to determine if lysine acetylation in all four proteins was dependent on Cdu1s’ Act activity or if these PTMs are protective. Why the DUB activity of Cdu1 is unable to compensate for loss of its Act activity remains unknown. It is possible that Cdu1, like other DUBs, is regulated by PTMs (<xref ref-type="bibr" rid="bib36">Komander et al., 2009a</xref>). For instance, phosphorylation of human CYLD inhibits its DUB activity towards TRAF2 while phosphorylation of human USP8 inhibits its DUB activity toward EGFR (<xref ref-type="bibr" rid="bib66">Reiley et al., 2005</xref>; <xref ref-type="bibr" rid="bib55">Mizuno et al., 2007</xref>). Mass spectrometry analysis of immunoprecipitated Flag tagged Cdu1 expressed in Ct revealed that Cdu1 is phosphorylated at multiple serine and threonine residues (<xref ref-type="fig" rid="fig4">Figure 4H</xref>) as previously suggested (<xref ref-type="bibr" rid="bib89">Zadora et al., 2019</xref>). We identified three PX(S/T)P MAPK phosphorylation consensus sequence motifs in the proline rich domain (PRD) of Cdu1, suggesting that MAPKs may regulate the DUB activity of Cdu1.</p><p>Cdu1 homologs are found in multiple <italic>Chlamydia</italic> species including <italic>C. trachomatis</italic>, <italic>C. muridarum</italic>, <italic>C. suis</italic>, <italic>C. psitacci</italic>, <italic>C. abortus</italic>, <italic>C. caviae</italic>, and <italic>C. felis</italic> but is notably absent in the genomes of <italic>C. pneumoniae</italic> and <italic>C. pecorum</italic>. The acquisition of a second deubiquitinase paralog (Cdu2) has also occurred in <italic>C. trachomatis</italic>, <italic>C. muridarum</italic>, and <italic>C. suis</italic>. In the genomes of all three species, <italic>cdu2</italic> resides directly adjacent to <italic>cdu1</italic>; an arrangement that presumptively arose from a gene duplication event. Cdu2 is a dedicated ULP with deubiquitinating and deneddylating activities (<xref ref-type="bibr" rid="bib52">Misaghi et al., 2006</xref>; <xref ref-type="bibr" rid="bib64">Pruneda et al., 2016</xref>). New evidence suggest that both paralogues might not be functionally redundant. The crystal structure of Cdu2 has revealed differences in residues involved in substrate recognition between Cdu1 and Cdu2 and that each paralog might recognize polyUb chains differently (<xref ref-type="bibr" rid="bib27">Hausman et al., 2020</xref>). The processivity rates for removal of terminal Ub from polyUb chains also differs between both isopeptidases with Cdu2 exhibiting limited trimming of polyUb as compared to Cdu1 (<xref ref-type="bibr" rid="bib27">Hausman et al., 2020</xref>). Moreover, Cdu2 lacks the proline rich domain found in Cdu1 which might be important for regulation of Cdu1 enzymatic activity. The presence of Cdu2 might also explain the low incidence of human and Ct proteins that were differentially ubiquitinated in the absence of Cdu1 (<xref ref-type="fig" rid="fig1">Figure 1</xref>). Whereas several <italic>Chlamydia</italic> species have acquired either one or two deubiquitinase paralogs, both <italic>C. pneumoniae</italic> and <italic>C. pecorum</italic> have not. Instead, both species have acquired an unrelated deubiquitinase (<italic>Chla</italic>OTU) belonging to the OTU family of proteases (<xref ref-type="bibr" rid="bib50">Makarova et al., 2000</xref>; <xref ref-type="bibr" rid="bib22">Furtado et al., 2013</xref>). Curiously, <italic>Chla</italic>OTU is also found in <italic>C. psitacci</italic>, <italic>C. abortus</italic>, <italic>C. caviae</italic>, and <italic>C. felis</italic> all of which encode only Cdu1 and is absent in <italic>C. trachomatis</italic>, <italic>C. muridarum</italic>, and <italic>C. suis</italic>, all of which encode Cdu1 and Cdu2. It is noteworthy that <italic>Chlamydi</italic>a species have independently acquired deubiquitinases multiple times (Cdu1, Cdu2, <italic>Chla</italic>OTU) and that some of these deubiquitinases have evolved into moonlighting enzymes reflecting the diverse strategies adopted by pathogenic <italic>Chlamydia</italic> as they adapt to their particular niche.</p></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><sec id="s4-1"><title>Key resource table</title><p>See appendix 1.</p></sec><sec id="s4-2"><title>Resource availability</title><sec id="s4-2-1"><title>Materials availability</title><p>All newly generated materials associated with this study will be freely available upon request.</p></sec></sec><sec id="s4-3"><title>Experimental model and subject details</title><sec id="s4-3-1"><title>Cell lines</title><p>Vero (CCL-81; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:CVCL_0030">CVCL_0030</ext-link>), HeLa (CCL-2; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:CVCL_0059">CVCL_0059</ext-link>), HEK293T (CRL-3216; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:CVCL_0063">CVCL_0063</ext-link>), and A549 (CCL-185; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:CVCL_0023">CVCL_0023</ext-link>) cells were purchased from ATCC and cultured in High Glucose Dulbecco’s Modified Eagle’s Medium supplemented with L-glutamine, sodium pyruvate (DMEM; Gibco) and 10% fetal bovine serum (FBS; Sigma-Aldrich). Cells were grown at 37 °C in a 5% CO2 humidified incubator. Vero, HeLa, and HEK293T cells were derived from females while A549 cells were derived from a male. All four cell lines have been authenticated by the Duke Cell Culture and DNA analysis facility and routinely tested for the presence of Mycoplasma.</p></sec><sec id="s4-3-2"><title><italic>Chlamydia</italic> strains and propagation</title><p><italic>Chlamydia</italic> strains used in this study are listed in the Key Resources Table. Ct strains were propagated in Vero cells and harvested by osmotic lysis at 48 hpi. Following lysis extracts were sonicated and bacteria pelleted by centrifugation at 21,000 x <italic>g</italic>. Bacteria were resuspended in SPG storage buffer (75 g/L sucrose, 0.5 g/L KH<sub>4</sub>HPO<sub>4,</sub> 1.2 g/L Na<sub>2</sub>HPO<sub>4</sub>, 0.72 g/L glutamic acid, pH 7.5) and stored as single use aliquots at –80 °C.</p></sec></sec><sec id="s4-4"><title>Method etails</title><sec id="s4-4-1"><title><italic>Chlamydia</italic> infections</title><p><italic>Chlamydia</italic> infections were synchronized by centrifugation (2500 x <italic>g</italic> for 30 min at 10 °C) onto HeLa cell monolayers and incubated for the indicated times. Co-infections were performed by infecting HeLa cell monolayers at a 1:1 ratio using MOIs of 2 for each co-infecting strain.</p></sec><sec id="s4-4-2"><title>Insertional mutagenesis of CTL0247 (<italic>cdu1</italic>)</title><p>Primer sequences for TargeTron mediated mutagenesis of the LGV L2 434 Bu <italic>cdu1</italic> (CTL0247) ORF were designed at the TARGETRONICS, LLC web portal (<ext-link ext-link-type="uri" xlink:href="https://www.targetrons.com/">https://www.targetrons.com/</ext-link>). IBS1/2, EBS1/delta, and EBS2 primers (primer sequences are listed in <xref ref-type="supplementary-material" rid="supp10">Supplementary file 10</xref>) were used in a PCR reaction to generate homing sequences for TargeTron integration between nucleotides 635 and 636 of the <italic>cdu1</italic> ORF using a TargeTron gene knockout system (Sigma-Aldrich; TA0100) according to the manufacturer instructions. Homing sequences were gel purified, digested with HindIII and BsrGI, and ligated into HindIII and BsrGI digested pDFTT3-<italic>aadA</italic> (<xref ref-type="bibr" rid="bib47">Lowden et al., 2015</xref>). Ligations were transformed into <italic>E. coli</italic> DH5α, clones isolated, and <italic>cdu1</italic> redirected pDFTT3-aadA plasmids identified by restriction digest and verified by Sanger sequencing (Eton Bioscience) using a T7-promoter specific primer. The resulting plasmid was transformed into a <italic>C. trachomatis</italic> LGV L2 434 Bu strain and transformants selected with 150 μg/mL spectinomycin and plaque purified as previously described (<xref ref-type="bibr" rid="bib34">Kędzior and Bastidas, 2019</xref>). Insertion of the GII <italic>aadA</italic> intron at the <italic>cdu1</italic> locus was verified by PCR analysis (S. <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref>) using primers that amplify amplicons spanning the <italic>cdu1</italic>::GII 5’ (RBP409 and RBP436) and 3’ (RBP468 and RBP118) junctions, the <italic>cdu1</italic> CDS (RBP409 and RBP118), and the <italic>aadA</italic> CDS (RBP512 and RBP513). Primer sequences are listed in <xref ref-type="supplementary-material" rid="supp10">Supplementary file 10</xref>. Loss of Cdu1 protein was verified by western blot and indirect immunofluorescence analysis (S. <xref ref-type="fig" rid="fig2">Figure 2A and B</xref>).</p></sec><sec id="s4-4-3"><title>Analysis of <italic>cdu1</italic> and <italic>cdu2</italic> transcription by RT-PCR</title><p>Confluent HeLa cell monolayers (2.9x10<sup>6</sup> cells/infection) were infected with wild type L2 434 Bu or L2 <italic>cdu1</italic>::GII <italic>aadA</italic> strains. At 24 hpi, total RNA was isolated with a Qiagen RNeasy kit (Qiagen; 74004) according to the manufacturer instructions. Total RNA was treated twice with DNAse I (NEB; M0303S) and used for cDNA synthesis using a SuperScript IV Reverse Transcriptase kit (Thermo Fisher Scientific; 18090010). cDNAs synthesized with and without reverse transcriptase were used as templates for PCR analysis (S. <xref ref-type="fig" rid="fig2">Figure 2C</xref>) using primers that amplify amplicons spanning the <italic>cdu</italic>1 (CTL0247_F and CTL0247_R) and <italic>cdu2</italic> ORFs (CTL0246_F and CTL0247_R), and the intergenic junction between the <italic>cdu1</italic> and <italic>cdu2</italic> ORFs (CTL0246-0247_F and CTL0246-0247_R). Primer sequences can be found in <xref ref-type="supplementary-material" rid="supp10">Supplementary file 10</xref>.</p></sec><sec id="s4-4-4"><title>TUBE1 based global ubiquitin profiling</title><p>Confluent HeLa cell monolayers (5.04x10<sup>6</sup> cells/infection) were mock infected or separately infected with WT LGV L2 434 Bu or a L2 <italic>cdu1</italic>::GII <italic>aadA</italic> strain at MOIs of 3. At 24 hpi cells were collected and spun down (700 x <italic>g</italic> for 10 min), frozen at –80 °C and shipped on dry ice to LifeSensors (Malvern, PA) for quantitative TUBE1-based Mass Spectrometry Analysis. Cell pellets from three independent biological replicates were sent to LifeSensors for analysis. Cell were subsequently lysed in lysis buffer (50 mM Tris-HCL, pH 7.5, 150 mM NaCl, 2 mM EDTA, 1% NP-40, 10% glycerol, 1% Sodium Deoxycholate) supplemented with a protease inhibitor cocktail, the DUB inhibitor PR-619 (Sigma-Aldrich; SML0430), and the proteasomal inhibitor MG-132 (Sigma-Aldrich; 474791). Lysates were clarified by high-speed centrifugation (14,000 x <italic>g</italic>, 10 min, 4 °C) and supernatants containing 5 mg of protein were equilibrated with magnetic TUBE-1 (LifeSensors; UM401M) and incubated overnight at 4 °C under rotation. TUBEs were isolated with a magnetic stand and washed sequentially with PBST and TUBE wash buffer. Poly-ubiquitinated and associated proteins were eluted with TUBE elution buffer. Eluted supernatants were neutralized with neutralization buffer and loaded onto SDS-gels and run until SDS buffer reached 0.5 cm into the gel. Gels were stained with Coomassie Blue and lanes excised, reduced with TCEP, alkylated with iodoacetamide, and digested with Trypsin (Trypsin Gold, Mass Spectrometry Grade) (Promega; V5280). Tryptic digests were analyzed using a 150 min LC run on a Thermo Scientific Q Exactive HF Orbitrap LC-MS/MS system. MS data was searched against the UniProt human database (UniProt; Proteome ID: UP000005640) and the <italic>Chlamydia trachomatis</italic> L2 434 Bu reference database (NCBI:txid47472) using <ext-link ext-link-type="uri" xlink:href="https://www.maxquant.org">MaxQuant 1.6.2.3</ext-link> (<xref ref-type="bibr" rid="bib15">Cox and Mann, 2018</xref>). Proteins, peptides, and site identification was set to a false discovery rate of 1%. N-terminal acetylation, Met oxidation, and diGly remnant on lysine residues was also identified. All peptides and proteins identified can be found in <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>. The intensities (sum of all peptide MS peak areas for a protein or ubiquitinated peptide) for each protein and ubiquitinated peptide across all three biological replicates were used to determine mean intensities and to calculate <italic>p</italic>-values based on one-way student t-tests. Volcano plots of mean intensities vs. p-values were generated with <ext-link ext-link-type="uri" xlink:href="https://huygens.science.uva.nl/VolcaNoseR/">VolcaNoseR</ext-link> (<xref ref-type="bibr" rid="bib23">Goedhart and Luijsterburg, 2020</xref>) and used to identify significantly enriched proteins and ubiquitinated peptides. Data used to generate each Volcano plot can be found in <xref ref-type="supplementary-material" rid="supp2">Supplementary file 2</xref>. Pathway enrichment analysis was performed with <ext-link ext-link-type="uri" xlink:href="https://metascape.org/gp/index.html#/main/step1">Metascape</ext-link> (<xref ref-type="bibr" rid="bib90">Zhou et al., 2019</xref>) and <ext-link ext-link-type="uri" xlink:href="https://david.ncifcrf.gov/tools.jsp">DAVID bioinformatic resources</ext-link> (<xref ref-type="bibr" rid="bib28">Huang et al., 2009a</xref>; <xref ref-type="bibr" rid="bib29">Huang et al., 2009b</xref>).</p></sec><sec id="s4-4-5"><title>Inhibitors, antibodies, western blots, and densitometry analysis</title><p>MG-132 (25 μM) (Sigma-Aldrich; 474791) was added to infected cell monolayers 5 h prior to extract preparations. Recombinant Cdu1 protein (LGV L2 434 Bu, amino acids 71–401) was generated as previously described (<xref ref-type="bibr" rid="bib65">Pruneda et al., 2018</xref>) and kindly provided by Jonathan Pruneda (Oregon Health and Science University, OR). Recombinant Cdu1 protein was used to generate antibodies in immunized New Zealand White rabbits. Cdu1 antisera was pre-adsorbed with crude cell extracts from HeLa cells infected with a <italic>cdu1</italic>::GII <italic>aadA</italic> strain. Pre-adsorbed antisera was used for western blot analysis at a 1:500 dilution in a solution containing 5% BSA supplemented with crude extracts from HeLa cells infected with a <italic>cdu1</italic>::GII <italic>aadA</italic> strain (0.1 mg/mL total protein). Antibodies, antibody dilutions, and antibody diluents used in this study are listed in <xref ref-type="supplementary-material" rid="supp9">Supplementary file 9</xref>. For western blot analysis, lysates from infected HeLa cell monolayers (2.4x10<sup>6</sup> cells) were prepared by incubating cell monolayers with boiling hot 1% SDS lysis buffer (1% SDS, 100 mM NaCl, 50 mM Tris, pH 7.5). Lysates were collected, briefly sonicated, and total protein concentration measured with a DC Protein Assay Kit (BIO-RAD; 5000111). Eight μg (Slc1 and alpha Tubulin blots) and 25 μg of total protein lysates (all other blots) were loaded onto 4–15% Mini-PROTEAN and TGX Stain Free Protein Gels (Bio-Rad; 4568084), transferred to PVDF membranes (Bio-Rad; 1620177), blocked with 5% Milk/TBSt, and incubated with primary antibodies overnight at 4 °C. Protein signals were detected with Goat anti mouse (H+L) IgG (Thermo Fisher Scientific; 31430) or Goat anti-rabbit (H+L) IgG HRP (Thermo Fisher Scientific; 31460) conjugated secondary antibodies (1:1000 in 5% Milk/TBSt) and SuperSignal West Femto HRP substrate (ThermoFisher scientific; 34096). Antibody-bound membranes were imaged with a LI-COR Odyssey Fc Imager (LI-COR, Inc). Varying amounts of protein extracts were used to determine the linear range of detection for InaC, IpaM, and Slc1 antibodies prior to quantification of western blot images (data not shown). Protein bands were quantified using western blot densitometry analysis with LI-COR Image Studio Software (LI-COR, Inc). InaC and IpaM densitometry measurments were normalized to corresponding Slc1 densitometry measurments.</p></sec><sec id="s4-4-6"><title>Immunofluorescence microscopy</title><p>HeLa cells were grown on coverslips to 50% confluency (0.1x10<sup>5</sup> cells) and infected at MOIs of 0.6. At indicated times, infected cells were separately fixed with ice cold Methanol or with warm PBS containing 4% formaldehyde for 20 min. After fixative removal, cells were washed with PBS and formaldehyde fixed cells were incubated either in 5% BSA/PBS supplemented with 0.1% Triton X-100 or in 5% BSA/PBS supplemented with 0.05% Saponin for 30 min with gentle rocking. Following washing with PBS, Methanol fixed cells were incubated with primary antibodies diluted in 5% BSA/PBS and formaldehyde fixed cells were incubated with primary antibodies diluted in 5% BSA/PBS supplemented with 0.1% Triton X-100 or 0.05% Saponin for 1 hr with gentle rocking. Dilutions for each antibody used can be found in <xref ref-type="supplementary-material" rid="supp9">Supplementary file 9</xref>. Methanol fixed cells were washed with PBS and incubated with secondary antibodies diluted in 5% BSA/PBS and supplemented with Hoechst 33342 (2 μg/mL) (Thermo Fisher Scientific; H3570). Formaldehyde fixed cells were washed and incubated with 5% BSA/PBS supplemented with 0.1% Triton X-100 and Hoechst or 0.05% Saponin and Hoechst for 1 hr protected from light and with gentle rocking. For detection of F-actin, Phalloidin conjugated to Alexa Fluor 488 (1:5000) (Act-Stain 488 Phalloidin; Cytoskeleton Inc; PHDG1) was added for the last 20 min of incubation with the secondary antibodies. Coverslips were transferred to glass slides, mounted with 10 μL of Vectashield (Vector Labs; H-1000) and incubated over night at room temperature prior to imaging. Secondary antibodies used were goat anti-mouse (H+L) IgG (Thermo Fisher Scientific; A-11001 and A-21235) and goat anti-rabbit (H+L) IgG (Thermo Fisher Scientific; A-11008 and A-21244) conjugated to Alexa Fluor 488 and Alexa Fluor 647. All the antibodies used for indirect immunofluorescence analysis were analyzed under all three staining conditions (Methanol, Formaldehyde/Triton X-100, and Formaldehyde/Saponin).</p><p>Quantitative immunofluorescent microscopy for RNF213 was performed as previously described (<xref ref-type="bibr" rid="bib84">Walsh et al., 2022</xref>). Briefly, A549 cells were grown on coverslips in 24-well plates to full confluency (~2 x 10<sup>5</sup> cells). Cells were infected with indicated <italic>C. trachomatis</italic> strains at an MOI of 2. At 3 hr post-infection, all cells were given fresh DMEM supplemented with L-tryptophan (100 µg/mL) with half of the wells given interferon-gamma (100 U/mL; Millipore, IF005). At 24 hr post-infection, cells were fixed with cold, 4% PFA in PBS for 20 min. Cells were permeabilized with ice-cold methanol for 1 min and blocked in PBS containing 5% BSA and 2.2% glycine for 30 min. Antibody incubations and microscope slide mounting was performed as described. Samples were blinded using tape and imaged on a Zeiss Axio Observer.Z1 epifluorescent microscope. For each sample, at least 6 separate fields of view and 100 <italic>Chlamydia</italic> inclusions were captured, saved and further blinded using the <ext-link ext-link-type="uri" xlink:href="https://imagej.net/plugins/blind-analysis-tools">ImageJ Blind Analysis Tool plugin</ext-link>. Quantification of the number of inclusions with RNF213 targeted to the inclusion membrane was performed using ImageJ (<xref ref-type="bibr" rid="bib72">Schneider et al., 2012</xref>). Targeted inclusions were scored as having the indicated protein signal colocalize with &gt;50% of the inclusion membrane signal (incA-positive antibody staining).</p><p>Representative images were acquired with an inverted confocal laser scanning microscope (Zeiss 880) equipped with an Airyscan detector (Hamamatsu) and with diode (405 nm), argon ion (488 nm), double solid-state (561 nm), and helium-neon (633) lasers. Images were acquired with a 63 x C-Apochromatic NA 1.2 oil-objective (Zeiss). Images acquired in Airyscan mode were deconvoluted using automatic Airyscan processing in Zen software (Zeiss). Image acquisition was performed at the Light Microscopy Core Facility at Duke University. Images used for quantification were captured in an inverted microscope (Ti2-Nikon instruments) equipped with an ORCA Flash 4.0 V3 sCMOS camera (Hamamatsu) and a SOLA solid-state white light illuminator (Lumencro). Images were acquired using a 60 x Plan Apochromatic NA 1.40 oil objective. All images were opened with ImageJ (<xref ref-type="bibr" rid="bib72">Schneider et al., 2012</xref>) and only linear adjustments were made to fluorescence intensity for the entire image. Images were exported as TIFFs and compiled with Adobe suite software (Illustrator).</p></sec><sec id="s4-4-7"><title>Vector construction and <italic>C. trachomatis</italic> transformation</title><sec id="s4-4-7-1"><title>Constructs used in co-transfection experiments</title><p>Mammalian vectors expressing Cdu1-GFP constructs were kindly provided by Jonathan Pruneda (Oregon Health and Science University, OR). Briefly, geneblocks encoding full length Cdu1 (LGV L2 434 Bu, CTL0247) (amino acids 1–401), Cdu1 lacking its transmembrane domain (amino acids 71–401), and Cdu1 lacking its catalytic domain (amino acids 1–130) were generated and inserted into the pOPIN-GFP vector <xref ref-type="bibr" rid="bib8">Berrow et al., 2007</xref> by In-Fusion cloning (Takara Bio; 638947), resulting in Cdu1 constructs with a C-terminal eGFP-His tag preceded by a 3 C protease cleavage site. The Flag-InaC mammalian expression vector was derived from a Gateway entry clone containing the <italic>C. trachomatis</italic> Serovar D/UW-3/CX CT813 (<italic>inaC</italic>) ORF (amino acids 41–264) obtained from a <italic>C. trachomatis</italic> ORFeome library (<xref ref-type="bibr" rid="bib67">Roan et al., 2006</xref>). The entry vector was used as a donor plasmid for Gateway based transfer into a modified pcDNA DEST53 (Thermo Fisher Scientific; 12288015) vector in which the cycle 3 <italic>GFP</italic> ORF was removed. A NEB Q5-Site Directed Mutagenesis Kit (New England Biolabs; E0554S) was used to introduce a 3 X Flag epitope tag at the N-terminus of the CT813 ORF and a stop codon at the end of the CT813 ORF. L2 <italic>ipaM</italic> (CTL0476), L2 CTL0480, and L2 <italic>cpoS</italic> (CTL0481) ORFs were PCR amplified from cell lysates derived from Vero cells infected with wild type L2 LGV 434 Bu with primers containing attB sequences (primers <italic>ipaM</italic> forward, <italic>ipaM</italic> reverse, CTL0480 forward, CTL0480 reverse, <italic>cpoS</italic> forward, and <italic>cpoS</italic> reverse). Primer sequences can be found in <xref ref-type="supplementary-material" rid="supp10">Supplementary file 10</xref>. PCR amplicons were used as donors for Gateway BP Clonase based transfers into the donor vector pDONR221 (ThermoFisher Scientific; 12536017) to generate entry plasmids. Entry plasmids were used to transfer <italic>ipaM</italic>, CTL0480, and <italic>cpoS</italic> into the Gateway destination vector pcDNA3.1/nV5-DEST (ThermoFisher Scientific; 12290010) by Gateway LR Clonase based reactions. The resulting mammalian expression vectors express IpaM, CTL0480, and CpoS with V5-epitopes fused to their N-terminus.</p></sec><sec id="s4-4-7-2"><title>pBOMB4-MCI-based plasmids</title><p>CTL0480 and <italic>ipaM</italic> ORFs were amplified by PCR from cell extracts derived from Vero cells infected with wild type LGV L2 434 Bu. The CTL0480 ORF, 149 b.p of upstream sequence, and a 3 X FLAG epitope was amplified by PCR using primers RBP628 and RBP629. The CTL0476 (<italic>ipaM</italic>) ORF, 400 b.p of upstream sequence, and a 3 X FLAG epitope was amplified with primers RBP623 and RBP624. CTL0480 and <italic>ipaM</italic> amplicons were digested with Not1 and Pst1 and cloned into Not1 and Pst1 digested pBOMB4-MCI (<xref ref-type="bibr" rid="bib7">Bauler and Hackstadt, 2014</xref>) to generate pBOMB4-MCI_CTL0480-3X Flag and pBOMB4-MCI_IpaM-3X Flag plasmids, respectively. pBOMB4-MCI_Cdu1-3XFlag plasmids were generated by PCR amplification of 175 b.p of genomic sequence directly upstream of the L2 434 Bu CTL0247 (<italic>cdu1</italic>) ORF and the entire <italic>cdu1</italic> ORF tagged with a C-terminal 3 X Flag epitope tag (primers RBP460 and RBP461). PCR amplicons were generated from gradient purified LGV L2 434 Bu EBs and cloned into a pCR-Blunt II TOPO vector using a Zero Blunt TOPO PCR cloning Kit (Thermo Fisher Scientific; K2800J10) according to the manufacturer instructions. Cdu1 catalytic variants were generated with a NEB Q5-Site Directed Mutagenesis Kit (New England Biolabs; E0554S) using the <italic>cdu1</italic>p-<italic>cdu1</italic>-3X Flag construct cloned into pCR-Blunt II TOPO as a template and following the manufacturer instructions. Primers for introducing base pair changes were designed on the <ext-link ext-link-type="uri" xlink:href="https://nebasechanger.neb.com">NEBaseChanger website</ext-link>. The Cdu1<sup>C345A</sup> variant was generated by changing the <italic>TGC</italic> codon located at positions 1033–1035 in the <italic>cdu1</italic> ORF to <italic>GCT</italic> (primers RBP525 and RBP526). The Cdu1<sup>I225A</sup> variant was generated by substituting the <italic>ATC</italic> codon located at positions 673–675 for <italic>GCT</italic> (primers RBP527and RBP528). The Cdu1<sup>K268E</sup> variant was generated by introducing an <italic>A802G</italic> base pair substitution (primers RBP529 and RBP530). Wild type <italic>cdu1</italic>p-<italic>cdu1-</italic>3XFLAG and all three <italic>cdu1</italic> variants were digested with Not1 and Pst1 and ligated into Not1 and Pst1 digested pBOMB4-MCI (<xref ref-type="bibr" rid="bib7">Bauler and Hackstadt, 2014</xref>). Primer sequences can be found in <xref ref-type="supplementary-material" rid="supp10">Supplementary file 10</xref>.</p></sec><sec id="s4-4-7-3"><title>p2TK2_SW2-inaC-3XFlag</title><p>The CTL0184 (<italic>inaC</italic>) ORF and 250 b.p of upstream sequence was amplified by PCR from cell extracts derived from Vero cells infected with L2 434 Bu and cloned into the p2TK2_SW2 vector (<xref ref-type="bibr" rid="bib2">Agaisse and Derré, 2013</xref>). A NEB Q5-Site Directed Mutagenesis Kit (New England Biolabs; E0554S) was used to insert a 3 X FLAG epitope sequence at the C-terminus (stop codon removed) of the CTL0184 ORF to generate the p2TK2_SW2-InaC-3XFlag plasmid.</p><p>pBOMB4-MCI based plasmids and p2TK2_SW2-InaC-3X Flag plasmids were transformed into corresponding <italic>Chlamydia</italic> strains, and transformants were selected with 10 U/mL Penicillin G and plaque purified as previously described (<xref ref-type="bibr" rid="bib34">Kędzior and Bastidas, 2019</xref>). All primer sequences and plasmids generated in this study are listed in <xref ref-type="supplementary-material" rid="supp10">Supplementary file 10</xref> and Key Resources Table.</p></sec></sec></sec><sec id="s4-5"><title>Subcellular fractionation</title><p>HeLa cells (2.16x10<sup>7</sup> cells/strain) seeded in six well plates were mock infected or infected with <italic>Chlamydia</italic> L2 434 Bu strains. At indicated time points, cells were washed with ice-cold PBS, collected in ice-cold PBS with a cell scraper, and transferred to 15 mL conical tubes. Cell suspensions were centrifuged at 500 x <italic>g</italic> for 5 min at 4 °C and cell pellets were resuspended in 400 μL of ice-cold subcellular fractionation buffer (20 mM HEPES (pH 7.4), 10 mM KCl, 2 mM MgCl<sub>2</sub>, 1 mM EDTA, 1 mM EGTA) supplemented with 1 mM DTT and a 1 x cOmplete Mini-EDTA free protease inhibitor cocktail (Sigma-Aldrich; 11836170001). Cells were incubated on ice for 20 min and lysed with 30 strokes of a Dounce homogenizer. Cell lysates were sequentially centrifuged twice at 720 x <italic>g</italic> for 5 min at 4 °C to remove intact nuclei. Supernatants were centrifuged at 10,000 x <italic>g</italic> for 5 min at 4 °C and the heavy membrane (inclusion) fraction was recovered and resuspended in IP lysis buffer (25 mM Tris-Hcl, 150 mM NaCl, 1% NP-40, 5% Glycerol) supplemented with 1 mM PMSF and a 1 x cOmplete Mini-EDTA free protease inhibitor cocktail (Sigma-Aldrich; 11836170001).</p></sec><sec id="s4-6"><title>Immunoprecipitations (IPs)</title><sec id="s4-6-1"><title>Transfections and GFP-immunoprecipitations</title><p>HEK 293T cell monolayers (1.32x10<sup>7</sup> cells/transfection) seeded in 10 cm cell culture dishes pre coated with poly-L-Lysine (Sigma-Aldrich; P4707) were grown to 50% confluency and transfected with 10 μg of each plasmid used per co-transfection in a 1.5–1 ratio of jetOPTIMUS (Polyplus; 101000051) transfection reagent to total plasmid DNA according to the manufacturer instructions. At 24 hpi, transfected cells were lysed in IP lysis buffer (described above) supplemented with 1 mM PMSF and 1 x cOmplete Mini-EDTA free protease inhibitor cocktail (Sigma-Aldrich; 11836170001). Lysates were transferred to Eppendorf tubes, sonicated, and cleared by centrifugation (21,000 x <italic>g</italic>, 15 min, 4 °C). Supernatants containing 2 mg of total protein were incubated with magnetic GFP-Trap agarose (Proteintech; gta) for 1 hr at 4 °C with rotation. Beads were washed according to manufacturer instructions and immunoprecipitated proteins eluted with 2 X Laemmli sample buffer.</p></sec><sec id="s4-6-2"><title>Flag immunoprecipitations</title><p>Mock and infected HeLa cell monolayers (1.44x10<sup>7</sup> cells) grown in six well plates were lysed in IP lysis buffer (described above) and transferred to Eppendorf tubes. Lysates were sonicated and cleared by centrifugation (21,000 x <italic>g</italic>, 15 minutes, 4 °C). Supernatants containing 2 mg of total protein were pre-cleared by incubating with Protein A/G PLUS-Agarose (Santa Cruz Biotechnology; sc-2203) for 30 min at 4 °C followed by sedimentation of agarose resins by centrifugation. Supernatants were incubated with M2-anti Flag mouse mAb (1:400) (Sigma-Aldrich; F1804) overnight at 4 °C with rotation followed by incubation with Protein A/G PLUS-Agarose for 3 hours at 4 °C with rotation. Agarose resins were sedimented and washed according to manufacturer instructions and immunoprecipitated proteins eluted with 50 μL of 100 μg/mL 3xFLAG peptides (APExBIO; A6001).</p></sec><sec id="s4-6-3"><title>Acetylated lysine immunoprecipitations</title><p>Heavy membrane (inclusion) subcellular fractions isolated from infected HeLa cells and containing 1 mg of total protein were pre-cleared by incubating with Protein A/G PLUS-Agarose (Santa Cruz Biotechnology; sc-2203) for 30 min at 4 °C followed by sedimentation of agarose resins by centrifugation. Supernatants were incubated with an anti-acetylated lysine rabbit antibody (Cell signaling; #9441) (1:100) overnight at 4 °C with rotation followed by incubation with Protein A/G PLUS-Agarose for 3 hr at 4 °C with rotation. Agarose resins were sedimented and washed according to manufacturer instructions and immunoprecipitated proteins eluted with 50 μL of 2 X Laemmli sample buffer.</p><p>Input (8 μg of total protein for Slc1 and alpha Tubulin blots, and 25 μg for all other blots) and immunoprecipitates (GFP, Flag, proteins acetylated at lysines) were loaded onto 4–15% Mini-PROTEAN and TGX Stain Free Protein Gels (BIO-RAD; 4568084), transferred to PVDF membranes (Bio-Rad; 1620177), blocked with 5% Milk/TBSt, and incubated with primary antibodies overnight at 4 °C. Protein signals were detected with Goat anti-mouse (H+L) IgG (Thermo Fisher scientific; 31430) or Goat anti rabbit (H+L) IgG HRP (Thermo Fisher Scientific; 31460) conjugated secondary antibodies (1:1000 in 5% Milk/TBSt) and SuperSignal West Femto HRP substrate (Thermo Fisher Scientific; 34096). Antibody-bound membranes were imaged with a LI-COR imaging system (LI-COR, Inc).</p></sec></sec><sec id="s4-7"><title>Identification Cdu1 lysine acetylation and phosphorylation sites by LC-MS/MS</title><p>HeLa cell monolayers (8.64x10<sup>7</sup> cells/strain) grown in six well plates were infected with a wild type L2 strain transformed with empty pBOMB4-MCI (<xref ref-type="bibr" rid="bib7">Bauler and Hackstadt, 2014</xref>) plasmid or with a wild type L2 strain transformed with a pBOMB4-MCI_<italic>cdu1</italic>-3X Flag plasmid. At 24 hpi infected cells were lysed and Flag tagged Cdu1 was immunoprecipitated as described above. Flag eluates from 3 independent biological replicates were sent to the Proteomics and Metabolomics Shared Resource Facility at Duke University for quantitative LC-MS/MS analysis. Samples were spiked with undigested casein, reduced with 10 mM dithiothreitol, and alkylated with 20 mM iodoacetamide. Eluates were then supplemented with 1.2% phosphoric acid and S-Trap (Protifi) binding buffer (90% Methanol, 100 mM TEAB). Proteins were trapped on the S-Trap, digested with 20 ng/μL Trypsin (Trypsin Gold, Mass Spectrometry Grade) (Promega; V5280), and eluted with 50 mM TEAB, 0.2% FA, and 50% ACN/0.2% FA. Samples were lyophilized and resuspended in 1% TFA/2% acetonitrile containing 12.5 fmol/μL yeast alcohol dehydrogenase. Quantitative LC/MS/MS was performed using a nanoAcquitiy UPLC system (Waters Corp) coupled to Thermo Scientific Orbitrap Fusion Lumos high-resolution accurate mass tandem mass spectrometer via a nanoelectrospray ionization source. Data was analyzed with Proteome Discoverer 2.3 (Thermo Fisher Scientific.) and MS/MS data searched against the <italic>Chlamydia trachomatis</italic> LGV L2 434 Bu reference database (NCBI:txid47472). Cdu1-Flag MS/MS data was analyzed with Mascot software (Matrix Science) using Trypsin/P specificity for N-terminal acetylation, lysine acetylation, lysine Ub, and S/T/Y phosphorylation identification. Analysis identified multiple acetylated and phosphorylated Cdu1 peptides and no Cdu1 ubiquitinated peptides. Data was viewed in Scaffold with Scaffold PTM (Scaffold Software).</p></sec><sec id="s4-8"><title>Interferon gamma sensitivity assays</title><p>Ct sensitivities to interferon-gamma was assayed as previously described (<xref ref-type="bibr" rid="bib84">Walsh et al., 2022</xref>). Briefly, A549 cells were seeded in black 96-well clear-bottomed plates (Corning). The next day, cells were stimulated with 0 U/mL or 100 U/mL interferon gamma (IFNγ; Millipore, IF005) in DMEM supplemented with L-tryptophan (100 µg/mL). After 20 hr, cells were infected in technical duplicate with indicated <italic>Chlamydia</italic> strains at an MOI of 2. At 24 hr post-infection, plates were fixed with cold 4% PFA in PBS for 20 min. Samples were nuclear stained with Hoechst in PBS for 10 min and sealed using an aluminum adhesive (Thermo Fisher). Inclusions and host cell nuclei were imaged and quantified using the CellInsight CX5 High Content Screening platform (Thermo Fisher; CX51110). Relative bacterial infectivities were calculated as the number of inclusions divided by the total number of host nuclei for each sample. Interferon sensitivity was calculated by normalizing the infectivities of each strain to it’s ‘untreated’ (-IFNγ) control and expressed as a percentage.</p></sec><sec id="s4-9"><title>Isolation and imaging of <italic>Chlamydia</italic> inclusion extrusions</title><p>HeLa cell monolayers (1.2x10<sup>6</sup> cells) were infected with Ct strains at MOIs of 0.8. At 48 hpi, infected monolayers were imaged using an EVOS FL Cell Imaging System (ThermoFisher Scientific) equipped with a 20 x/0.4 NA objective and a CCD camera. Following imaging, growth media was removed, cell monolayers washed with fresh growth media, and monolayers incubated for an additional 4 hr at 37 °C. At 52 hpi growth supernatants were collected and transferred to Eppendorf tubes. Extrusions were enriched by centrifugation (1500 rpm, 5 min) and pellets (not always visible) containing extrusions were resuspended in 30 μL of 4% Formaldehyde/PBS supplemented with Hoechst (2 μg/mL) and 0.2% Trypan Blue Solution (Gibco, 0.4%). Extrusions were analyzed by plating 10 μL drops on a glass side (without coverslips) and immediately imaged using an EVOS FL Cell Imaging System (ThermoFisher Scientific) equipped with a 20 x/0.4 NA objective and a CCD camera. Intact extrusions were identified based on morphology, lacking nuclei, and being impermeable to trypan blue. Images were opened in ImageJ (<xref ref-type="bibr" rid="bib72">Schneider et al., 2012</xref>) and enumeration of inclusions and extrusions was performed manually. The sizes of individual extrusions and inclusions were determined by manually tracing a line around the perimeter of each extrusion and inclusion in ImageJ and measuring perimeter length. All measurements were exported to Microsoft Excel. Data plots and statistical analyses were done with Prism 9 (GraphPad) software. Datasets were analyzed for significance using a paired student t-test.</p></sec><sec id="s4-10"><title>Image analysis</title><p>Line scan profiles of Cdu1 co-localization with inclusion membrane proteins was performed with ImageJ <xref ref-type="bibr" rid="bib72">Schneider et al., 2012</xref> by tracing a line through regions of interest and plotting fluorescent signal intensities with the Plot Profile function. Localization of CTL0480, recruitment of MYPT1, and association of Ub with Ct inclusions was performed manually from maximum projections in ImageJ. Assessment of F-actin recruitment to Ct inclusions was performed manually in ImageJ by projecting four to five sections in order to capture the entire inclusion. Redistribution of Golgi around the Ct inclusion was measured in ImageJ from maximum projections. The perimeters of individual inclusions were manually traced, and lengths measured. The length of dispersed Golgi was measured by tracing and measuring the length of the GM130 signal directly adjacent to each inclusion. Dispersed Golgi length was divided by inclusion perimeter length. All measurements were exported to Microsoft Excel for quantification. Data plots and statistical analyses were done with Prism 9 (GraphPad).</p></sec><sec id="s4-11"><title>Quantification and statistical analysis</title><p>Quantifications were generated from three independent experiments and measurements derived from blinded images. Data plots and statistical analyses were done with Prism 9 (GraphPad) software. Datasets were analyzed for significance using a paired student t-test, one-way ANOVAs with a Student-Newman-Keuls post hoc test, or two-way ANOVAS with a Turkey post hoc test. Data graphs show means and error bars represent standard error. p-values less than 0.05 are defined as statistically significant. The indicated statistical test for each experiment can be found in the figure legends.</p></sec></sec></body><back><sec sec-type="additional-information" id="s5"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Conceptualization, Data curation, Formal analysis, Supervision, Funding acquisition, Validation, Investigation, Visualization, Methodology, Writing - original draft, Project administration, Writing – review and editing</p></fn><fn fn-type="con" id="con2"><p>Investigation, Methodology, Verified generation of the cdu1::GII mutant strain and showed interaction of Cdu1-GFP variants with InaC, IpaM, and CTL0480 in transfected HEK cells</p></fn><fn fn-type="con" id="con3"><p>Investigation, Methodology, Quantified inclusion production and RNF213 localization in unprimed and IFNgamma-primed A549 cells</p></fn><fn fn-type="con" id="con4"><p>Investigation, Methodology, Quantified inclusion production and RNF213 localization in unprimed and IFNgamma-primed A549 cells</p></fn><fn fn-type="con" id="con5"><p>Resources, Generated the cdu1::GII strain</p></fn><fn fn-type="con" id="con6"><p>Resources</p></fn><fn fn-type="con" id="con7"><p>Resources</p></fn><fn fn-type="con" id="con8"><p>Resources</p></fn><fn fn-type="con" id="con9"><p>Conceptualization, Data curation, Supervision, Funding acquisition, Writing – review and editing</p></fn></fn-group></sec><sec sec-type="supplementary-material" id="s6"><title>Additional files</title><supplementary-material id="supp1"><label>Supplementary file 1.</label><caption><title>TUBE1 co-precipitating proteins mass spectrometry data for all biological replicates.</title></caption><media xlink:href="elife-87386-supp1-v2.xlsx" mimetype="application" mime-subtype="xlsx"/></supplementary-material><supplementary-material id="supp2"><label>Supplementary file 2.</label><caption><title>Numerical data used to generate all volcano plots.</title></caption><media xlink:href="elife-87386-supp2-v2.xlsx" mimetype="application" mime-subtype="xlsx"/></supplementary-material><supplementary-material id="supp3"><label>Supplementary file 3.</label><caption><title>Numerical mass spectrometry data used to identify high confidence TUBE1 human co-precipitating proteins.</title></caption><media xlink:href="elife-87386-supp3-v2.xlsx" mimetype="application" mime-subtype="xlsx"/></supplementary-material><supplementary-material id="supp4"><label>Supplementary file 4.</label><caption><title>Numerical data for Gene Ontology (GO) classification of TUBE1 human co-precipitating proteins.</title></caption><media xlink:href="elife-87386-supp4-v2.xlsx" mimetype="application" mime-subtype="xlsx"/></supplementary-material><supplementary-material id="supp5"><label>Supplementary file 5.</label><caption><title>Numerical mass spectrometry data used to identify high confidence TUBE1 <italic>Chlamydia</italic> co-precipitating proteins.</title></caption><media xlink:href="elife-87386-supp5-v2.xlsx" mimetype="application" mime-subtype="xlsx"/></supplementary-material><supplementary-material id="supp6"><label>Supplementary file 6.</label><caption><title>Human ubiquitinated peptides mass spectrometry data.</title></caption><media xlink:href="elife-87386-supp6-v2.xlsx" mimetype="application" mime-subtype="xlsx"/></supplementary-material><supplementary-material id="supp7"><label>Supplementary file 7.</label><caption><title><italic>Chlamydia</italic> ubiquitinated peptides mass spectrometry data.</title></caption><media xlink:href="elife-87386-supp7-v2.xlsx" mimetype="application" mime-subtype="xlsx"/></supplementary-material><supplementary-material id="supp8"><label>Supplementary file 8.</label><caption><title>Numerical mass spectrometry data used tp identify high confidence ubiquitinated proteins.</title></caption><media xlink:href="elife-87386-supp8-v2.xlsx" mimetype="application" mime-subtype="xlsx"/></supplementary-material><supplementary-material id="supp9"><label>Supplementary file 9.</label><caption><title>Antibodies used in this study.</title></caption><media xlink:href="elife-87386-supp9-v2.docx" mimetype="application" mime-subtype="docx"/></supplementary-material><supplementary-material id="supp10"><label>Supplementary file 10.</label><caption><title>Primer sequences used in this study.</title></caption><media xlink:href="elife-87386-supp10-v2.xlsx" mimetype="application" mime-subtype="xlsx"/></supplementary-material><supplementary-material id="mdar"><label>MDAR checklist</label><media xlink:href="elife-87386-mdarchecklist1-v2.pdf" mimetype="application" mime-subtype="pdf"/></supplementary-material></sec><sec sec-type="data-availability" id="s7"><title>Data availability</title><p>Unprocessed (raw) proteomics data received from LifeSensors can be found in Supplementary Table 1. Original data used for microscopy and western blots in this study can be found at <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.17632/xt3nmkm375.1">Mendeley data repository</ext-link>. Source data for each Figure contains numerical data used to generate the figures.</p><p>The following dataset was generated:</p><p><element-citation publication-type="data" specific-use="isSupplementedBy" id="dataset1"><person-group person-group-type="author"><name><surname>Robert</surname><given-names>B</given-names></name><name><surname>Mateusz</surname><given-names>K</given-names></name><name><surname>Robert</surname><given-names>D</given-names></name><name><surname>Stephen</surname><given-names>W</given-names></name><name><surname>Lee</surname><given-names>D</given-names></name><name><surname>Barbara</surname><given-names>S</given-names></name><name><surname>Jonathan</surname><given-names>P</given-names></name><name><surname>Jorn</surname><given-names>C</given-names></name><name><surname>Raphael</surname><given-names>V</given-names></name></person-group><year iso-8601-date="2023">2023</year><data-title>The acetylase activity of Cdu1 regulates bacterial exit from infected cells by protecting Chlamydia effectors from degradation</data-title><source>Mendeley Data</source><pub-id pub-id-type="doi">10.17632/xt3nmkm375.1</pub-id></element-citation></p></sec><ack id="ack"><title>Acknowledgements</title><p>We thank LifeSensors and the Duke Proteomics and Metabolomics Shared Resource Center for their proteomics services. We thank the Duke Light Microscopy Core Facility for microscopy services. We also thank Marcela Kokes for generating the IncA-Flag constructs used in this study. This work was supported by NIH grants GM142486 to JNP, AI103197 to JC, AI140019 to RJB and AI134891 to RHV.</p></ack><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abdelrahman</surname><given-names>YM</given-names></name><name><surname>Belland</surname><given-names>RJ</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>The chlamydial developmental cycle</article-title><source>FEMS Microbiology Reviews</source><volume>29</volume><fpage>949</fpage><lpage>959</lpage><pub-id pub-id-type="doi">10.1016/j.femsre.2005.03.002</pub-id><pub-id pub-id-type="pmid">16043254</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Agaisse</surname><given-names>H</given-names></name><name><surname>Derré</surname><given-names>I</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>A <italic>C. trachomatis</italic> cloning vector and the generation of <italic>C. trachomatis</italic> strains expressing fluorescent proteins under the control of A <italic>C. trachomatis</italic> promoter</article-title><source>PLOS ONE</source><volume>8</volume><elocation-id>e57090</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0057090</pub-id><pub-id pub-id-type="pmid">23441233</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Albrecht</surname><given-names>M</given-names></name><name><surname>Sharma</surname><given-names>CM</given-names></name><name><surname>Reinhardt</surname><given-names>R</given-names></name><name><surname>Vogel</surname><given-names>J</given-names></name><name><surname>Rudel</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Deep sequencing-based discovery of the <italic>Chlamydia trachomatis</italic> transcriptome</article-title><source>Nucleic Acids Research</source><volume>38</volume><fpage>868</fpage><lpage>877</lpage><pub-id pub-id-type="doi">10.1093/nar/gkp1032</pub-id><pub-id pub-id-type="pmid">19923228</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alzhanov</surname><given-names>DT</given-names></name><name><surname>Weeks</surname><given-names>SK</given-names></name><name><surname>Burnett</surname><given-names>JR</given-names></name><name><surname>Rockey</surname><given-names>DD</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Cytokinesis is blocked in mammalian cells transfected with <italic>Chlamydia trachomatis</italic> gene CT223</article-title><source>BMC Microbiology</source><volume>9</volume><elocation-id>2</elocation-id><pub-id pub-id-type="doi">10.1186/1471-2180-9-2</pub-id><pub-id pub-id-type="pmid">19123944</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Auer</surname><given-names>D</given-names></name><name><surname>Hügelschäffer</surname><given-names>SD</given-names></name><name><surname>Fischer</surname><given-names>AB</given-names></name><name><surname>Rudel</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>The chlamydial deubiquitinase Cdu1 supports recruitment of Golgi vesicles to the inclusion</article-title><source>Cellular Microbiology</source><volume>22</volume><elocation-id>e13136</elocation-id><pub-id pub-id-type="doi">10.1111/cmi.13136</pub-id><pub-id pub-id-type="pmid">31677225</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bannantine</surname><given-names>JP</given-names></name><name><surname>Griffiths</surname><given-names>RS</given-names></name><name><surname>Viratyosin</surname><given-names>W</given-names></name><name><surname>Brown</surname><given-names>WJ</given-names></name><name><surname>Rockey</surname><given-names>DD</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>A secondary structure motif predictive of protein localization to the chlamydial inclusion membrane</article-title><source>Cellular Microbiology</source><volume>2</volume><fpage>35</fpage><lpage>47</lpage><pub-id pub-id-type="doi">10.1046/j.1462-5822.2000.00029.x</pub-id><pub-id pub-id-type="pmid">11207561</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bauler</surname><given-names>LD</given-names></name><name><surname>Hackstadt</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Expression and targeting of secreted proteins from <italic>Chlamydia trachomatis</italic></article-title><source>Journal of Bacteriology</source><volume>196</volume><fpage>1325</fpage><lpage>1334</lpage><pub-id pub-id-type="doi">10.1128/JB.01290-13</pub-id><pub-id pub-id-type="pmid">24443531</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Berrow</surname><given-names>NS</given-names></name><name><surname>Alderton</surname><given-names>D</given-names></name><name><surname>Sainsbury</surname><given-names>S</given-names></name><name><surname>Nettleship</surname><given-names>J</given-names></name><name><surname>Assenberg</surname><given-names>R</given-names></name><name><surname>Rahman</surname><given-names>N</given-names></name><name><surname>Stuart</surname><given-names>DI</given-names></name><name><surname>Owens</surname><given-names>RJ</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>A versatile ligation-independent cloning method suitable for high-throughput expression screening applications</article-title><source>Nucleic Acids Research</source><volume>35</volume><elocation-id>e45</elocation-id><pub-id pub-id-type="doi">10.1093/nar/gkm047</pub-id><pub-id pub-id-type="pmid">17317681</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bremm</surname><given-names>A</given-names></name><name><surname>Freund</surname><given-names>SMV</given-names></name><name><surname>Komander</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Lys11-linked ubiquitin chains adopt compact conformations and are preferentially hydrolyzed by the deubiquitinase Cezanne</article-title><source>Nature Structural &amp; Molecular Biology</source><volume>17</volume><fpage>939</fpage><lpage>947</lpage><pub-id pub-id-type="doi">10.1038/nsmb.1873</pub-id><pub-id pub-id-type="pmid">20622874</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bugalhão</surname><given-names>JN</given-names></name><name><surname>Mota</surname><given-names>LJ</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>The multiple functions of the numerous <italic>Chlamydia trachomatis</italic> secreted proteins: the tip of the iceberg</article-title><source>Microbial Cell</source><volume>6</volume><fpage>414</fpage><lpage>449</lpage><pub-id pub-id-type="doi">10.15698/mic2019.09.691</pub-id><pub-id pub-id-type="pmid">31528632</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Catic</surname><given-names>A</given-names></name><name><surname>Misaghi</surname><given-names>S</given-names></name><name><surname>Korbel</surname><given-names>GA</given-names></name><name><surname>Ploegh</surname><given-names>HL</given-names></name><name><surname>Carr</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>ElaD, a Deubiquitinating protease expressed by <italic>E. coli</italic></article-title><source>PLOS ONE</source><volume>2</volume><elocation-id>e381</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0000381</pub-id><pub-id pub-id-type="pmid">17440617</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>C</given-names></name><name><surname>Chen</surname><given-names>D</given-names></name><name><surname>Sharma</surname><given-names>J</given-names></name><name><surname>Cheng</surname><given-names>W</given-names></name><name><surname>Zhong</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>K</given-names></name><name><surname>Jensen</surname><given-names>J</given-names></name><name><surname>Shain</surname><given-names>R</given-names></name><name><surname>Arulanandam</surname><given-names>B</given-names></name><name><surname>Zhong</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>The hypothetical protein CT813 is localized in the <italic>Chlamydia trachomatis</italic> inclusion membrane and is immunogenic in women urogenitally infected with <italic>C. trachomatis</italic></article-title><source>Infection and Immunity</source><volume>74</volume><fpage>4826</fpage><lpage>4840</lpage><pub-id pub-id-type="doi">10.1128/IAI.00081-06</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chin</surname><given-names>E</given-names></name><name><surname>Kirker</surname><given-names>K</given-names></name><name><surname>Zuck</surname><given-names>M</given-names></name><name><surname>James</surname><given-names>G</given-names></name><name><surname>Hybiske</surname><given-names>K</given-names></name><name><surname>Rudel</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Actin recruitment to the Chlamydia inclusion is spatiotemporally regulated by a mechanism that requires host and bacterial factors</article-title><source>PLOS ONE</source><volume>7</volume><elocation-id>e46949</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0046949</pub-id><pub-id pub-id-type="pmid">23071671</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Claessen</surname><given-names>JHL</given-names></name><name><surname>Witte</surname><given-names>MD</given-names></name><name><surname>Yoder</surname><given-names>NC</given-names></name><name><surname>Zhu</surname><given-names>AY</given-names></name><name><surname>Spooner</surname><given-names>E</given-names></name><name><surname>Ploegh</surname><given-names>HL</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Catch-and-release probes applied to semi-intact cells reveal ubiquitin-specific protease expression in <italic>Chlamydia trachomatis</italic> infection</article-title><source>Chembiochem</source><volume>14</volume><fpage>343</fpage><lpage>352</lpage><pub-id pub-id-type="doi">10.1002/cbic.201200701</pub-id><pub-id pub-id-type="pmid">23335262</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="software"><person-group person-group-type="author"><name><surname>Cox</surname><given-names>J</given-names></name><name><surname>Mann</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2018">2018</year><data-title>Maxquant</data-title><version designator="1.6.2.3">1.6.2.3</version><source>Max-Planck-Institute of Biochemistry</source><ext-link ext-link-type="uri" xlink:href="https://maxquant.org/">https://maxquant.org/</ext-link></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Datta</surname><given-names>AB</given-names></name><name><surname>Hura</surname><given-names>GL</given-names></name><name><surname>Wolberger</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>The structure and conformation of Lys63-linked tetraubiquitin</article-title><source>Journal of Molecular Biology</source><volume>392</volume><fpage>1117</fpage><lpage>1124</lpage><pub-id pub-id-type="doi">10.1016/j.jmb.2009.07.090</pub-id><pub-id pub-id-type="pmid">19664638</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dehoux</surname><given-names>P</given-names></name><name><surname>Flores</surname><given-names>R</given-names></name><name><surname>Dauga</surname><given-names>C</given-names></name><name><surname>Zhong</surname><given-names>G</given-names></name><name><surname>Subtil</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Multi-genome identification and characterization of chlamydiae-specific type III secretion substrates: the Inc proteins</article-title><source>BMC Genomics</source><volume>12</volume><elocation-id>109</elocation-id><pub-id pub-id-type="doi">10.1186/1471-2164-12-109</pub-id><pub-id pub-id-type="pmid">21324157</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dumoux</surname><given-names>M</given-names></name><name><surname>Menny</surname><given-names>A</given-names></name><name><surname>Delacour</surname><given-names>D</given-names></name><name><surname>Hayward</surname><given-names>RD</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>A Chlamydia effector recruits CEP170 to reprogram host microtubule organization</article-title><source>Journal of Cell Science</source><volume>128</volume><fpage>3420</fpage><lpage>3434</lpage><pub-id pub-id-type="doi">10.1242/jcs.169318</pub-id><pub-id pub-id-type="pmid">26220855</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eddins</surname><given-names>MJ</given-names></name><name><surname>Varadan</surname><given-names>R</given-names></name><name><surname>Fushman</surname><given-names>D</given-names></name><name><surname>Pickart</surname><given-names>CM</given-names></name><name><surname>Wolberger</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Crystal structure and solution NMR studies of Lys48-linked tetraubiquitin at neutral pH</article-title><source>Journal of Molecular Biology</source><volume>367</volume><fpage>204</fpage><lpage>211</lpage><pub-id pub-id-type="doi">10.1016/j.jmb.2006.12.065</pub-id><pub-id pub-id-type="pmid">17240395</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fischer</surname><given-names>A</given-names></name><name><surname>Harrison</surname><given-names>KS</given-names></name><name><surname>Ramirez</surname><given-names>Y</given-names></name><name><surname>Auer</surname><given-names>D</given-names></name><name><surname>Chowdhury</surname><given-names>SR</given-names></name><name><surname>Prusty</surname><given-names>BK</given-names></name><name><surname>Sauer</surname><given-names>F</given-names></name><name><surname>Dimond</surname><given-names>Z</given-names></name><name><surname>Kisker</surname><given-names>C</given-names></name><name><surname>Hefty</surname><given-names>PS</given-names></name><name><surname>Rudel</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title><italic>Chlamydia trachomatis</italic>-containing vacuole serves as deubiquitination platform to stabilize Mcl-1 and to interfere with host defense</article-title><source>eLife</source><volume>6</volume><elocation-id>e21465</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.21465</pub-id><pub-id pub-id-type="pmid">28347402</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fiskin</surname><given-names>E</given-names></name><name><surname>Bionda</surname><given-names>T</given-names></name><name><surname>Dikic</surname><given-names>I</given-names></name><name><surname>Behrends</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Global analysis of host and bacterial ubiquitinome in response to <italic>Salmonella</italic> typhimurium infection</article-title><source>Molecular Cell</source><volume>62</volume><fpage>967</fpage><lpage>981</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2016.04.015</pub-id><pub-id pub-id-type="pmid">27211868</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Furtado</surname><given-names>AR</given-names></name><name><surname>Essid</surname><given-names>M</given-names></name><name><surname>Perrinet</surname><given-names>S</given-names></name><name><surname>Balañá</surname><given-names>ME</given-names></name><name><surname>Yoder</surname><given-names>N</given-names></name><name><surname>Dehoux</surname><given-names>P</given-names></name><name><surname>Subtil</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>The chlamydial OTU domain-containing protein ChlaOTU is an early type III secretion effector targeting ubiquitin and NDP52</article-title><source>Cellular Microbiology</source><volume>15</volume><fpage>2064</fpage><lpage>2079</lpage><pub-id pub-id-type="doi">10.1111/cmi.12171</pub-id><pub-id pub-id-type="pmid">23869922</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goedhart</surname><given-names>J</given-names></name><name><surname>Luijsterburg</surname><given-names>MS</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>VolcaNoseR is a web app for creating, exploring, labeling and sharing volcano plots</article-title><source>Scientific Reports</source><volume>10</volume><elocation-id>20560</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-020-76603-3</pub-id><pub-id pub-id-type="pmid">33239692</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hackstadt</surname><given-names>T</given-names></name><name><surname>Scidmore-Carlson</surname><given-names>MA</given-names></name><name><surname>Shaw</surname><given-names>EI</given-names></name><name><surname>Fischer</surname><given-names>ER</given-names></name></person-group><year iso-8601-date="1999">1999</year><article-title>The <italic>Chlamydia trachomatis</italic> IncA protein is required for homotypic vesicle fusion</article-title><source>Cellular Microbiology</source><volume>1</volume><fpage>119</fpage><lpage>130</lpage><pub-id pub-id-type="doi">10.1046/j.1462-5822.1999.00012.x</pub-id><pub-id pub-id-type="pmid">11207546</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Haggerty</surname><given-names>CL</given-names></name><name><surname>Gottlieb</surname><given-names>SL</given-names></name><name><surname>Taylor</surname><given-names>BD</given-names></name><name><surname>Low</surname><given-names>N</given-names></name><name><surname>Xu</surname><given-names>F</given-names></name><name><surname>Ness</surname><given-names>RB</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Risk of sequelae after <italic>Chlamydia trachomatis</italic> genital infection in women</article-title><source>The Journal of Infectious Diseases</source><volume>201 Suppl 2</volume><fpage>S134</fpage><lpage>S155</lpage><pub-id pub-id-type="doi">10.1086/652395</pub-id><pub-id pub-id-type="pmid">20470050</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Haines</surname><given-names>A</given-names></name><name><surname>Wesolowski</surname><given-names>J</given-names></name><name><surname>Ryan</surname><given-names>NM</given-names></name><name><surname>Monteiro-Brás</surname><given-names>T</given-names></name><name><surname>Paumet</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Cross talk between ARF1 and RhoA coordinates the formation of cytoskeletal scaffolds during <italic>Chlamydia</italic> infection</article-title><source>mBio</source><volume>12</volume><elocation-id>e0239721</elocation-id><pub-id pub-id-type="doi">10.1128/mBio.02397-21</pub-id><pub-id pub-id-type="pmid">34903051</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hausman</surname><given-names>JM</given-names></name><name><surname>Kenny</surname><given-names>S</given-names></name><name><surname>Iyer</surname><given-names>S</given-names></name><name><surname>Babar</surname><given-names>A</given-names></name><name><surname>Qiu</surname><given-names>J</given-names></name><name><surname>Fu</surname><given-names>J</given-names></name><name><surname>Luo</surname><given-names>ZQ</given-names></name><name><surname>Das</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>The two deubiquitinating enzymes from <italic>Chlamydia trachomatis</italic> have distinct ubiquitin recognition properties</article-title><source>Biochemistry</source><volume>59</volume><fpage>1604</fpage><lpage>1617</lpage><pub-id pub-id-type="doi">10.1021/acs.biochem.9b01107</pub-id><pub-id pub-id-type="pmid">32275137</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>DW</given-names></name><name><surname>Sherman</surname><given-names>BT</given-names></name><name><surname>Lempicki</surname><given-names>RA</given-names></name></person-group><year iso-8601-date="2009">2009a</year><article-title>Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists</article-title><source>Nucleic Acids Research</source><volume>37</volume><fpage>1</fpage><lpage>13</lpage><pub-id pub-id-type="doi">10.1093/nar/gkn923</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>DW</given-names></name><name><surname>Sherman</surname><given-names>BT</given-names></name><name><surname>Lempicki</surname><given-names>RA</given-names></name></person-group><year iso-8601-date="2009">2009b</year><article-title>Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources</article-title><source>Nature Protocols</source><volume>4</volume><fpage>44</fpage><lpage>57</lpage><pub-id pub-id-type="doi">10.1038/nprot.2008.211</pub-id><pub-id pub-id-type="pmid">19131956</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hybiske</surname><given-names>K</given-names></name><name><surname>Stephens</surname><given-names>RS</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Mechanisms of host cell exit by the intracellular bacterium <italic>Chlamydia</italic></article-title><source>PNAS</source><volume>104</volume><fpage>11430</fpage><lpage>11435</lpage><pub-id pub-id-type="doi">10.1073/pnas.0703218104</pub-id><pub-id pub-id-type="pmid">17592133</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Iyer</surname><given-names>S</given-names></name><name><surname>Das</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>The unity of opposites: Strategic interplay between bacterial effectors to regulate cellular homeostasis</article-title><source>The Journal of Biological Chemistry</source><volume>297</volume><elocation-id>101340</elocation-id><pub-id pub-id-type="doi">10.1016/j.jbc.2021.101340</pub-id><pub-id pub-id-type="pmid">34695417</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jeong</surname><given-names>KC</given-names></name><name><surname>Sexton</surname><given-names>JA</given-names></name><name><surname>Vogel</surname><given-names>JP</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Spatiotemporal regulation of a Legionella pneumophila T4SS substrate by the metaeffector SidJ</article-title><source>PLOS Pathogens</source><volume>11</volume><elocation-id>e1004695</elocation-id><pub-id pub-id-type="doi">10.1371/journal.ppat.1004695</pub-id><pub-id pub-id-type="pmid">25774515</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jones</surname><given-names>RM</given-names></name><name><surname>Wu</surname><given-names>H</given-names></name><name><surname>Wentworth</surname><given-names>C</given-names></name><name><surname>Luo</surname><given-names>L</given-names></name><name><surname>Collier-Hyams</surname><given-names>L</given-names></name><name><surname>Neish</surname><given-names>AS</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title><italic>Salmonella</italic> AvrA coordinates suppression of host immune and apoptotic defenses via JNK pathway blockade</article-title><source>Cell Host &amp; Microbe</source><volume>3</volume><fpage>233</fpage><lpage>244</lpage><pub-id pub-id-type="doi">10.1016/j.chom.2008.02.016</pub-id><pub-id pub-id-type="pmid">18407067</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kędzior</surname><given-names>M</given-names></name><name><surname>Bastidas</surname><given-names>RJ</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Forward and reverse genetic analysis of <italic>Chlamydia</italic></article-title><source>Methods in Molecular Biology</source><volume>2042</volume><fpage>185</fpage><lpage>204</lpage><pub-id pub-id-type="doi">10.1007/978-1-4939-9694-0_13</pub-id><pub-id pub-id-type="pmid">31385277</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kokes</surname><given-names>M</given-names></name><name><surname>Dunn</surname><given-names>JD</given-names></name><name><surname>Granek</surname><given-names>JA</given-names></name><name><surname>Nguyen</surname><given-names>BD</given-names></name><name><surname>Barker</surname><given-names>JR</given-names></name><name><surname>Valdivia</surname><given-names>RH</given-names></name><name><surname>Bastidas</surname><given-names>RJ</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Integrating chemical mutagenesis and whole-genome sequencing as a platform for forward and reverse genetic analysis of <italic>Chlamydia</italic></article-title><source>Cell Host &amp; Microbe</source><volume>17</volume><fpage>716</fpage><lpage>725</lpage><pub-id pub-id-type="doi">10.1016/j.chom.2015.03.014</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Komander</surname><given-names>D</given-names></name><name><surname>Clague</surname><given-names>MJ</given-names></name><name><surname>Urbé</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2009">2009a</year><article-title>Breaking the chains: structure and function of the deubiquitinases</article-title><source>Nature Reviews. Molecular Cell Biology</source><volume>10</volume><fpage>550</fpage><lpage>563</lpage><pub-id pub-id-type="doi">10.1038/nrm2731</pub-id><pub-id pub-id-type="pmid">19626045</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Komander</surname><given-names>D</given-names></name><name><surname>Reyes-Turcu</surname><given-names>F</given-names></name><name><surname>Licchesi</surname><given-names>JDF</given-names></name><name><surname>Odenwaelder</surname><given-names>P</given-names></name><name><surname>Wilkinson</surname><given-names>KD</given-names></name><name><surname>Barford</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2009">2009b</year><article-title>Molecular discrimination of structurally equivalent Lys 63-linked and linear polyubiquitin chains</article-title><source>EMBO Reports</source><volume>10</volume><fpage>466</fpage><lpage>473</lpage><pub-id pub-id-type="doi">10.1038/embor.2009.55</pub-id><pub-id pub-id-type="pmid">19373254</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Komander</surname><given-names>D</given-names></name><name><surname>Rape</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>The ubiquitin code</article-title><source>Annual Review of Biochemistry</source><volume>81</volume><fpage>203</fpage><lpage>229</lpage><pub-id pub-id-type="doi">10.1146/annurev-biochem-060310-170328</pub-id><pub-id pub-id-type="pmid">22524316</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kubori</surname><given-names>T</given-names></name><name><surname>Shinzawa</surname><given-names>N</given-names></name><name><surname>Kanuka</surname><given-names>H</given-names></name><name><surname>Nagai</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Legionella metaeffector exploits host proteasome to temporally regulate cognate effector</article-title><source>PLOS Pathogens</source><volume>6</volume><elocation-id>e1001216</elocation-id><pub-id pub-id-type="doi">10.1371/journal.ppat.1001216</pub-id><pub-id pub-id-type="pmid">21151961</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kubori</surname><given-names>T</given-names></name><name><surname>Kitao</surname><given-names>T</given-names></name><name><surname>Nagai</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Emerging insights into bacterial deubiquitinases</article-title><source>Current Opinion in Microbiology</source><volume>47</volume><fpage>14</fpage><lpage>19</lpage><pub-id pub-id-type="doi">10.1016/j.mib.2018.10.001</pub-id><pub-id pub-id-type="pmid">30391778</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kumar</surname><given-names>Y</given-names></name><name><surname>Valdivia</surname><given-names>RH</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Actin and intermediate filaments stabilize the <italic>Chlamydia trachomatis</italic> vacuole by forming dynamic structural scaffolds</article-title><source>Cell Host &amp; Microbe</source><volume>4</volume><fpage>159</fpage><lpage>169</lpage><pub-id pub-id-type="doi">10.1016/j.chom.2008.05.018</pub-id><pub-id pub-id-type="pmid">18692775</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kunz</surname><given-names>TC</given-names></name><name><surname>Götz</surname><given-names>R</given-names></name><name><surname>Sauer</surname><given-names>M</given-names></name><name><surname>Rudel</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Detection of <italic>Chlamydia</italic> developmental forms and secreted effectors by expansion microscopy</article-title><source>Frontiers in Cellular and Infection Microbiology</source><volume>9</volume><elocation-id>276</elocation-id><pub-id pub-id-type="doi">10.3389/fcimb.2019.00276</pub-id><pub-id pub-id-type="pmid">31448242</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Le Negrate</surname><given-names>G</given-names></name><name><surname>Krieg</surname><given-names>A</given-names></name><name><surname>Faustin</surname><given-names>B</given-names></name><name><surname>Loeffler</surname><given-names>M</given-names></name><name><surname>Godzik</surname><given-names>A</given-names></name><name><surname>Krajewski</surname><given-names>S</given-names></name><name><surname>Reed</surname><given-names>JC</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>ChlaDub1 of <italic>Chlamydia trachomatis</italic> suppresses NF-kappaB activation and inhibits IkappaBalpha ubiquitination and degradation</article-title><source>Cellular Microbiology</source><volume>10</volume><fpage>1879</fpage><lpage>1892</lpage><pub-id pub-id-type="doi">10.1111/j.1462-5822.2008.01178.x</pub-id><pub-id pub-id-type="pmid">18503636</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>JK</given-names></name><name><surname>Enciso</surname><given-names>GA</given-names></name><name><surname>Boassa</surname><given-names>D</given-names></name><name><surname>Chander</surname><given-names>CN</given-names></name><name><surname>Lou</surname><given-names>TH</given-names></name><name><surname>Pairawan</surname><given-names>SS</given-names></name><name><surname>Guo</surname><given-names>MC</given-names></name><name><surname>Wan</surname><given-names>FYM</given-names></name><name><surname>Ellisman</surname><given-names>MH</given-names></name><name><surname>Sütterlin</surname><given-names>C</given-names></name><name><surname>Tan</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Replication-dependent size reduction precedes differentiation in <italic>Chlamydia trachomatis</italic></article-title><source>Nature Communications</source><volume>9</volume><elocation-id>45</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-017-02432-0</pub-id><pub-id pub-id-type="pmid">29298975</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>Z</given-names></name><name><surname>Chen</surname><given-names>C</given-names></name><name><surname>Chen</surname><given-names>D</given-names></name><name><surname>Wu</surname><given-names>Y</given-names></name><name><surname>Zhong</surname><given-names>Y</given-names></name><name><surname>Zhong</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Characterization of fifty putative inclusion membrane proteins encoded in the <italic>Chlamydia trachomatis</italic> genome</article-title><source>Infection and Immunity</source><volume>76</volume><fpage>2746</fpage><lpage>2757</lpage><pub-id pub-id-type="doi">10.1128/IAI.00010-08</pub-id><pub-id pub-id-type="pmid">18391011</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Chai</surname><given-names>QY</given-names></name><name><surname>Liu</surname><given-names>CH</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>The ubiquitin system: a critical regulator of innate immunity and pathogen-host interactions</article-title><source>Cellular &amp; Molecular Immunology</source><volume>13</volume><fpage>560</fpage><lpage>576</lpage><pub-id pub-id-type="doi">10.1038/cmi.2016.40</pub-id><pub-id pub-id-type="pmid">27524111</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lowden</surname><given-names>NM</given-names></name><name><surname>Yeruva</surname><given-names>L</given-names></name><name><surname>Johnson</surname><given-names>CM</given-names></name><name><surname>Bowlin</surname><given-names>AK</given-names></name><name><surname>Fisher</surname><given-names>DJ</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Use of aminoglycoside 3’ adenyltransferase as a selection marker for <italic>Chlamydia trachomatis</italic> intron-mutagenesis and in vivo intron stability</article-title><source>BMC Research Notes</source><volume>8</volume><elocation-id>570</elocation-id><pub-id pub-id-type="doi">10.1186/s13104-015-1542-9</pub-id><pub-id pub-id-type="pmid">26471806</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lutter</surname><given-names>EI</given-names></name><name><surname>Martens</surname><given-names>C</given-names></name><name><surname>Hackstadt</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Evolution and conservation of predicted inclusion membrane proteins in chlamydiae</article-title><source>Comparative and Functional Genomics</source><volume>2012</volume><elocation-id>362104</elocation-id><pub-id pub-id-type="doi">10.1155/2012/362104</pub-id><pub-id pub-id-type="pmid">22454599</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lutter</surname><given-names>EI</given-names></name><name><surname>Barger</surname><given-names>AC</given-names></name><name><surname>Nair</surname><given-names>V</given-names></name><name><surname>Hackstadt</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title><italic>Chlamydia trachomatis</italic> inclusion membrane protein CT228 recruits elements of the myosin phosphatase pathway to regulate release mechanisms</article-title><source>Cell Reports</source><volume>3</volume><fpage>1921</fpage><lpage>1931</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2013.04.027</pub-id><pub-id pub-id-type="pmid">23727243</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Makarova</surname><given-names>KS</given-names></name><name><surname>Aravind</surname><given-names>L</given-names></name><name><surname>Koonin</surname><given-names>EV</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>A novel superfamily of predicted cysteine proteases from eukaryotes, viruses and Chlamydia pneumoniae</article-title><source>Trends in Biochemical Sciences</source><volume>25</volume><fpage>50</fpage><lpage>52</lpage><pub-id pub-id-type="doi">10.1016/s0968-0004(99)01530-3</pub-id><pub-id pub-id-type="pmid">10664582</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meier</surname><given-names>K</given-names></name><name><surname>Jachmann</surname><given-names>LH</given-names></name><name><surname>Türköz</surname><given-names>G</given-names></name><name><surname>Babu Sait</surname><given-names>MR</given-names></name><name><surname>Pérez</surname><given-names>L</given-names></name><name><surname>Kepp</surname><given-names>O</given-names></name><name><surname>Valdivia</surname><given-names>RH</given-names></name><name><surname>Kroemer</surname><given-names>G</given-names></name><name><surname>Sixt</surname><given-names>BS</given-names></name><name><surname>Ouellette</surname><given-names>SP</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>The <italic>Chlamydia</italic> effector CpoS modulates the inclusion microenvironment and restricts the interferon response by acting on Rab35</article-title><source>mBio</source><volume>14</volume><elocation-id>e0319022</elocation-id><pub-id pub-id-type="doi">10.1128/mbio.03190-22</pub-id><pub-id pub-id-type="pmid">37530528</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Misaghi</surname><given-names>S</given-names></name><name><surname>Balsara</surname><given-names>ZR</given-names></name><name><surname>Catic</surname><given-names>A</given-names></name><name><surname>Spooner</surname><given-names>E</given-names></name><name><surname>Ploegh</surname><given-names>HL</given-names></name><name><surname>Starnbach</surname><given-names>MN</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title><italic>Chlamydia trachomatis</italic>-derived deubiquitinating enzymes in mammalian cells during infection</article-title><source>Molecular Microbiology</source><volume>61</volume><fpage>142</fpage><lpage>150</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2958.2006.05199.x</pub-id><pub-id pub-id-type="pmid">16824101</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mital</surname><given-names>J</given-names></name><name><surname>Miller</surname><given-names>NJ</given-names></name><name><surname>Fischer</surname><given-names>ER</given-names></name><name><surname>Hackstadt</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Specific chlamydial inclusion membrane proteins associate with active Src family kinases in microdomains that interact with the host microtubule network</article-title><source>Cellular Microbiology</source><volume>12</volume><fpage>1235</fpage><lpage>1249</lpage><pub-id pub-id-type="doi">10.1111/j.1462-5822.2010.01465.x</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mittal</surname><given-names>R</given-names></name><name><surname>Peak-Chew</surname><given-names>SY</given-names></name><name><surname>McMahon</surname><given-names>HT</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Acetylation of MEK2 and I kappa B kinase (IKK) activation loop residues by YopJ inhibits signaling</article-title><source>PNAS</source><volume>103</volume><fpage>18574</fpage><lpage>18579</lpage><pub-id pub-id-type="doi">10.1073/pnas.0608995103</pub-id><pub-id pub-id-type="pmid">17116858</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mizuno</surname><given-names>E</given-names></name><name><surname>Kitamura</surname><given-names>N</given-names></name><name><surname>Komada</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>14-3-3-dependent inhibition of the deubiquitinating activity of UBPY and its cancellation in the M phase</article-title><source>Experimental Cell Research</source><volume>313</volume><fpage>3624</fpage><lpage>3634</lpage><pub-id pub-id-type="doi">10.1016/j.yexcr.2007.07.028</pub-id><pub-id pub-id-type="pmid">17720156</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moulder</surname><given-names>JW</given-names></name></person-group><year iso-8601-date="1991">1991</year><article-title>Interaction of chlamydiae and host cells in vitro</article-title><source>Microbiological Reviews</source><volume>55</volume><fpage>143</fpage><lpage>190</lpage><pub-id pub-id-type="doi">10.1128/mr.55.1.143-190.1991</pub-id><pub-id pub-id-type="pmid">2030670</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mukherjee</surname><given-names>S</given-names></name><name><surname>Keitany</surname><given-names>G</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Ball</surname><given-names>HL</given-names></name><name><surname>Goldsmith</surname><given-names>EJ</given-names></name><name><surname>Orth</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Yersinia YopJ acetylates and inhibits kinase activation by blocking phosphorylation</article-title><source>Science</source><volume>312</volume><fpage>1211</fpage><lpage>1214</lpage><pub-id pub-id-type="doi">10.1126/science.1126867</pub-id><pub-id pub-id-type="pmid">16728640</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Neunuebel</surname><given-names>MR</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Gaspar</surname><given-names>AH</given-names></name><name><surname>Backlund</surname><given-names>PS</given-names></name><name><surname>Yergey</surname><given-names>A</given-names></name><name><surname>Machner</surname><given-names>MP</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>De-AMPylation of the small GTPase Rab1 by the pathogen Legionella pneumophila</article-title><source>Science</source><volume>333</volume><fpage>453</fpage><lpage>456</lpage><pub-id pub-id-type="doi">10.1126/science.1207193</pub-id><pub-id pub-id-type="pmid">21680813</pub-id></element-citation></ref><ref id="bib59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nguyen</surname><given-names>BD</given-names></name><name><surname>Valdivia</surname><given-names>RH</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Virulence determinants in the obligate intracellular pathogen <italic>Chlamydia trachomatis</italic> revealed by forward genetic approaches</article-title><source>PNAS</source><volume>109</volume><fpage>1263</fpage><lpage>1268</lpage><pub-id pub-id-type="doi">10.1073/pnas.1117884109</pub-id><pub-id pub-id-type="pmid">22232666</pub-id></element-citation></ref><ref id="bib60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nguyen</surname><given-names>PH</given-names></name><name><surname>Lutter</surname><given-names>EI</given-names></name><name><surname>Hackstadt</surname><given-names>T</given-names></name><name><surname>Coers</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title><italic>Chlamydia trachomatis</italic> inclusion membrane protein MrcA interacts with the inositol 1,4,5-trisphosphate receptor type 3 (ITPR3) to regulate extrusion formation</article-title><source>PLOS Pathogens</source><volume>14</volume><elocation-id>e1006911</elocation-id><pub-id pub-id-type="doi">10.1371/journal.ppat.1006911</pub-id><pub-id pub-id-type="pmid">29543918</pub-id></element-citation></ref><ref id="bib61"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ohtake</surname><given-names>F</given-names></name><name><surname>Tsuchiya</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>The emerging complexity of ubiquitin architecture</article-title><source>Journal of Biochemistry</source><volume>161</volume><fpage>125</fpage><lpage>133</lpage><pub-id pub-id-type="doi">10.1093/jb/mvw088</pub-id><pub-id pub-id-type="pmid">28011818</pub-id></element-citation></ref><ref id="bib62"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pannekoek</surname><given-names>Y</given-names></name><name><surname>Spaargaren</surname><given-names>J</given-names></name><name><surname>Langerak</surname><given-names>AAJ</given-names></name><name><surname>Merks</surname><given-names>J</given-names></name><name><surname>Morré</surname><given-names>SA</given-names></name><name><surname>van der Ende</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Interrelationship between polymorphisms of incA, fusogenic properties of <italic>Chlamydia trachomatis</italic> strains, and clinical manifestations in patients in The Netherlands</article-title><source>Journal of Clinical Microbiology</source><volume>43</volume><fpage>2441</fpage><lpage>2443</lpage><pub-id pub-id-type="doi">10.1128/JCM.43.5.2441-2443.2005</pub-id><pub-id pub-id-type="pmid">15872278</pub-id></element-citation></ref><ref id="bib63"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peng</surname><given-names>J</given-names></name><name><surname>Schwartz</surname><given-names>D</given-names></name><name><surname>Elias</surname><given-names>JE</given-names></name><name><surname>Thoreen</surname><given-names>CC</given-names></name><name><surname>Cheng</surname><given-names>D</given-names></name><name><surname>Marsischky</surname><given-names>G</given-names></name><name><surname>Roelofs</surname><given-names>J</given-names></name><name><surname>Finley</surname><given-names>D</given-names></name><name><surname>Gygi</surname><given-names>SP</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>A proteomics approach to understanding protein ubiquitination</article-title><source>Nature Biotechnology</source><volume>21</volume><fpage>921</fpage><lpage>926</lpage><pub-id pub-id-type="doi">10.1038/nbt849</pub-id><pub-id pub-id-type="pmid">12872131</pub-id></element-citation></ref><ref id="bib64"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pruneda</surname><given-names>JN</given-names></name><name><surname>Durkin</surname><given-names>CH</given-names></name><name><surname>Geurink</surname><given-names>PP</given-names></name><name><surname>Ovaa</surname><given-names>H</given-names></name><name><surname>Santhanam</surname><given-names>B</given-names></name><name><surname>Holden</surname><given-names>DW</given-names></name><name><surname>Komander</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>The molecular basis for ubiquitin and ubiquitin-like specificities in bacterial effector proteases</article-title><source>Molecular Cell</source><volume>63</volume><fpage>261</fpage><lpage>276</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2016.06.015</pub-id><pub-id pub-id-type="pmid">27425412</pub-id></element-citation></ref><ref id="bib65"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pruneda</surname><given-names>JN</given-names></name><name><surname>Bastidas</surname><given-names>RJ</given-names></name><name><surname>Bertsoulaki</surname><given-names>E</given-names></name><name><surname>Swatek</surname><given-names>KN</given-names></name><name><surname>Santhanam</surname><given-names>B</given-names></name><name><surname>Clague</surname><given-names>MJ</given-names></name><name><surname>Valdivia</surname><given-names>RH</given-names></name><name><surname>Urbé</surname><given-names>S</given-names></name><name><surname>Komander</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>A Chlamydia effector combining deubiquitination and acetylation activities induces Golgi fragmentation</article-title><source>Nature Microbiology</source><volume>3</volume><fpage>1377</fpage><lpage>1384</lpage><pub-id pub-id-type="doi">10.1038/s41564-018-0271-y</pub-id><pub-id pub-id-type="pmid">30397340</pub-id></element-citation></ref><ref id="bib66"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reiley</surname><given-names>W</given-names></name><name><surname>Zhang</surname><given-names>M</given-names></name><name><surname>Wu</surname><given-names>X</given-names></name><name><surname>Granger</surname><given-names>E</given-names></name><name><surname>Sun</surname><given-names>SC</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Regulation of the deubiquitinating enzyme CYLD by IkappaB kinase gamma-dependent phosphorylation</article-title><source>Molecular and Cellular Biology</source><volume>25</volume><fpage>3886</fpage><lpage>3895</lpage><pub-id pub-id-type="doi">10.1128/MCB.25.10.3886-3895.2005</pub-id><pub-id pub-id-type="pmid">15870263</pub-id></element-citation></ref><ref id="bib67"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roan</surname><given-names>NR</given-names></name><name><surname>Gierahn</surname><given-names>TM</given-names></name><name><surname>Higgins</surname><given-names>DE</given-names></name><name><surname>Starnbach</surname><given-names>MN</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Monitoring the T cell response to genital tract infection</article-title><source>PNAS</source><volume>103</volume><fpage>12069</fpage><lpage>12074</lpage><pub-id pub-id-type="doi">10.1073/pnas.0603866103</pub-id><pub-id pub-id-type="pmid">16880389</pub-id></element-citation></ref><ref id="bib68"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rockey</surname><given-names>DD</given-names></name><name><surname>Scidmore</surname><given-names>MA</given-names></name><name><surname>Bannantine</surname><given-names>JP</given-names></name><name><surname>Brown</surname><given-names>WJ</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Proteins in the chlamydial inclusion membrane</article-title><source>Microbes and Infection</source><volume>4</volume><fpage>333</fpage><lpage>340</lpage><pub-id pub-id-type="doi">10.1016/s1286-4579(02)01546-0</pub-id><pub-id pub-id-type="pmid">11909744</pub-id></element-citation></ref><ref id="bib69"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ronau</surname><given-names>JA</given-names></name><name><surname>Beckmann</surname><given-names>JF</given-names></name><name><surname>Hochstrasser</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Substrate specificity of the ubiquitin and Ubl proteases</article-title><source>Cell Research</source><volume>26</volume><fpage>441</fpage><lpage>456</lpage><pub-id pub-id-type="doi">10.1038/cr.2016.38</pub-id><pub-id pub-id-type="pmid">27012468</pub-id></element-citation></ref><ref id="bib70"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rytkönen</surname><given-names>A</given-names></name><name><surname>Poh</surname><given-names>J</given-names></name><name><surname>Garmendia</surname><given-names>J</given-names></name><name><surname>Boyle</surname><given-names>C</given-names></name><name><surname>Thompson</surname><given-names>A</given-names></name><name><surname>Liu</surname><given-names>M</given-names></name><name><surname>Freemont</surname><given-names>P</given-names></name><name><surname>Hinton</surname><given-names>JCD</given-names></name><name><surname>Holden</surname><given-names>DW</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>SseL, a <italic>Salmonella</italic> deubiquitinase required for macrophage killing and virulence</article-title><source>PNAS</source><volume>104</volume><fpage>3502</fpage><lpage>3507</lpage><pub-id pub-id-type="doi">10.1073/pnas.0610095104</pub-id><pub-id pub-id-type="pmid">17360673</pub-id></element-citation></ref><ref id="bib71"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saeki</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Ubiquitin recognition by the proteasome</article-title><source>Journal of Biochemistry</source><volume>161</volume><fpage>113</fpage><lpage>124</lpage><pub-id pub-id-type="doi">10.1093/jb/mvw091</pub-id><pub-id pub-id-type="pmid">28069863</pub-id></element-citation></ref><ref id="bib72"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schneider</surname><given-names>CA</given-names></name><name><surname>Rasband</surname><given-names>WS</given-names></name><name><surname>Eliceiri</surname><given-names>KW</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>NIH image to imageJ: 25 years of image analysis</article-title><source>Nature Methods</source><volume>9</volume><fpage>671</fpage><lpage>675</lpage><pub-id pub-id-type="doi">10.1038/nmeth.2089</pub-id><pub-id pub-id-type="pmid">22930834</pub-id></element-citation></ref><ref id="bib73"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schubert</surname><given-names>AF</given-names></name><name><surname>Nguyen</surname><given-names>JV</given-names></name><name><surname>Franklin</surname><given-names>TG</given-names></name><name><surname>Geurink</surname><given-names>PP</given-names></name><name><surname>Roberts</surname><given-names>CG</given-names></name><name><surname>Sanderson</surname><given-names>DJ</given-names></name><name><surname>Miller</surname><given-names>LN</given-names></name><name><surname>Ovaa</surname><given-names>H</given-names></name><name><surname>Hofmann</surname><given-names>K</given-names></name><name><surname>Pruneda</surname><given-names>JN</given-names></name><name><surname>Komander</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Identification and characterization of diverse OTU deubiquitinases in bacteria</article-title><source>The EMBO Journal</source><volume>39</volume><elocation-id>e105127</elocation-id><pub-id pub-id-type="doi">10.15252/embj.2020105127</pub-id><pub-id pub-id-type="pmid">32567101</pub-id></element-citation></ref><ref id="bib74"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shaw</surname><given-names>JH</given-names></name><name><surname>Key</surname><given-names>CE</given-names></name><name><surname>Snider</surname><given-names>TA</given-names></name><name><surname>Sah</surname><given-names>P</given-names></name><name><surname>Shaw</surname><given-names>EI</given-names></name><name><surname>Fisher</surname><given-names>DJ</given-names></name><name><surname>Lutter</surname><given-names>EI</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Genetic inactivation of <italic>Chlamydia trachomatis</italic> inclusion membrane protein CT228 Alters MYPT1 recruitment, extrusion production, and longevity of infection</article-title><source>Frontiers in Cellular and Infection Microbiology</source><volume>8</volume><elocation-id>415</elocation-id><pub-id pub-id-type="doi">10.3389/fcimb.2018.00415</pub-id><pub-id pub-id-type="pmid">30555802</pub-id></element-citation></ref><ref id="bib75"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sheedlo</surname><given-names>MJ</given-names></name><name><surname>Qiu</surname><given-names>J</given-names></name><name><surname>Tan</surname><given-names>Y</given-names></name><name><surname>Paul</surname><given-names>LN</given-names></name><name><surname>Luo</surname><given-names>ZQ</given-names></name><name><surname>Das</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Structural basis of substrate recognition by a bacterial deubiquitinase important for dynamics of phagosome ubiquitination</article-title><source>PNAS</source><volume>112</volume><fpage>15090</fpage><lpage>15095</lpage><pub-id pub-id-type="doi">10.1073/pnas.1514568112</pub-id><pub-id pub-id-type="pmid">26598703</pub-id></element-citation></ref><ref id="bib76"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sixt</surname><given-names>BS</given-names></name><name><surname>Bastidas</surname><given-names>RJ</given-names></name><name><surname>Finethy</surname><given-names>R</given-names></name><name><surname>Baxter</surname><given-names>RM</given-names></name><name><surname>Carpenter</surname><given-names>VK</given-names></name><name><surname>Kroemer</surname><given-names>G</given-names></name><name><surname>Coers</surname><given-names>J</given-names></name><name><surname>Valdivia</surname><given-names>RH</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>The <italic>Chlamydia trachomatis</italic> inclusion membrane protein CpoS counteracts STING-mediated cellular surveillance and suicide programs</article-title><source>Cell Host &amp; Microbe</source><volume>21</volume><fpage>113</fpage><lpage>121</lpage><pub-id pub-id-type="doi">10.1016/j.chom.2016.12.002</pub-id><pub-id pub-id-type="pmid">28041929</pub-id></element-citation></ref><ref id="bib77"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smith</surname><given-names>EP</given-names></name><name><surname>Cotto-Rosario</surname><given-names>A</given-names></name><name><surname>Borghesan</surname><given-names>E</given-names></name><name><surname>Held</surname><given-names>K</given-names></name><name><surname>Miller</surname><given-names>CN</given-names></name><name><surname>Celli</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Epistatic interplay between type IV secretion effectors engages the small GTPase Rab2 in the <italic>Brucella</italic> Intracellular cycle</article-title><source>mBio</source><volume>11</volume><elocation-id>e03350-19</elocation-id><pub-id pub-id-type="doi">10.1128/mBio.03350-19</pub-id><pub-id pub-id-type="pmid">32234817</pub-id></element-citation></ref><ref id="bib78"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Suchland</surname><given-names>RJ</given-names></name><name><surname>Rockey</surname><given-names>DD</given-names></name><name><surname>Bannantine</surname><given-names>JP</given-names></name><name><surname>Stamm</surname><given-names>WE</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>Isolates of <italic>Chlamydia trachomatis</italic> that occupy nonfusogenic inclusions lack IncA, a protein localized to the inclusion membrane</article-title><source>Infection and Immunity</source><volume>68</volume><fpage>360</fpage><lpage>367</lpage><pub-id pub-id-type="doi">10.1128/IAI.68.1.360-367.2000</pub-id><pub-id pub-id-type="pmid">10603409</pub-id></element-citation></ref><ref id="bib79"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Swatek</surname><given-names>KN</given-names></name><name><surname>Komander</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Ubiquitin modifications</article-title><source>Cell Research</source><volume>26</volume><fpage>399</fpage><lpage>422</lpage><pub-id pub-id-type="doi">10.1038/cr.2016.39</pub-id><pub-id pub-id-type="pmid">27012465</pub-id></element-citation></ref><ref id="bib80"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tenno</surname><given-names>T</given-names></name><name><surname>Fujiwara</surname><given-names>K</given-names></name><name><surname>Tochio</surname><given-names>H</given-names></name><name><surname>Iwai</surname><given-names>K</given-names></name><name><surname>Morita</surname><given-names>EH</given-names></name><name><surname>Hayashi</surname><given-names>H</given-names></name><name><surname>Murata</surname><given-names>S</given-names></name><name><surname>Hiroaki</surname><given-names>H</given-names></name><name><surname>Sato</surname><given-names>M</given-names></name><name><surname>Tanaka</surname><given-names>K</given-names></name><name><surname>Shirakawa</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Structural basis for distinct roles of Lys63- and Lys48-linked polyubiquitin chains</article-title><source>Genes to Cells</source><volume>9</volume><fpage>865</fpage><lpage>875</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2443.2004.00780.x</pub-id><pub-id pub-id-type="pmid">15461659</pub-id></element-citation></ref><ref id="bib81"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Urbanus</surname><given-names>ML</given-names></name><name><surname>Quaile</surname><given-names>AT</given-names></name><name><surname>Stogios</surname><given-names>PJ</given-names></name><name><surname>Morar</surname><given-names>M</given-names></name><name><surname>Rao</surname><given-names>C</given-names></name><name><surname>Di Leo</surname><given-names>R</given-names></name><name><surname>Evdokimova</surname><given-names>E</given-names></name><name><surname>Lam</surname><given-names>M</given-names></name><name><surname>Oatway</surname><given-names>C</given-names></name><name><surname>Cuff</surname><given-names>ME</given-names></name><name><surname>Osipiuk</surname><given-names>J</given-names></name><name><surname>Michalska</surname><given-names>K</given-names></name><name><surname>Nocek</surname><given-names>BP</given-names></name><name><surname>Taipale</surname><given-names>M</given-names></name><name><surname>Savchenko</surname><given-names>A</given-names></name><name><surname>Ensminger</surname><given-names>AW</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Diverse mechanisms of metaeffector activity in an intracellular bacterial pathogen, Legionella pneumophila</article-title><source>Molecular Systems Biology</source><volume>12</volume><elocation-id>893</elocation-id><pub-id pub-id-type="doi">10.15252/msb.20167381</pub-id><pub-id pub-id-type="pmid">27986836</pub-id></element-citation></ref><ref id="bib82"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Varadan</surname><given-names>R</given-names></name><name><surname>Walker</surname><given-names>O</given-names></name><name><surname>Pickart</surname><given-names>C</given-names></name><name><surname>Fushman</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Structural properties of polyubiquitin chains in solution</article-title><source>Journal of Molecular Biology</source><volume>324</volume><fpage>637</fpage><lpage>647</lpage><pub-id pub-id-type="doi">10.1016/s0022-2836(02)01198-1</pub-id><pub-id pub-id-type="pmid">12460567</pub-id></element-citation></ref><ref id="bib83"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vozandychova</surname><given-names>V</given-names></name><name><surname>Stojkova</surname><given-names>P</given-names></name><name><surname>Hercik</surname><given-names>K</given-names></name><name><surname>Rehulka</surname><given-names>P</given-names></name><name><surname>Stulik</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>The ubiquitination system within bacterial host-pathogen interactions</article-title><source>Microorganisms</source><volume>9</volume><elocation-id>638</elocation-id><pub-id pub-id-type="doi">10.3390/microorganisms9030638</pub-id><pub-id pub-id-type="pmid">33808578</pub-id></element-citation></ref><ref id="bib84"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Walsh</surname><given-names>SC</given-names></name><name><surname>Reitano</surname><given-names>JR</given-names></name><name><surname>Dickinson</surname><given-names>MS</given-names></name><name><surname>Kutsch</surname><given-names>M</given-names></name><name><surname>Hernandez</surname><given-names>D</given-names></name><name><surname>Barnes</surname><given-names>AB</given-names></name><name><surname>Schott</surname><given-names>BH</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Ko</surname><given-names>DC</given-names></name><name><surname>Kim</surname><given-names>SY</given-names></name><name><surname>Valdivia</surname><given-names>RH</given-names></name><name><surname>Bastidas</surname><given-names>RJ</given-names></name><name><surname>Coers</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>The bacterial effector GarD shields <italic>Chlamydia trachomatis</italic> inclusions from RNF213-mediated ubiquitylation and destruction</article-title><source>Cell Host &amp; Microbe</source><volume>30</volume><fpage>1671</fpage><lpage>1684</lpage><pub-id pub-id-type="doi">10.1016/j.chom.2022.08.008</pub-id><pub-id pub-id-type="pmid">36084633</pub-id></element-citation></ref><ref id="bib85"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Hybiske</surname><given-names>K</given-names></name><name><surname>Stephens</surname><given-names>RS</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Direct visualization of the expression and localization of chlamydial effector proteins within infected host cells</article-title><source>Pathogens and Disease</source><volume>76</volume><elocation-id>fty011</elocation-id><pub-id pub-id-type="doi">10.1093/femspd/fty011</pub-id><pub-id pub-id-type="pmid">29390129</pub-id></element-citation></ref><ref id="bib86"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weber</surname><given-names>MM</given-names></name><name><surname>Bauler</surname><given-names>LD</given-names></name><name><surname>Lam</surname><given-names>J</given-names></name><name><surname>Hackstadt</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Expression and localization of predicted inclusion membrane proteins in <italic>Chlamydia trachomatis</italic></article-title><source>Infection and Immunity</source><volume>83</volume><fpage>4710</fpage><lpage>4718</lpage><pub-id pub-id-type="doi">10.1128/IAI.01075-15</pub-id><pub-id pub-id-type="pmid">26416906</pub-id></element-citation></ref><ref id="bib87"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weeks</surname><given-names>SD</given-names></name><name><surname>Grasty</surname><given-names>KC</given-names></name><name><surname>Hernandez-Cuebas</surname><given-names>L</given-names></name><name><surname>Loll</surname><given-names>PJ</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Crystal structures of Lys-63-linked tri- and di-ubiquitin reveal a highly extended chain architecture</article-title><source>Proteins</source><volume>77</volume><fpage>753</fpage><lpage>759</lpage><pub-id pub-id-type="doi">10.1002/prot.22568</pub-id><pub-id pub-id-type="pmid">19731378</pub-id></element-citation></ref><ref id="bib88"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wesolowski</surname><given-names>J</given-names></name><name><surname>Weber</surname><given-names>MM</given-names></name><name><surname>Nawrotek</surname><given-names>A</given-names></name><name><surname>Dooley</surname><given-names>CA</given-names></name><name><surname>Calderon</surname><given-names>M</given-names></name><name><surname>St Croix</surname><given-names>CM</given-names></name><name><surname>Hackstadt</surname><given-names>T</given-names></name><name><surname>Cherfils</surname><given-names>J</given-names></name><name><surname>Paumet</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title><italic>Chlamydia</italic> hijacks ARF GTPases to coordinate microtubule posttranslational modifications and golgi complex positioning</article-title><source>mBio</source><volume>8</volume><elocation-id>e02280-16</elocation-id><pub-id pub-id-type="doi">10.1128/mBio.02280-16</pub-id><pub-id pub-id-type="pmid">28465429</pub-id></element-citation></ref><ref id="bib89"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zadora</surname><given-names>PK</given-names></name><name><surname>Chumduri</surname><given-names>C</given-names></name><name><surname>Imami</surname><given-names>K</given-names></name><name><surname>Berger</surname><given-names>H</given-names></name><name><surname>Mi</surname><given-names>Y</given-names></name><name><surname>Selbach</surname><given-names>M</given-names></name><name><surname>Meyer</surname><given-names>TF</given-names></name><name><surname>Gurumurthy</surname><given-names>RK</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Integrated phosphoproteome and transcriptome analysis reveals chlamydia-induced epithelial-to-mesenchymal transition in host cells</article-title><source>Cell Reports</source><volume>26</volume><fpage>1286</fpage><lpage>1302</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2019.01.006</pub-id><pub-id pub-id-type="pmid">30699355</pub-id></element-citation></ref><ref id="bib90"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>Y</given-names></name><name><surname>Zhou</surname><given-names>B</given-names></name><name><surname>Pache</surname><given-names>L</given-names></name><name><surname>Chang</surname><given-names>M</given-names></name><name><surname>Khodabakhshi</surname><given-names>AH</given-names></name><name><surname>Tanaseichuk</surname><given-names>O</given-names></name><name><surname>Benner</surname><given-names>C</given-names></name><name><surname>Chanda</surname><given-names>SK</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Metascape provides a biologist-oriented resource for the analysis of systems-level datasets</article-title><source>Nature Communications</source><volume>10</volume><elocation-id>1523</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-019-09234-6</pub-id><pub-id pub-id-type="pmid">30944313</pub-id></element-citation></ref><ref id="bib91"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zuck</surname><given-names>M</given-names></name><name><surname>Sherrid</surname><given-names>A</given-names></name><name><surname>Suchland</surname><given-names>R</given-names></name><name><surname>Ellis</surname><given-names>T</given-names></name><name><surname>Hybiske</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Conservation of extrusion as an exit mechanism for Chlamydia</article-title><source>Pathogens and Disease</source><volume>74</volume><elocation-id>ftw093</elocation-id><pub-id pub-id-type="doi">10.1093/femspd/ftw093</pub-id><pub-id pub-id-type="pmid">27620201</pub-id></element-citation></ref><ref id="bib92"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zuck</surname><given-names>M</given-names></name><name><surname>Ellis</surname><given-names>T</given-names></name><name><surname>Venida</surname><given-names>A</given-names></name><name><surname>Hybiske</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Extrusions are phagocytosed and promote Chlamydia survival within macrophages</article-title><source>Cellular Microbiology</source><volume>19</volume><elocation-id>12683</elocation-id><pub-id pub-id-type="doi">10.1111/cmi.12683</pub-id><pub-id pub-id-type="pmid">27739160</pub-id></element-citation></ref></ref-list><app-group><app id="appendix-1"><title>Appendix 1</title><table-wrap id="app1keyresource" position="anchor"><label>Appendix 1—key resources table</label><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">Reagent type (species) or resource</th><th align="left" valign="bottom">Designation</th><th align="left" valign="bottom">Source or reference</th><th align="left" valign="bottom">Identifiers</th><th align="left" valign="bottom">Additional information</th></tr></thead><tbody><tr><td align="left" valign="bottom">Gene<break/>(<italic>Chlamydia trachomatis</italic> L2 434 Bu)</td><td align="left" valign="bottom"><italic>cdu1</italic></td><td align="left" valign="bottom">BV-BRC<break/>(Bacterial and Viral Bioinformatics resource center);<break/>Refseq<break/>(NCBI Reference Sequence Database)</td><td align="left" valign="bottom">fig|471472.4.peg.264<break/>(BV-BRC)<break/>CTL0247 (Refseq)</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Gene<break/>(<italic>Chlamydia trachomatis</italic> L2 434 Bu)</td><td align="left" valign="bottom"><italic>inaC</italic></td><td align="left" valign="bottom">BV-BRC;<break/>Refseq</td><td align="left" valign="bottom">fig|471472.4.peg.199 (BV-BRC)<break/>CTL0184 (Refseq)</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Gene<break/>(<italic>Chlamydia trachomatis</italic> L2 434 Bu)</td><td align="left" valign="bottom"><italic>ipaM</italic></td><td align="left" valign="bottom">BV-BRC;<break/>Refseq</td><td align="left" valign="bottom">fig|471472.4.peg.511 (BV-BRC)<break/>CTL0476 (Refseq)</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Gene<break/>(<italic>Chlamydia trachomatis</italic> L2 434 Bu)</td><td align="left" valign="bottom">CTL0480</td><td align="left" valign="bottom">BV-BRC;<break/>Refseq</td><td align="left" valign="bottom">fig|471472.4.peg.516 (BV-BRC)<break/>CTL0480 (Refseq)</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Gene<break/>(<italic>Chlamydia trachomatis</italic> L2 434 Bu)</td><td align="left" valign="bottom"><italic>cpoS</italic></td><td align="left" valign="bottom">BV-BRC;<break/>Refseq</td><td align="left" valign="bottom">fig|471472.4.peg.517<break/>(BV-BRC)<break/>CTL0481 (Refseq)</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Gene<break/>(<italic>Chlamydia trachomatis</italic> L2 434 Bu)</td><td align="left" valign="bottom"><italic>incA</italic></td><td align="left" valign="bottom">BV-BRC;<break/>Refseq</td><td align="left" valign="bottom">fig|471472.4.peg.406<break/>(BV-BRC)<break/>CTL0374 (Refseq)</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Gene<break/>(<italic>Chlamydia trachomatis</italic> L2 434 Bu)</td><td align="left" valign="bottom"><italic>slc1</italic></td><td align="left" valign="bottom">BV-BRC;<break/>Refseq</td><td align="left" valign="bottom">fig|471472.4.peg.323<break/>(BV-BRC)<break/>CTL0299 (Refseq)</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Gene<break/>(<italic>Chlamydia trachomatis</italic> L2 434 Bu)</td><td align="left" valign="bottom"><italic>rpoB</italic></td><td align="left" valign="bottom">BV-BRC;<break/>Refseq</td><td align="left" valign="bottom">fig|471472.4.peg.608<break/>(BV-BRC)<break/>CTL0567 (Refseq)</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Gene<break/>(<italic>Chlamydia trachomatis</italic> L2 434 Bu)</td><td align="left" valign="bottom"><italic>garD</italic></td><td align="left" valign="bottom">BV-BRC;<break/>Refseq</td><td align="left" valign="bottom">fig|471472.4.peg.421<break/>(BV-BRC)<break/>CTL0390 (Refseq)</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Gene<break/>(<italic>Homo sapiens</italic>)</td><td align="left" valign="bottom"><italic>MYPT1</italic></td><td align="left" valign="bottom">NCBI</td><td align="left" valign="bottom">PPP1R12A</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Cell line<break/>(<italic>Homo sapiens</italic>)</td><td align="left" valign="bottom">Hela</td><td align="left" valign="bottom">ATCC</td><td align="left" valign="bottom">Cat# CCL-2<break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:CVCL_0030">CVCL_0030</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Cell line (<italic>Cercopithecus aethiops</italic>)</td><td align="left" valign="bottom">Vero</td><td align="left" valign="bottom">ATCC</td><td align="left" valign="bottom">Cat# CCL-81<break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:CVCL_0059">CVCL_0059</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Cell line<break/>(<italic>Homo sapiens</italic>)</td><td align="left" valign="bottom">HEK 293T</td><td align="left" valign="bottom">ATCC</td><td align="left" valign="bottom">Cat# CRL-3216<break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:CVCL_0063">CVCL_0063</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Cell line<break/>(<italic>Homo sapiens</italic>)</td><td align="left" valign="bottom">A549</td><td align="left" valign="bottom">ATCC</td><td align="left" valign="bottom">Cat# CCL-185<break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:CVCL_0023">CVCL_0023</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Transfected construct (<italic>Chlamydia trachomatis</italic> L2 43 Bu)</td><td align="left" valign="bottom">pOPIN-GFP_Cdu1 FL (aa 1–401)</td><td align="left" valign="bottom">Jonathan Pruneda (Oregon Health and Science University)</td><td align="left" valign="bottom">N/A</td><td align="left" valign="bottom">Used for Cdu1 co-immunoprecipitations in transfected cells</td></tr><tr><td align="left" valign="bottom">Transfected construct (<italic>Chlamydia trachomatis</italic> L2 43 Bu)</td><td align="left" valign="bottom">pOPIN-GFP_Cdu1 TMD- (aa 71–401)</td><td align="left" valign="bottom">Jonathan Pruneda (Oregon Health and Science University)</td><td align="left" valign="bottom">N/A</td><td align="left" valign="bottom">Used for Cdu1 co-immunoprecipitations in transfected cells</td></tr><tr><td align="left" valign="bottom">Transfected construct (<italic>Chlamydia trachomatis</italic> L2 43 Bu)</td><td align="left" valign="bottom">pOPIN-GFP_Cdu1 CD- (aa 1–130)</td><td align="left" valign="bottom">Jonathan Pruneda (Oregon Health and Science University)</td><td align="left" valign="bottom">N/A</td><td align="left" valign="bottom">Used for Cdu1 co-immunoprecipitations in transfected cells</td></tr><tr><td align="left" valign="bottom">Transfected construct (<italic>Chlamydia trachomatis</italic> L2 43 Bu)</td><td align="left" valign="bottom">pCDNA-DEST53 (w/o GFP)_InaC (CT813)–3XFLAG</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">N/A</td><td align="left" valign="bottom">Construct for showing Cdu1-InaC co-IP in transfected cells</td></tr><tr><td align="left" valign="bottom">Transfected construct (<italic>Chlamydia trachomatis</italic> L2 43 Bu)</td><td align="left" valign="bottom">pcDNA3.1/nV5-DEST_IpaM</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">N/A</td><td align="left" valign="bottom">Construct for showing Cdu1-IpaM co-IP in transfected cells</td></tr><tr><td align="left" valign="bottom">Transfected construct (<italic>Chlamydia trachomatis</italic> L2 43 Bu)</td><td align="left" valign="bottom">pcDNA3.1/nV5-DEST_CTL0480</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">N/A</td><td align="left" valign="bottom">Construct for showing Cdu1-CTL0480 co-IP in transfected cells</td></tr><tr><td align="left" valign="bottom">Transfected construct (<italic>Chlamydia trachomatis</italic> L2 43 Bu)</td><td align="left" valign="bottom">pcDNA3.1/nV5-DEST_CpoS</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">N/A</td><td align="left" valign="bottom">Construct for showing lack of Cdu1-Cpos co-IP in transfected cells</td></tr><tr><td align="left" valign="bottom">Biological sample (<italic>Chlamydia trachomatis</italic> L2 434 Bu)</td><td align="left" valign="bottom"><italic>Chlamydia trachomatis</italic> LGV biovar L2 434 Bu (L2)</td><td align="left" valign="bottom">Richard Stephens (UC Berkeley)</td><td align="left" valign="bottom">N/A</td><td align="left" valign="bottom">Reference <italic>Chlamydia trachomatis</italic> (L2) strain</td></tr><tr><td align="left" valign="bottom">Biological sample (<italic>Chlamydia trachomatis</italic> L2 434 Bu)</td><td align="left" valign="bottom">L2 pBOMB-MCI<break/>(Parent: LGV L2 434 Bu)</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">N/A</td><td align="left" valign="bottom">L2 strain transformed with empty expression plasmid</td></tr><tr><td align="left" valign="bottom">Biological sample (<italic>Chlamydia trachomatis</italic> L2 434 Bu)</td><td align="left" valign="bottom">L2 pBOMB-MCI_CTL0480-3XFlag<break/>(Parent: LGV L2 434 Bu)</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">N/A</td><td align="left" valign="bottom">L2 strain transformed with plasmid expressing CTL0480-3XFlag</td></tr><tr><td align="left" valign="bottom">Biological sample (<italic>Chlamydia trachomatis</italic> L2 434 Bu)</td><td align="left" valign="bottom">L2 pBOMB-MCI_IpaM-3XFlag<break/>(Parent: LGV L2 434 Bu)</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">N/A</td><td align="left" valign="bottom">L2 strain transformed with plasmid expressing IpaM-3XFlag</td></tr><tr><td align="left" valign="bottom">Biological sample (<italic>Chlamydia trachomatis</italic> L2 434 Bu)</td><td align="left" valign="bottom">L2 pBOMB-MCI_Cdu1-3XFlag<break/>(Parent: LGV L2 434 Bu)</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">N/A</td><td align="left" valign="bottom">L2 strain transformed with plasmid expressing Cdu1-3XFlag</td></tr><tr><td align="left" valign="bottom">Biological sample (<italic>Chlamydia trachomatis</italic> L2 434 Bu)</td><td align="left" valign="bottom">L2 pBOMB-MCI_Cdu1<sup>C345A</sup>-3XFlag<break/>(Parent: LGV L2 434 Bu)</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">N/A</td><td align="left" valign="bottom">L2 strain transformed with plasmid expressing Cdu1<sup>C345A</sup> –3XFlag</td></tr><tr><td align="left" valign="bottom">Biological sample (<italic>Chlamydia trachomatis</italic> L2 434 Bu)</td><td align="left" valign="bottom">L2 pBOMB-MCI_Cdu1<sup>K268E</sup>-3XFlag<break/>(Parent: LGV L2 434 Bu)</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">N/A</td><td align="left" valign="bottom">L2 strain transformed with plasmid expressing Cdu1<sup>K268E</sup> –3XFlag</td></tr><tr><td align="left" valign="bottom">Biological sample (<italic>Chlamydia trachomatis</italic> L2 434 Bu)</td><td align="left" valign="bottom">L2 <italic>cdu1</italic>::GII <italic>aadA</italic><break/>(Parent: LGV L2 434 Bu)</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">N/A</td><td align="left" valign="bottom">L2 <italic>cdu1</italic> null strain (Spec<sup>R</sup>)</td></tr><tr><td align="left" valign="bottom">Biological sample (<italic>Chlamydia trachomatis</italic> L2 434 Bu)</td><td align="left" valign="bottom">L2 <italic>cdu1</italic>::GII <italic>aadA</italic> pBOMB-MCI<break/>(Parent: L2 <italic>cdu1</italic>::GII <italic>aadA</italic>)</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">N/A</td><td align="left" valign="bottom">L2 <italic>cdu1</italic> null strain transformed with empty expression plasmid</td></tr><tr><td align="left" valign="bottom">Biological sample (<italic>Chlamydia trachomatis</italic> L2 434 Bu)</td><td align="left" valign="bottom">L2 <italic>cdu1</italic>::GII <italic>aadA</italic> pBOMB-MCI_Cdu1-3XFlag<break/>(Parent: L2 <italic>cdu1</italic>::GII <italic>aadA</italic>)</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">N/A</td><td align="left" valign="bottom">L2 <italic>cdu1</italic> null strain transformed with plasmid expressing WT Cdu1-3XFlag</td></tr><tr><td align="left" valign="bottom">Biological sample (<italic>Chlamydia trachomatis</italic> L2 434 Bu)</td><td align="left" valign="bottom">L2 <italic>cdu1</italic>::GII <italic>aadA</italic> pBOMB-MCI_Cdu1<sup>C345A</sup>-3XFlag<break/>(Parent: L2 <italic>cdu1</italic>::GII <italic>aadA</italic>)</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">N/A</td><td align="left" valign="bottom">L2 <italic>cdu1</italic> null strain transformed with plasmid expressing WT Cdu1<sup>C345A</sup>-3XFlag</td></tr><tr><td align="left" valign="bottom">Biological sample (<italic>Chlamydia trachomatis</italic> L2 434 Bu)</td><td align="left" valign="bottom">L2 <italic>cdu1</italic>::GII <italic>aadA</italic> pBOMB-MCI_Cdu1<sup>I225A</sup>-3XFlag<break/>(Parent: L2 <italic>cdu1</italic>::GII <italic>aadA</italic>)</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">N/A</td><td align="left" valign="bottom">L2 <italic>cdu1</italic> null strain transformed with plasmid expressing WT Cdu1<sup>I225A</sup>-3XFlag</td></tr><tr><td align="left" valign="bottom">Biological sample (<italic>Chlamydia trachomatis</italic> L2 434 Bu)</td><td align="left" valign="bottom">L2 <italic>cdu1</italic>::GII <italic>aadA</italic> pBOMB-MCI_Cdu1<sup>K268E</sup>-3XFlag<break/>(Parent: L2 <italic>cdu1</italic>::GII <italic>aadA</italic>)</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">N/A</td><td align="left" valign="bottom">L2 <italic>cdu1</italic> null strain transformed with plasmid expressing WT Cdu1<sup>K268E</sup>-3XFlag</td></tr><tr><td align="left" valign="bottom">Biological sample (<italic>Chlamydia trachomatis</italic> L2 434 Bu)</td><td align="left" valign="bottom">L2 Rif-R<break/>(Parent: L2 434 Bu)</td><td align="left" valign="bottom">PMID:<ext-link ext-link-type="uri" xlink:href="https://pubmed.ncbi.nlm.nih.gov/22232666/">22232666</ext-link></td><td align="left" valign="bottom">N/A</td><td align="left" valign="bottom">Rifampin resistant L2 strain (L2 434 Bu)</td></tr><tr><td align="left" valign="bottom">Biological sample (<italic>Chlamydia trachomatis</italic> L2 434 Bu)</td><td align="left" valign="bottom">M407 (<italic>inaC C307T</italic>, InaC Q103*)<break/>(Parent: L2 Rif-R)</td><td align="left" valign="bottom">PMID:<ext-link ext-link-type="uri" xlink:href="https://pubmed.ncbi.nlm.nih.gov/25920978/">25920978</ext-link></td><td align="left" valign="bottom">N/A</td><td align="left" valign="bottom">L2 strain bearing a nonsense mutation in <italic>inaC (inaC</italic> null srain)</td></tr><tr><td align="left" valign="bottom">Biological sample (<italic>Chlamydia trachomatis</italic> L2 434 Bu)</td><td align="left" valign="bottom">M407 p2TK2<break/>(Parent: M407)</td><td align="left" valign="bottom">PMID:<ext-link ext-link-type="uri" xlink:href="https://pubmed.ncbi.nlm.nih.gov/25920978/">25920978</ext-link></td><td align="left" valign="bottom">N/A</td><td align="left" valign="bottom">L2 <italic>inaC</italic> null strain transformed with empty expression plasmid</td></tr><tr><td align="left" valign="bottom">Biological sample (<italic>Chlamydia trachomatis</italic> L2 434 Bu)</td><td align="left" valign="bottom">M407 p2TK2_InaC<break/>(Parent: M407)</td><td align="left" valign="bottom">PMID:<ext-link ext-link-type="uri" xlink:href="https://pubmed.ncbi.nlm.nih.gov/25920978/">25920978</ext-link></td><td align="left" valign="bottom">N/A</td><td align="left" valign="bottom">L2 <italic>inaC</italic> null strain transformed with plasmid expressing WT InaC (untagged)</td></tr><tr><td align="left" valign="bottom">Biological sample (<italic>Chlamydia trachomatis</italic> L2 434 Bu)</td><td align="left" valign="bottom">M407 p2TK2_InaC-3X Flag<break/>(Parent: M407)</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">N/A</td><td align="left" valign="bottom">L2 <italic>inaC</italic> null strain transformed with plasmid expressing WT InaC-3X Flag</td></tr><tr><td align="left" valign="bottom">Biological sample (<italic>Chlamydia trachomatis</italic> L2 434 Bu)</td><td align="left" valign="bottom"><italic>inaC</italic>::GII <italic>bla</italic><break/>(Parent: L2 434 Bu)</td><td align="left" valign="bottom">PMID:<ext-link ext-link-type="uri" xlink:href="https://pubmed.ncbi.nlm.nih.gov/28465429/">28465429</ext-link></td><td align="left" valign="bottom">N/A</td><td align="left" valign="bottom">L2 <italic>inaC</italic> null strain (Penicillin<sup>R</sup>)</td></tr><tr><td align="left" valign="bottom">Biological sample (<italic>Chlamydia trachomatis</italic> L2 434 Bu)</td><td align="left" valign="bottom"><italic>ipaM</italic>::GII <italic>cat</italic><break/>(Parent: L2 434 Bu)</td><td align="left" valign="bottom">PMID:<ext-link ext-link-type="uri" xlink:href="https://pubmed.ncbi.nlm.nih.gov/37530528/">37530528</ext-link></td><td align="left" valign="bottom">N/A</td><td align="left" valign="bottom">L2 <italic>ipaM</italic> null strain (Chloramphenicol<sup>R</sup>)</td></tr><tr><td align="left" valign="bottom">Biological sample (<italic>Chlamydia trachomatis</italic> L2 434 Bu)</td><td align="left" valign="bottom"><italic>ctl0480</italic>::GII <italic>aadA</italic><break/>(Parent: L2 434 Bu)</td><td align="left" valign="bottom">PMID:<ext-link ext-link-type="uri" xlink:href="https://pubmed.ncbi.nlm.nih.gov/30555802/">30555802</ext-link></td><td align="left" valign="bottom">N/A</td><td align="left" valign="bottom">L2 <italic>ctl0480</italic> null strain (Spec<sup>R</sup>)</td></tr><tr><td align="left" valign="bottom">Biological sample (<italic>Chlamydia trachomatis</italic> L2 434 Bu)</td><td align="left" valign="bottom">M923 (<italic>incA C589T</italic>, IncA R197*)<break/>(Parent: L2 Rif-R)</td><td align="left" valign="bottom">PMID:<ext-link ext-link-type="uri" xlink:href="https://pubmed.ncbi.nlm.nih.gov/25920978/">25920978</ext-link></td><td align="left" valign="bottom">N/A</td><td align="left" valign="bottom">L2 strain bearing a nonsense mutation in <italic>incA (incA</italic> null srain)</td></tr><tr><td align="left" valign="bottom">Biological sample (<italic>Chlamydia trachomatis</italic> L2 434 Bu)</td><td align="left" valign="bottom">M923 pBOMB-MCl<break/>(Parent: L2 M923)</td><td align="left" valign="bottom">PMID:<ext-link ext-link-type="uri" xlink:href="https://pubmed.ncbi.nlm.nih.gov/28041929/">28041929</ext-link></td><td align="left" valign="bottom">N/A</td><td align="left" valign="bottom">L2 <italic>incA</italic> null strain transformed with empty expression plasmid</td></tr><tr><td align="left" valign="bottom">Biological sample (<italic>Chlamydia trachomatis</italic> L2 434 Bu)</td><td align="left" valign="bottom">L2 434 Bu<break/>(Parent of L2 <italic>garD</italic>::GII)</td><td align="left" valign="bottom">PMID:<ext-link ext-link-type="uri" xlink:href="https://pubmed.ncbi.nlm.nih.gov/36084633/">36084633</ext-link></td><td align="left" valign="bottom">N/A</td><td align="left" valign="bottom">Wild type L2 parent of <italic>garD</italic> null strain</td></tr><tr><td align="left" valign="bottom">Biological sample (<italic>Chlamydia trachomatis</italic> L2 434 Bu)</td><td align="left" valign="bottom">L2 <italic>ctl0390</italic>::GII <italic>aadA</italic> (<italic>garD</italic>::GII)</td><td align="left" valign="bottom">PMID:<ext-link ext-link-type="uri" xlink:href="https://pubmed.ncbi.nlm.nih.gov/36084633/">36084633</ext-link></td><td align="left" valign="bottom">N/A</td><td align="left" valign="bottom">L2 <italic>garD</italic> null strain<break/>(Spec<sup>R</sup>)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">CT L2 Cdu1 (a.a 71–401)<break/>Rabbit polyclonal</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">N/A</td><td align="left" valign="bottom">Dilution IF: 1:100<break/>Dilution WB 1:500<break/>Antibody raised against L2 Cdu1</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">CT Cap1<break/>Rabbit polyclonal</td><td align="left" valign="bottom">PMID:<ext-link ext-link-type="uri" xlink:href="https://pubmed.ncbi.nlm.nih.gov/26981769/">26981769</ext-link></td><td align="left" valign="bottom">N/A</td><td align="left" valign="bottom">Dilution IF: 1:250</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">CT CT813 (InaC)<break/>(D/UW-3/CX)<break/>Mouse monoclonal</td><td align="left" valign="bottom">PMID:<ext-link ext-link-type="uri" xlink:href="https://pubmed.ncbi.nlm.nih.gov/16861671/">16861671</ext-link></td><td align="left" valign="bottom">N/A</td><td align="left" valign="bottom">Dilution IF: 1:100</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">CT CTL0480<break/>Rabbit polyclonal</td><td align="left" valign="bottom">PMID:<ext-link ext-link-type="uri" xlink:href="https://pubmed.ncbi.nlm.nih.gov/23727243/">23727243</ext-link></td><td align="left" valign="bottom">N/A</td><td align="left" valign="bottom">Dilution IF: 1:100</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">CT IncA<break/>Mouse monoclonal</td><td align="left" valign="bottom">Dan Rockey Oregon State Univ. Corvallis</td><td align="left" valign="bottom">N/A</td><td align="left" valign="bottom">Dilution IF: 1:100</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">CT IpaM<break/>Mouse monoclonal<break/>12ES IgG1</td><td align="left" valign="bottom">PMID:<ext-link ext-link-type="uri" xlink:href="https://pubmed.ncbi.nlm.nih.gov/11207561/">11207561</ext-link></td><td align="left" valign="bottom">N/A</td><td align="left" valign="bottom">Dilution IF: 1:100<break/>Dilution WB 1:200<break/>See <xref ref-type="supplementary-material" rid="supp9">Supplementary file 9</xref></td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">CT RpoB<break/>Rabbit polyclonal</td><td align="left" valign="bottom">Ming Tang<break/>(UC Irvine)</td><td align="left" valign="bottom">N/A</td><td align="left" valign="bottom">Dilution WB 1:100<break/>See <xref ref-type="supplementary-material" rid="supp9">Supplementary file 9</xref></td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">CT Slc1<break/>Rabbit polyclonal</td><td align="left" valign="bottom">PMID:<ext-link ext-link-type="uri" xlink:href="https://pubmed.ncbi.nlm.nih.gov/24586162/">24586162</ext-link></td><td align="left" valign="bottom">N/A</td><td align="left" valign="bottom">Dilution WB 1:400<break/>See <xref ref-type="supplementary-material" rid="supp9">Supplementary file 9</xref></td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Hs Acetylated lysine<break/>Rabbit polyclonal</td><td align="left" valign="bottom">Cell signalling</td><td align="left" valign="bottom">Cat# 9441<break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_331805">AB_331805</ext-link></td><td align="left" valign="bottom">Dilution WB 1:4000<break/>See <xref ref-type="supplementary-material" rid="supp9">Supplementary file 9</xref></td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Hs Alpha tubulin clone B-5-1-2<break/>Mouse monoclonal</td><td align="left" valign="bottom">Sigma-Aldrich</td><td align="left" valign="bottom">Cat# T5168<break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_477579">AB_477579</ext-link></td><td align="left" valign="bottom">Dilution WB 1:500<break/>See <xref ref-type="supplementary-material" rid="supp9">Supplementary file 9</xref></td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Flag epitope<break/>Mouse monoclonal</td><td align="left" valign="bottom">Sigma-Aldrich</td><td align="left" valign="bottom">Cat# F3165<break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_259529">AB_259529</ext-link></td><td align="left" valign="bottom">Dilution WB 1:1000<break/>See <xref ref-type="supplementary-material" rid="supp9">Supplementary file 9</xref></td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Flag epitope<break/>Mouse monoclonal</td><td align="left" valign="bottom">Sigma-Aldrich</td><td align="left" valign="bottom">Cat# F1804<break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_262044">AB_262044</ext-link></td><td align="left" valign="bottom">Dilution IF: 1:250</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Hs GM130<break/>Mouse monoclonal</td><td align="left" valign="bottom">BD Biosciences</td><td align="left" valign="bottom">Cat# 610822<break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_398141">AB_398141</ext-link></td><td align="left" valign="bottom">Dilution IF: 1:1000</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Lys48-linkage specific polyubiquitin (D9D5)<break/>Rabbit monoclonal</td><td align="left" valign="bottom">Cell signalling</td><td align="left" valign="bottom">Cat# 8081<break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_10859893">AB_10859893</ext-link></td><td align="left" valign="bottom">Dilution WB 1:1000<break/>See <xref ref-type="supplementary-material" rid="supp9">Supplementary file 9</xref></td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Hs MYPT1<break/>Rabbit polyclonal</td><td align="left" valign="bottom">US Biological</td><td align="left" valign="bottom">Cat# M9925-01C<break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2927397">AB_2927397</ext-link></td><td align="left" valign="bottom">Dilution IF: 1:100</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Hs Ubiquitin<break/>(P4D1)<break/>Mouse monoclonal</td><td align="left" valign="bottom">Cell signalling</td><td align="left" valign="bottom">Cat# 3936<break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_331292">AB_331292</ext-link></td><td align="left" valign="bottom">Dilution IF: 1:50</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">V5 epitope<break/>Mouse monoclonal</td><td align="left" valign="bottom">Abcam</td><td align="left" valign="bottom">Cat# ab27671<break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_471093">AB_471093</ext-link></td><td align="left" valign="bottom">Dilution WB 1:5000<break/>See <xref ref-type="supplementary-material" rid="supp9">Supplementary file 9</xref></td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Hs RNF213<break/>Rabbit<break/>Polyclonal</td><td align="left" valign="bottom">Sigma</td><td align="left" valign="bottom">Cat# HPA003347<break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_1079204">AB_1079204</ext-link></td><td align="left" valign="bottom">Dilution IF: 1:1000</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Rabbit IgG-HRP<break/>Goat polyclonal</td><td align="left" valign="bottom">ThermoFisher</td><td align="left" valign="bottom">Cat# 31460<break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_228341">AB_228341</ext-link></td><td align="left" valign="bottom">Dilution WB 1:1000<break/>See <xref ref-type="supplementary-material" rid="supp9">Supplementary file 9</xref></td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Mouse IgG-HRP<break/>Goat polyclonal</td><td align="left" valign="bottom">ThermoFisher</td><td align="left" valign="bottom">Cat# 31430<break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_228307">AB_228307</ext-link></td><td align="left" valign="bottom">Dilution WB 1:1000<break/>See <xref ref-type="supplementary-material" rid="supp9">Supplementary file 9</xref></td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Rabbit IgG-A488<break/>Goat polyclonal</td><td align="left" valign="bottom">ThermoFisher</td><td align="left" valign="bottom">Cat# A-11008<break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_143165">AB_143165</ext-link></td><td align="left" valign="bottom">Dilution IF: 1:1000</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Rabbit IgG-A647<break/>Goat polyclonal</td><td align="left" valign="bottom">ThermoFisher</td><td align="left" valign="bottom">Cat# A-21244<break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2535812">AB_2535812</ext-link></td><td align="left" valign="bottom">Dilution IF: 1:1000</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Mouse IgG-A488<break/>Goat polyclonal</td><td align="left" valign="bottom">ThermoFisher</td><td align="left" valign="bottom">Cat# A-11001<break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2534069">AB_2534069</ext-link></td><td align="left" valign="bottom">Dilution IF: 1:1000</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Mouse IgG-A647<break/>Goat polyclonal</td><td align="left" valign="bottom">ThermoFisher</td><td align="left" valign="bottom">Cat# A-21235<break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2535804">AB_2535804</ext-link></td><td align="left" valign="bottom">Dilution IF: 1:1000</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">See <xref ref-type="supplementary-material" rid="supp10">Supplementary file 10</xref></td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom"/><td align="left" valign="bottom">Primers used in this study</td></tr><tr><td align="left" valign="bottom">Peptide, recombinant protein</td><td align="left" valign="bottom">3xFLAG peptide</td><td align="left" valign="bottom">APExBIO</td><td align="left" valign="bottom">Cat# A6001</td><td align="left" valign="bottom">Peptide for eluting Flag immunoprecipitated proteins</td></tr><tr><td align="left" valign="bottom">Peptide, recombinant protein</td><td align="left" valign="bottom">Recombinant human interferon gamma (IFNγ)</td><td align="left" valign="bottom">Millipore</td><td align="left" valign="bottom">Cat# IF005</td><td align="left" valign="bottom">For inducing Type II interferon responses in cell cultures</td></tr><tr><td align="left" valign="bottom">Peptide, recombinant protein</td><td align="left" valign="bottom">LGV L2 434 Bu Cdu1 recombinant protein</td><td align="left" valign="bottom">Jonathan Pruneda (Oregon Health and Science University)</td><td align="left" valign="bottom">N/A</td><td align="left" valign="bottom">Recombinant Cdu1 protein used to generate Rabbit polyclonal antibodies against Cdu1</td></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">TargeTron gene knockout system</td><td align="left" valign="bottom">Sigma-Aldrich</td><td align="left" valign="bottom">Cat# TA0100</td><td align="left" valign="bottom">Kit for generating <italic>cdu1</italic>::GII null strain</td></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">PR-619 (DUB inhibitor)</td><td align="left" valign="bottom">Sigma-Aldrich</td><td align="left" valign="bottom">Cat# SML0430</td><td align="left" valign="bottom">Used during TUBE affinity enrichment</td></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">MG132</td><td align="left" valign="bottom">Sigma-Aldrich</td><td align="left" valign="bottom">Cat# 474791</td><td align="left" valign="bottom">Proteasome inhibitor</td></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">TUBE-1</td><td align="left" valign="bottom">LifeSensors</td><td align="left" valign="bottom">Cat# UM401M</td><td align="left" valign="bottom">Pan-polyubiquitination affinity capture reagent</td></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Acti-stain 488 (Phalloidin 488)</td><td align="left" valign="bottom">Cytoskeleton Inc.</td><td align="left" valign="bottom">Cat# PHDG1</td><td align="left" valign="bottom">Reagent for visualizing Actin by IF</td></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">ChromoTek GFP-Trap Agarose</td><td align="left" valign="bottom">Proteintech</td><td align="left" valign="bottom">Cat# gta</td><td align="left" valign="bottom">Agarose for immunoprecipitating GFP tagged proteins</td></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Protein A/G PLUS-Agarose</td><td align="left" valign="bottom">Santa Cruz Biotechnology</td><td align="left" valign="bottom">Cat# sc-2203</td><td align="left" valign="bottom">Agarose for immunoprecipitations</td></tr><tr><td align="left" valign="bottom">Software</td><td align="left" valign="bottom">Targetronics</td><td align="left" valign="bottom">Targetronics, LLC; <ext-link ext-link-type="uri" xlink:href="https://www.targetrons.com/">https://www.targetrons.com/</ext-link></td><td align="left" valign="bottom"/><td align="left" valign="bottom">Algorithm for generating TargeTron homing sequences</td></tr><tr><td align="left" valign="bottom">Software</td><td align="left" valign="bottom">Proteome Discoverer 2.3</td><td align="left" valign="bottom">Thermo Fisher;<break/><ext-link ext-link-type="uri" xlink:href="https://www.thermofisher.com/in/en/home/industrial/mass-spectrometry/liquid-chromatography-mass-spectrometry-lc-ms/lc-ms-software/multi-omics-data-analysis/proteome-discoverer-software.html">https://www.thermofisher.com/in/en/home/industrial/mass-spectrometry/liquid-chromatography-mass-spectrometry-lc-ms/lc-ms-software/multi-omics-data-analysis/proteome-discoverer-software.html</ext-link></td><td align="left" valign="bottom"/><td align="left" valign="bottom">Proteomics software</td></tr><tr><td align="left" valign="bottom">Software</td><td align="left" valign="bottom">Mascot software</td><td align="left" valign="bottom">Matrix Science;<break/><ext-link ext-link-type="uri" xlink:href="https://www.matrixscience.com">https://www.matrixscience.com</ext-link></td><td align="left" valign="bottom"/><td align="left" valign="bottom">Proteomics software</td></tr><tr><td align="left" valign="bottom">Software</td><td align="left" valign="bottom">MaxQuant 1.6.2.3</td><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="https://www.maxquant.org">https://www.maxquant.org</ext-link></td><td align="left" valign="bottom"/><td align="left" valign="bottom">Proteomics software</td></tr><tr><td align="left" valign="bottom">Software</td><td align="left" valign="bottom">Scaffold PTM</td><td align="left" valign="bottom">Proteome Software;<break/><ext-link ext-link-type="uri" xlink:href="https://www.proteomesoftware.com/products/scaffold-ptm">https://www.proteomesoftware.com/products/scaffold-ptm</ext-link></td><td align="left" valign="bottom"/><td align="left" valign="bottom">Software for viewing proteomics data</td></tr><tr><td align="left" valign="bottom">Software</td><td align="left" valign="bottom">VolcaNoseR</td><td align="left" valign="bottom">PMID:<ext-link ext-link-type="uri" xlink:href="https://pubmed.ncbi.nlm.nih.gov/33239692/">33239692</ext-link>;<break/><ext-link ext-link-type="uri" xlink:href="https://huygens.science.uva.nl/VolcaNoseR/">https://huygens.science.uva.nl/VolcaNoseR/</ext-link></td><td align="left" valign="bottom"/><td align="left" valign="bottom">Online software for generating volcano plots</td></tr><tr><td align="left" valign="bottom">Software</td><td align="left" valign="bottom">Metascape</td><td align="left" valign="bottom">PMID:<ext-link ext-link-type="uri" xlink:href="https://pubmed.ncbi.nlm.nih.gov/30944313/">30944313</ext-link>;<break/><ext-link ext-link-type="uri" xlink:href="https://metascape.org/gp/index.htm#/main/step1">https://metascape.org/gp/index.htm#/main/step1</ext-link></td><td align="left" valign="bottom"/><td align="left" valign="bottom">Online program for Gene Ontology clustering</td></tr><tr><td align="left" valign="bottom">Software</td><td align="left" valign="bottom">DAVID Bioinformatic Resources</td><td align="left" valign="bottom">PMID:<ext-link ext-link-type="uri" xlink:href="https://pubmed.ncbi.nlm.nih.gov/19033363/">19033363</ext-link>;<break/>PMID:<ext-link ext-link-type="uri" xlink:href="https://pubmed.ncbi.nlm.nih.gov/19131956/">19131956</ext-link><break/><ext-link ext-link-type="uri" xlink:href="https://david.ncifcrf.gov/tools.jsp">https://david.ncifcrf.gov/tools.jsp</ext-link></td><td align="left" valign="bottom"/><td align="left" valign="bottom">Online program for Gene Ontology clustering</td></tr><tr><td align="left" valign="bottom">Software</td><td align="left" valign="bottom">Image J</td><td align="left" valign="bottom">PMID:<ext-link ext-link-type="uri" xlink:href="https://pubmed.ncbi.nlm.nih.gov/22930834/">22930834</ext-link>;<break/><ext-link ext-link-type="uri" xlink:href="https://imagej.nih.gov/ij/">https://imagej.nih.gov/ij/</ext-link></td><td align="left" valign="bottom"/><td align="left" valign="bottom">Software for image viewing and processing</td></tr><tr><td align="left" valign="bottom">Software</td><td align="left" valign="bottom">NEBaseChanger</td><td align="left" valign="bottom">New England Biolabs;<break/><ext-link ext-link-type="uri" xlink:href="https://nebasechanger.neb.com">https://nebasechanger.neb.com</ext-link></td><td align="left" valign="bottom"/><td align="left" valign="bottom">Cloning website</td></tr><tr><td align="left" valign="bottom">Software</td><td align="left" valign="bottom">Prism 9</td><td align="left" valign="bottom">GraphPad;<break/><ext-link ext-link-type="uri" xlink:href="https://www.graphpad.com/updates/prism-900-release-notes">https://www.graphpad.com/updates/prism-900-release-notes</ext-link></td><td align="left" valign="bottom"/><td align="left" valign="bottom">Software for statistical analysis</td></tr><tr><td align="left" valign="bottom">Software</td><td align="left" valign="bottom">HCS Studio Cell Analysis Software</td><td align="left" valign="bottom">Thermo Fischer Scientific</td><td align="left" valign="bottom">Cat# CX51110</td><td align="left" valign="bottom">Software for high content image analysis</td></tr></tbody></table></table-wrap></app></app-group></back><sub-article article-type="editor-report" id="sa0"><front-stub><article-id pub-id-type="doi">10.7554/eLife.87386.3.sa0</article-id><title-group><article-title>eLife assessment</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Kana</surname><given-names>Bavesh D</given-names></name><role specific-use="editor">Reviewing Editor</role><aff><institution>University of the Witwatersrand</institution><country>South Africa</country></aff></contrib></contrib-group><kwd-group kwd-group-type="claim-importance"><kwd>Important</kwd></kwd-group><kwd-group kwd-group-type="evidence-strength"><kwd>Solid</kwd></kwd-group></front-stub><body><p>This <bold>important</bold> study combines state-of-the art proteomics and genetic manipulation of <italic>Chlamydia trachomatis</italic> to study the function of a chlamydial effector, Cdu1, with deubiquitination and acetylation activities. <bold>Solid</bold> evidence is provided to show that Cdu1 is able to protect itself and three other chlamydial effectors, which are involved in the control of chlamydial egress from host cells, from ubiquitin-mediated degradation, and that this depends on the acetylation activity of Cdu1, but not on its deubiquitination activity. This work will be of interest to microbiologists and cell biologists studying host cell-pathogen interactions.</p></body></sub-article><sub-article article-type="referee-report" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.87386.3.sa1</article-id><title-group><article-title>Reviewer #1 (Public Review):</article-title></title-group><contrib-group><contrib contrib-type="author"><anonymous/><role specific-use="referee">Reviewer</role></contrib></contrib-group></front-stub><body><p>The objective of this study was to investigate the influence of the <italic>C. trachomatis</italic> effector Cdu1 on the ubiquitination of proteins in infected host cells and its correlation with the previously identified role of Cdu1 in facilitating Golgi distribution around the Chlamydia inclusion.</p><p>To achieve this, the authors created a cdu1-null mutant in <italic>C. trachomatis</italic> and employed proteomics to analyze ubiquitinated proteins in cells infected with Cdu1-producing and Cdu1-deficient chlamydiae, comparing them to mock-infected cells. The results revealed that, among the proteins specifically ubiquitinated after infection with Cdu1-deficient chlamydiae, three were other <italic>C. trachomatis</italic> effectors (InaC, IpaM, and CTL0480), members of a large family of Chlamydia effectors (Incs) that insert in the inclusion membrane.</p><p>Subsequently, the authors focused on understanding how Cdu1 shields InaC, IpaM, and CTL0480 from ubiquitination and the implications of this protection for the protein levels and functions of these Incs during infection. Data is presented showing that Cdu1 can bind to InaC, IpaM, and CTL0480, and protects these Incs and itself from ubiquitination and proteasomal degradation. This protective role of Cdu1 is dependent on its acetylation, but not on its deubiquitinating activity. Host cells infected by the cdu1 null mutant displayed defects resembling those observed in cells infected by inaC, ipaM, or ctl0480 null mutants.</p><p>Additionally, it was previously established that CTL0480 inhibits a chlamydial egress pathway involving the extrusion of the inclusion. This study now revealed that InaC and IpaM also play a role in promoting the extrusion of <italic>C. trachomatis</italic> inclusion, and the cdu1 null mutant exhibited a defect in this process. This leads to the title's conclusion that Cdu1 regulates chlamydial exit from host cells by safeguarding specific <italic>C. trachomatis</italic> effectors from degradation.</p><p>In summary, this work is excellent and impressive, both technically and conceptually, providing mechanistic insights into the action of Cdu1. The data provides convincing support for the proposed model, illustrating how the acetylation activity of Cdu1 protects itself and three Incs (InaC, IpaM, and CTL0480) from degradation. While the study indicates that the observed phenotypes in cells infected by the cdu1 null mutant are linked to reduced levels of InaC, IpaM, and CTL0480, these Incs are still detectable in cells infected by the cdu1 null mutant. Even if very unlikely, this leaves room for the possibility that Cdu1 directly promotes assembly of F-actin and Golgi repositioning around the inclusion, MYPT1 recruitment to the inclusion, and extrusion of the inclusion. Nevertheless, the major significance of this work lies in the integration of proteomics and chlamydial genetics to unveil a unique mechanism in which one effector controls the levels of other effectors, emphasizing the intricate relationships among bacterial effectors injected into host cells.</p></body></sub-article><sub-article article-type="referee-report" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.87386.3.sa2</article-id><title-group><article-title>Reviewer #2 (Public Review):</article-title></title-group><contrib-group><contrib contrib-type="author"><anonymous/><role specific-use="referee">Reviewer</role></contrib></contrib-group></front-stub><body><p>Based on the corresponding author's response, the questions I raised were not addressed for various reasons. This is not necessarily a negative. The authors indicated that most of the points raised will be addressed in a separate manuscript. Specifically, the Cdu1 targeting of IkBa. They mentioned intriguing findings regarding IkBa in cells infected with a cdu1-null strain <italic>C. trachomatis</italic> in their response to reviewers. Similar to this, there appears to be a planned manuscript that will address the question of the timing of CTL0480's function in inclusion extrusion.</p><p>The lack of more direct infection-related evidence of Cdu1 interaction with various type III effectors was raised; and the authors attributed this to technical difficulties and low abundance of starting materials. It was not clear if they tried other approaches to demonstrate interaction.</p><p>Another suggestion was the quantitation of the three target effectors of Cdu1 in wild type and cdu1-null background. The authors provided western blot data and immunofluorescence images that revealed potential differences in stability/turnover kinetics. The authors might want to discuss the implications of the different kinetics of stability/turnover. For example, if all three proteins are necessary for optimal extrusion of inclusions, and concertedly act to mediate this process, all three would need to be present at the required levels. Could this be a temporal regulation strategy? Does acetylation also regulate function, interactions, etc.?</p><p>In short, the response to some of the questions is forthcoming in the form of follow-up manuscripts. New observations on the different stability profiles could be elaborated in the Discussion section, with a brief discussion on functional and/or regulatory implications.</p></body></sub-article><sub-article article-type="referee-report" id="sa3"><front-stub><article-id pub-id-type="doi">10.7554/eLife.87386.3.sa3</article-id><title-group><article-title>Reviewer #3 (Public Review):</article-title></title-group><contrib-group><contrib contrib-type="author"><anonymous/><role specific-use="referee">Reviewer</role></contrib></contrib-group></front-stub><body><p>In this article by Bastidas et al. the authors examine the functions of the Chlamydia deubiquitinating enzyme 1 (Cdu1) during infections of human cells. First, a mutant lacking Cdu1 but not Cdu2 was constructed using targetron and quantitative proteomics was used to identify differences in ubiquitinated proteins (both host and bacterial) during infection. While they found minimal changes in host protein ubiquitination, they identified three Chlamydia effector proteins, IpaM, InaC and CTL0480 were all ubiquitinated in the absence of Cdu1. Microscopy and immunoprecipitations found Cdu1 directly interacts with these Chlamydia effectors and confirmed that Cdu1 mediates the stabilization of these effectors at the inclusion membrane during late infection time points. Surprisingly rather than deubiquitination driving this stabilization, the acetylation function of Cdu1 was required, and acetylation on lysine residues prevented degradative ubiquitination of Cdu1, IpaM, InaC and CTL0480. In line with this observation the authors show that loss of Cdu1 phenocopies the loss of single effector mutants of InaC, IpaM and CTL0480, including golgi stack formation and the recruitment of MYPT1 to the inclusion. The aggregation of changes to the Chlamydia inclusion does not alter growth but controls extrusion of chlamydia from cells with reduced extrusion in Cdu1 mutant Chlamydia infections. The strengths of the manuscript are the range of assays used to convincingly examine the biochemical and cellular biology underlying Cdu1 functions. The finding that acetylation of lysine residues is a mechanisms for bacterial effectors to block degradative ubiqutination is impactful and will open new investigations into this mechanism for many intracellular pathogens. The authors revisions to the manuscript have addressed my primary concerns and the authors present compelling arguments for remaining questions that are outside the scope of this study. Altogether this is an important series of findings that help to understand the mechanisms underpinning Chlamydia pathogenesis using orthologous methods and is an impactful study.</p></body></sub-article><sub-article article-type="author-comment" id="sa4"><front-stub><article-id pub-id-type="doi">10.7554/eLife.87386.3.sa4</article-id><title-group><article-title>Author Response</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Bastidas</surname><given-names>Robert J</given-names></name><role specific-use="author">Author</role><aff><institution>Duke University</institution><addr-line><named-content content-type="city">Durham</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Kędzior</surname><given-names>Mateusz</given-names></name><role specific-use="author">Author</role><aff><institution>Duke University</institution><addr-line><named-content content-type="city">Durham</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Davidson</surname><given-names>Robert K</given-names></name><role specific-use="author">Author</role><aff><institution>Duke University</institution><addr-line><named-content content-type="city">Durham</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Walsh</surname><given-names>Stephen C</given-names></name><role specific-use="author">Author</role><aff><institution>Duke University</institution><addr-line><named-content content-type="city">Durham</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Dolat</surname><given-names>Lee</given-names></name><role specific-use="author">Author</role><aff><institution>Duke University</institution><addr-line><named-content content-type="city">Duke</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Sixt</surname><given-names>Barbara S</given-names></name><role specific-use="author">Author</role><aff><institution>Umeå University</institution><addr-line><named-content content-type="city">Umeå</named-content></addr-line><country>Sweden</country></aff></contrib><contrib contrib-type="author"><name><surname>Pruneda</surname><given-names>Jonathan N</given-names></name><role specific-use="author">Author</role><aff><institution>Oregon Health &amp; Science University</institution><addr-line><named-content content-type="city">Portland</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Coers</surname><given-names>Jorn</given-names></name><role specific-use="author">Author</role><aff><institution>Duke University Medical Center</institution><addr-line><named-content content-type="city">Durham</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Valdivia</surname><given-names>Raphael H</given-names></name><role specific-use="author">Author</role><aff><institution>Duke University</institution><addr-line><named-content content-type="city">Durham</named-content></addr-line><country>United States</country></aff></contrib></contrib-group></front-stub><body><p>The following is the authors’ response to the original reviews.</p><disp-quote content-type="editor-comment"><p><bold>RESPONSE TO REVIEWERS:</bold></p><p><bold>Reviewer #1 (Recommendations For The Authors):</bold></p><p>I think the manuscript of this excellent work can be improved, especially in writing (including a suggestion in the title) and presentation (Figure 6); Also some additional specific experiments and analyses could be important, as I suggest below,</p><p>1. For the title, perhaps a shorter &quot;The acetylase activity of Cdu1 protects Chlamydia effectors from degradation&quot; would be better to convey the major significance of this work. Of course, Cdu1 must regulate the function of InaC, IpaM and CTL0480. But perhaps it is speculative to think that egress is the major function of these effectors as their activity on other host cell processes during the cycle could eventually impact the extrusion process indirectly.</p></disp-quote><p>Although we concur with the insights provided by reviewer 1, we wish to underscore that a significant breakthrough presented in our study revolves around the regulation of Chlamydia exit by Cdu1. Consequently, we believe that this noteworthy discovery should be incorporated into the title.</p><disp-quote content-type="editor-comment"><p>2. For the writing:</p><p>a. The description of ubiquitination and DUBs could be synthesized to the essential, so that space is gained to explain things that then come a bit out of the blue in the results (what are Incs, the specific functions of InaC, IpaM, and CTL0480 - at least place the citations in lines 110-112 next to the corresponding Incs -, Cdu2, etc - see specifics below)</p></disp-quote><p>In lines 182-196 of the revised manuscript, we have incorporated additional contextual information concerning the roles of Incs, along with descriptions of the functions of InaC, IpaM, and CTL0480.</p><disp-quote content-type="editor-comment"><p>b. In the Results, there is a lot of Chlamydia- and maybe lab-specific jargon that could be significantly simplified for the more general reader. I detail some suggestions below in the specific issues.</p></disp-quote><p>We have improved the readability of our manuscript for a general audience by removing Chlamydia-specific terminology from the entire text and figures.</p><disp-quote content-type="editor-comment"><p>3. For the figures:</p><p>a. Figure 6, this figure could be reorganized: why two graphs in panel D? If detailed quantifications were done, perhaps in panel B just zoom on the examples of Golgi distributed/compacted? And again the labelling Rif-R L2, L2 pBOMB, M407 p2TK2, etc, simplify?</p></disp-quote><p>Figure 6 has undergone restructuring. The representative images have been relocated to Supplemental Figures 5 and 6, while we have introduced sample images demonstrating F-actin assembly and Golgi repositioning. Furthermore, the quantification of Golgi dispersal has been streamlined into a single panel. Additionally, we have simplified the labeling of the strains utilized in the study.</p><disp-quote content-type="editor-comment"><p>b. Figure 3, in the labelling, WT, inaC null, cdu1::GII wouldn't be enough? Leave the details to the legend and/or M&amp;M.</p></disp-quote><p>We have simplified the labeling of Ct strains in Figure 3.</p><disp-quote content-type="editor-comment"><p>c. Figure 3C, these arrowheads should not be so symmetric (small arrows instead?) and it is unclear that the indicated cells do not show CTL0480.</p></disp-quote><p>We have substituted arrowheads with small arrow symbols and have also revised the Figure to incorporate a new representative image that prominently illustrates the absence of CTL0480 at the inclusion membrane of some cdu1::GII inclusions within infected Hela cells at 36 hpi.</p><disp-quote content-type="editor-comment"><p>4. Experiments:</p><p>a. In Figure 7, at least extrusion should be analysed also with the Cdu1-deficient strain expressing Ac-deficient Cdu1 and the inaC and ipaM phenotypes should be complemented.</p></disp-quote><p>We have conducted additional experiments to analyze extrusion production in Hela cells infected with a cdu1 null strain expressing the acetylase-deficient Cdu1 variant. We have incorporated the relevant data into revised Figure 7, where the impact of this strain on extrusion production and size is presented. Additionally, we updated Supplemental Figure 8 to include data illustrating the number of inclusions produced by this strain. We have also addressed these new results in the revised manuscript (lines 424-432). We are currently complementing inaC and ipaM mutant strains with various InaC and IpaM constructs that will be used in a follow up manuscript.</p><disp-quote content-type="editor-comment"><p>b. Does overexpression of InaC, IpaM, or CTL0480 in a cdu1-null background prevent the degradation of these Incs and suppress the defects of cells infected by the cdu1 mutant (F-actin, Golgi, MYPT1)? This would show that the multiple phenotypes displayed by cells infected by the cdu1 null mutant are indeed related to the decreased levels of InaC, IpaM and CTL0480.</p></disp-quote><p>We opted not to include data from the overexpression of these effectors in a cdu1-null background due to an unexpected decrease in shuttle plasmid load during overexpression. This development prompted concerns regarding the potential detrimental effects of overexpressing these effectors in the absence of Cdu1. Data supporting this observation are not included in this report.</p><disp-quote content-type="editor-comment"><p>c. Figures 3A and 3B should be quantified (it says it is from 3 independent experiments). It would be important to have a relative perspective of how much Cdu1 protects these Incs over time (for InaC, it would also be nice to have the 36 and 48 hpi time-point). This is in contrast with the microscopy data in Figure 5, which illustrates very clear effects, and the quantification is a bit redundant.</p></disp-quote><p>In Figure 3, we have incorporated a new Western Blot image showing endogenous InaC protein levels in Hela cells following infection with both WT Ct and cdu1::GII strains at 24, 36, and 48 hours post-infection (hpi). Additionally, we have quantified the Western Blot signals for both InaC and IpaM, and these results are also presented in Figure 3. The quantification of MYPT1 recruitment has been relocated to a supplementary figure. We have also included details regarding the methodology employed for the quantification of Western Blot signals in the Materials and Methods section.</p><disp-quote content-type="editor-comment"><p>d. What is the subcellular localization of InaC, IpaM, CTL0480 and Cdu1 when analysed by transfection? Does Cdu1 bind to of InaC, IpaM, CTL0480 in infected cells? If this was attempted and unsuccessful it should be mentioned.</p></disp-quote><p>In transfected HEK cells, InaC, IpaM, CTL0480, and Cdu1 all exhibit cytoplasmic localization with a diffuse pattern (data not shown). Despite our efforts, we encountered challenges in observing co-immunoprecipitation of Cdu1 with all three Incs in infected Hela cells at 24 hpi, We have duly acknowledged this limitation in our findings, as reflected in line 221-226 of the revised manuscript.</p><disp-quote content-type="editor-comment"><p>5. Specific issues:</p><list list-type="bullet"><list-item><p>Line 87, &quot;propagule&quot; is really needed to describe the EB?</p></list-item></list></disp-quote><p>The EB is the infectious form of Chlamydia species that spreads within the host to renew its life cycle; thus, &quot;propagule&quot; is a suitable term to characterize the EB.</p><disp-quote content-type="editor-comment"><list list-type="bullet"><list-item><p>Exocytosis implies fusion with the plasma membrane so &quot;inclusion is exocytosed&quot; (line 91) is not entirely correct.</p></list-item></list></disp-quote><p>In line 91 of the revised manuscript, we referred to extrusion as the exit of an intact inclusion from the host cell and omitted the use of &quot;exocytosed&quot; to describe this process.</p><disp-quote content-type="editor-comment"><list list-type="bullet"><list-item><p>Line 126, &quot;a Ct L2 (LGV L2 434 Bu) background&quot;. Maybe &quot;a Ct cdu1-null strain&quot; would be enough and leave the detail for Materials and Methods.</p></list-item></list></disp-quote><p>In line 128 of the revised manuscript, we omitted &quot;(LGV L2 434 Bu)&quot; to avoid using jargon that may be unfamiliar to readers not well-versed in Chlamydia terminology.</p><disp-quote content-type="editor-comment"><list list-type="bullet"><list-item><p>Line 138, in the previous Pruneda et al, Nature Microbiol 2018, the title of figure 4 is &quot;ChlaDUB deubiquitinase activity is required for <italic>C. trachomatis</italic> Golgi fragmentation&quot;, so why raise this hypothesis? And why in the end is the acetylation activity of Cdu1 that promotes Golgi distribution? I think this related with infection vs transfection experiments but it deserved to be briefly explained/discussed.</p></list-item></list></disp-quote><p>In lines 140-142 of the revised manuscript, we provide clarification that the DUB activity of Cdu1 is required for Golgi fragmentation in transfected cells. This observation supports our initial hypothesis suggesting that the DUB activity of Cdu1 is also required for Golgi distribution in infected cells, and our rationale for identifying targets of its DUB activity.</p><disp-quote content-type="editor-comment"><list list-type="bullet"><list-item><p>Lines 147-155, what is the relevance of this non-ubiquitinated proteins that come along? Couldn't this be synthesized?</p></list-item></list></disp-quote><p>We have included a discussion on non-ubiquitinated proteins, as they could potentially encompass proteins that interact with those protected by Cdu1. This perspective provides supplementary insights into the roles of proteins targeted for ubiquitination in the absence of Cdu1. The results of this analysis have been succinctly summarized in a single paragraph within the initial manuscript (lines 151-159 of the revised manuscript).</p><disp-quote content-type="editor-comment"><list list-type="bullet"><list-item><p>Line 170, I think it is the first time that &quot;Type 3 secretion&quot;; perhaps explain in the introduction.</p></list-item></list></disp-quote><p>Type 3 secretion systems have been extensively characterized and discussed in the literature, and we anticipate that the majority of our readers are well-acquainted with this secretory mechanism.</p><disp-quote content-type="editor-comment"><list list-type="bullet"><list-item><p>Line 184, I think it is the first time &quot;microdomains&quot; are mentioned; perhaps mention in the introduction.</p></list-item></list></disp-quote><p>The definition of &quot;microdomains&quot; has been provided in line 191 of the revised manuscript.</p><disp-quote content-type="editor-comment"><list list-type="bullet"><list-item><p>Figure 2, as it stands the analysis with truncated Cdu1 proteins adds little to the work. Binding to the Incs seems to be affected when the TM domain is not present, but it still binds. And this is in a transfection context.</p></list-item></list></disp-quote><p>The results depicted in Figure 2, involving truncated Cdu1 proteins, illustrates that Cdu1 is capable of interacting with InaC, IpaM, and CTL0480 even in the absence of infection. This finding serves as evidence suggesting that all three Incs could potentially serve as direct targets for Cdu1 activity. As a result, we prefer to keep these findings in the manuscript.</p><disp-quote content-type="editor-comment"><list list-type="bullet"><list-item><p>Line 219, &quot;late stages of infection&quot;, this is shown (albeit not completely quantified) for IpaM and CTL0480, but not for InaC.</p></list-item></list></disp-quote><p>In the revised Figure 3, we show InaC protein levels at 24, 36, and 48 hours post-infection, and we have incorporated quantitative data for both InaC and IpaM protein levels in the context of Hela cells infected with both WT L2 and cdu1::GII strains. This updated figure serves to emphasize the pivotal role of Cdu1 in safeguarding all three Incs during the late stages of infection.</p><disp-quote content-type="editor-comment"><list list-type="bullet"><list-item><p>Line 233, &quot;pBOMB-MCI backbone&quot; - is this needed in the Results section? And this refers to Figure 4 while pBOMB appear already in Fig. 3.</p></list-item></list></disp-quote><p>We have removed “pBOMB-MCI backbone” in the revised manuscript.</p><disp-quote content-type="editor-comment"><list list-type="bullet"><list-item><p>Line 236, should be cdu1 endogenous promoter.</p></list-item></list></disp-quote><p>In line 265 of the revised manuscript we have replaced Cdu1 with cdu1 (italicized).</p><disp-quote content-type="editor-comment"><list list-type="bullet"><list-item><p>Line 263, WT.</p></list-item></list></disp-quote><p>In line 293 of the revised manuscript we replaced “wild type” with “WT”.</p><disp-quote content-type="editor-comment"><list list-type="bullet"><list-item><p>Line 277, IncA instead of &quot;the Inc protein IncA&quot;.</p></list-item></list></disp-quote><p>In the manuscript we wanted to emphasize that IncA is also an inclusion membrane protein, therefore we have included “the Inc protein IncA” in the revised manuscript to avoid any confusion.</p><disp-quote content-type="editor-comment"><list list-type="bullet"><list-item><p>How does the data in Figure 5 relates to the relatively few proteins ubiquitinated in cells infected with cdu1-mutant Ct? These Ub-labelling corresponds to ubiquitinated InaC, IpaM and CTL0480?</p></list-item></list></disp-quote><p>The findings presented in Figure 5 demonstrate that the acetylase activity of Cdu1 plays a crucial role in enabling Ct to block all ubiquitination events taking place on or in proximity to the periphery of the inclusion membrane. This encompasses Cdu1 targets that might not have been identified through our proteomic analysis.</p><disp-quote content-type="editor-comment"><list list-type="bullet"><list-item><p>Lines 299-301, &quot;M923 inclusions&quot;, there is certainly a clear way to write this.</p></list-item></list></disp-quote><p>In lines 326-327 and 332-332 of the revised manuscript, we have clarified that “M923” is an incA null strain to provide clarification.</p><disp-quote content-type="editor-comment"><list list-type="bullet"><list-item><p>Line 309, is &quot;peripheries&quot; correct?</p></list-item></list></disp-quote><p>We have changed “peripheries” with “periphery” in the revised manuscript (line 360).</p><disp-quote content-type="editor-comment"><list list-type="bullet"><list-item><p>Line 312, &quot;Rif-R L2&quot; and &quot;M407&quot; - can this be simplified?</p></list-item></list></disp-quote><p>In the revised manuscript, &quot;Rif-R L2&quot; was substituted with &quot;WT L2&quot; in lines 363 and 382, while &quot;M407&quot; was exchanged with &quot;an inaC null strain&quot; in lines 311, 367, and 368. These same replacements were applied to the Figures and their corresponding legends for consistency.</p><disp-quote content-type="editor-comment"><list list-type="bullet"><list-item><p>Lines 308-321, and 326-335, these % are all approximate figures and this should be made clear.</p></list-item></list></disp-quote><p>In lines 364-395 of the revised manuscript we have stated that all percentages are approximate values.</p><disp-quote content-type="editor-comment"><list list-type="bullet"><list-item><p>Fig. S1, kb and not k.b; what's the &quot;+ control&quot;; and is not really possible to have a PCR that works for the *? 3 kb is not that long.</p></list-item></list></disp-quote><p>In the updated Figure S1, we have corrected &quot;k.b&quot; to &quot;kb&quot;. In the legend of Figure S1, we have clarified that the + control corresponds to the cdu2 locus. Moreover, we could not cleanly amplify a 3 kb PCR product from bacteria in whole cell lysates of infected mammalian cells (Vero cells).</p><disp-quote content-type="editor-comment"><list list-type="bullet"><list-item><p>Fig. S2, kb and not k.b, bp and not b.p</p></list-item></list></disp-quote><p>In the updated Figure S2, we have corrected “k.b” with “kb” and “b.p” with “bp”.</p><disp-quote content-type="editor-comment"><p><bold>Reviewer #2 (Recommendations For The Authors):</bold></p><p>Figure 1 describes an affinity-based purification and mass spectrometric identification of differentially ubiquitinated proteins (host and chlamydial). Through different permutations of combinations of infection (mock, wild type, and Cdu1 mutant), three effectors, IpaM, InaC, and CTL0480, were identified as putative targets of Cdu1. The authors used a high-stringency cutoff, which could explain identification of only three targets. Having said this, the localization of Cdu1 to the inclusion membrane would be expected to also narrow down the number of targets. Interestingly, Cdu2, another deubiquitinase remained active in these experiments, which could have affected identification of Cdu1 targets. The authors addressed this issue by referring to previously reported structural studies. A somewhat glaring omission is the lack of reference to NF-kB as a substrate of ChlaDub1/Cdu1. In experiments by Le Negrate et al., ChlaDub1 ectopic overexpression in cells led to the deubiquitination of IkB-alpha, thus inhibiting the nuclear translation of NF-kB. Based on the inclusion membrane localization of Cdu1 during infection, is the identification of IkB an artifact of overexpression of Cdu1, or is it still a bona fide Cdu1 target?</p></disp-quote><p>We conducted experiments using our cdu1 null strain to investigate whether IκBα could be a target of Cdu1 activity. While our findings are intriguing and relevant, it is not feasible to determine, at this stage, whether our findings result from a direct or indirect consequence of Cdu1 localizing to the inclusion membrane. Consequently, these findings extend beyond the scope of the current manuscript. We plan to explore the implications of our observations more deeply in a subsequent manuscript, where we intend to provide a more comprehensive and mechanistic analysis based on these preliminary findings. Additionally, we have referenced the potential targeting of IκBα by Cdu1 in lines 100-101 and 166-171 of the revised manuscript.</p><disp-quote content-type="editor-comment"><p>Figure 2 demonstrates the individual interaction of the identified effectors with Cdu1. Interaction at the inclusion membrane is inferred from colocalization studies, while protein-protein interaction is monitored using ectopic overexpression of tagged versions of Cdu1 and the individual effectors. This is somewhat of a weakness of the manuscript because the mechanism of action of Cdu1 towards its target hinges on protein-protein interaction.</p></disp-quote><p>Despite our efforts, we encountered challenges in co-immunoprecipitating endogenous Cdu1 with all three Incs in infected Hela cells at 24 hpi. There are multiple technical reasons as to why these interactions, which are predicted to be transient, will not be captured by bulk affinity approaches such as immunoprecipitations, especially when the starting materials are present in very low abundance. We acknowledged these limitations in our findings, as reflected in lines 221-226 of the revised manuscript.</p><disp-quote content-type="editor-comment"><p>Figure 3 provides the first evidence in this paper of the importance of the inferred interaction of Cdu1 with the three effectors. The authors show that the loss of cdu1 has stability consequences on the three effectors. This figure would benefit from quantifying InaC- or IpaM-positive inclusions in the same manner done with CTL0480. The timepoint-dependent effect of Cdu1 loss of function is intriguing. Do InaC and IpaM retention at the inclusion show the same timepoint-dependent characteristic?</p></disp-quote><p>In the revised Figure 3, we have incorporated InaC protein levels at 24, 36, and 48 hours post-infection. Additionally, we have included quantitative data representing both InaC and IpaM protein levels in HeLa cells infected with both WT L2 and cdu1::GII strains. The quantification of CTL0480 localization to cdu1::GII inclusions has been moved to a supplementary figure.</p><p>This updated figure illustrates that the absence of Cdu1 has a time-dependent impact on both InaC and IpaM. However, it is noteworthy that the kinetics of degradation for these two proteins diverge significantly.</p><disp-quote content-type="editor-comment"><p>For Figure 7, the authors should consider monitoring timing of inclusion extrusion to gain additional insight into the functional interactions between the effectors. For example, the loss of CTL0480 leads to increased extrusion, implying a role in delaying or suppressing extrusion. In a time-course experiment, a CTL0480 mutant could exhibit an earlier occurrence of inclusion extrusion.</p></disp-quote><p>One of the principal discoveries of this study is that Cdu1, InaC, IpaM, and CTL0480 collaborate to facilitate optimal extrusion of Ct from host cells. These findings represent a significant contribution to our understanding of how Chlamydia controls its exit from infected cells. We are currently in the process of expanding on these results. A forthcoming follow-up manuscript will provide more detailed and comprehensive exploration of these findings.</p><disp-quote content-type="editor-comment"><p><bold>Reviewer #3 (Recommendations For The Authors):</bold></p><p>Specific comments.</p><p>a. I have some concerns related to the time point chosen for mass spec analysis and potential caveats and alternative interpretations. This work was done relatively early (24 hours) compared to the most convincing Cdu1 functions that occur later, thus this may limit the authors global understanding of protein changes. For example, the known substrate of Cdu1, Mcl-1 was not identified but this is altered relatively late during infection. Thus, the surprise that minimal host proteins are altered in ubiquitination may be partially driven by the timing of the assay. This should be more clearly discussed as a caveat.</p></disp-quote><p>In the revised manuscript (lines 166-171), we have acknowledged that there might be additional targets of Cdu1 that remain unidentified, primarily due to the specific time point we utilized in our study.</p><disp-quote content-type="editor-comment"><p>b. Another caveat to these studies is while the loss of Cdu1 alters different effectors stability and function and extrusion size, these changes do not modulate bacterial growth in cells. The authors speculate that regulating extrusion size may alter interactions with innate cells to drive dissemination. However, a previous study found defects in an animal model using a Cdu1 transposon mutant found decreased bacterial load in the genital tract. It is also possible that redundancy of effectors may mask importance in growth of Cdu1, but the authors strongly argue against redundancy of Cdu1 and Cdu2 so this weakens the authors argument here. These concepts and published data should be more directly discussed in the context of the authors proposed extrusion model and the role in driving Chlamydia growth and pathogenesis.</p></disp-quote><p>In our revised manuscript (lines 460-466) we propose that while we do not observe any growth impairments during Ct growth in the absence of Cdu1 in HeLa cells, the reduction in bacterial loads observed in murine models of infection with an independent cdu1 mutant strain (cdu1::Tn) may potentially be linked to defects in extrusion production or alterations in Cdu1-dependent regulation of extrusion size.</p><disp-quote content-type="editor-comment"><p>c. Recent studies have found that IFNg activation can result in dramatic changes in ubiquitination to pathogen containing vacuoles. While some of these are blocked by the newly found GarD, it seems possible that Cdu1 may also play a role (and perhaps use its deubiquinating activity) to further protect the inclusion. In light of published results showing that Cdu1 mutants have lower IFU burst size only in IFNg activated cells, this may be an important caveat in the current studies. This should be more directly addressed in the current manuscript.</p></disp-quote><p>We have incorporated two experimental findings indicating that the presence of Cdu1 is not required for Ct to defend itself against IFNγ cellular immunity in human cells. These recent discoveries are now presented in the updated Figure 5 and detailed in lines 338-355 of the revised manuscript.</p><disp-quote content-type="editor-comment"><p>d. On lines 433-434 the authors claim that Cdu1 is atypical since it is not encoded with the metaeffector/target pairs. However, this is an oversimplification of what is known about metaeffectors. For example, there are meta-effector/effector pairs that are not encoded together in Legionella (see table 1 DOI: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3390/pathogens10020108">https://doi.org/10.3390/pathogens10020108</ext-link>). Thus, the discussion should be adjusted. It seems Cdu1 is the first meta-effector found in Chlamydia, and maybe this should be highlighted more strongly rather than its uniqueness in this aspect of meta-effector/effector functions.</p></disp-quote><p>In lines 488-489 of the revised manuscript, we have removed the assertion that Cdu1 functions as an atypical metaeffector and emphasized that it represents the initial discovery of a metaeffector within Ct.</p></body></sub-article></article>